<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews - Fortin, PM - 2018 | Cochrane Library</title> <meta content="Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews - Fortin, PM - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012082.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews - Fortin, PM - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012082.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012082.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews" name="citation_title"/> <meta content="Patricia M Fortin" name="citation_author"/> <meta content="Sally Hopewell" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Lise J Estcourt" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="lise.estcourt@nhsbt.nhs.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD012082.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/08/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012082.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012082.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012082.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anemia, Sickle Cell [complications, *therapy]; Antisickling Agents [*therapeutic use]; *Erythrocyte Transfusion; Hydroxyurea [*therapeutic use]; Randomized Controlled Trials as Topic; Stroke [*prevention &amp; control]; *Systematic Reviews as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012082.pub2&amp;doi=10.1002/14651858.CD012082.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="QO4KtYGW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012082\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012082\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012082\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012082\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","ru","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012082.pub2",title:"Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews",firstPublishedDate:"Aug 1, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QO4KtYGW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012082.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012082.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012082.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012082.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012082.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012082.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012082.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012082.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012082.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012082.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3883 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012082.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full#CD012082-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full#CD012082-sec-0087"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full#CD012082-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full#CD012082-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full#CD012082-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full#CD012082-sec-0037"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full#CD012082-sec-0076"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/appendices#CD012082-sec-0092"> Search strategies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Overview</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/information#CD012082-cr-0002">Patricia M Fortin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/information#CD012082-cr-0003">Sally Hopewell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012082.pub2/information#CD012082-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Lise J Estcourt</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/information/en#CD012082-sec-0096">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 August 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012082.pub2">https://doi.org/10.1002/14651858.CD012082.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012082-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012082-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012082-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012082-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012082-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012082-abs-0001" lang="en"> <section id="CD012082-sec-0001"> <h3 class="title" id="CD012082-sec-0001">Background</h3> <p>Globally, sickle cell disease (SCD) is one of the commonest severe monogenic disorders, due to the inheritance of two abnormal haemoglobin (beta globin) genes. SCD can cause severe pain, significant end‐organ damage, pulmonary complications, and premature death. Red blood cell (RBC) transfusions are used to treat complications of SCD, e.g. acute chest syndrome (ACS) (this often involves a single transfusion episode), or they can be part of a regular long‐term transfusion programme to prevent SCD complications. </p> </section> <section id="CD012082-sec-0002"> <h3 class="title" id="CD012082-sec-0002">Objectives</h3> <p>To summarize the evidence in Cochrane Reviews of the effectiveness and safety of RBC transfusions versus no transfusion, or restrictive (to increase the total haemoglobin) versus liberal (to decrease the haemoglobin S level below a specified percentage) transfusion, for treating or preventing complications experienced by people with SCD. </p> </section> <section id="CD012082-sec-0003"> <h3 class="title" id="CD012082-sec-0003">Methods</h3> <p>We included Cochrane Reviews of randomised or quasi‐randomised controlled trials published in the Cochrane Database of Systematic Reviews, that addressed various SCD complications and had RBC transfusion as an intervention or comparator. We assessed the methodological quality of included reviews according to the AMSTAR quality assessment. </p> </section> <section id="CD012082-sec-0004"> <h3 class="title" id="CD012082-sec-0004">Main results</h3> <p>We included 15 Cochrane Reviews, 10 of which had no included studies with an RBC transfusion intervention (five reported RCTs with other interventions; and five contained no studies). Five of the 15 reviews included participants randomised to RBC transfusion, but in one of these reviews only 10 participants were randomised with no usable data. Four reviews (nine trials with 1502 participants) reported data comparing short‐ or long‐term RBC transfusions versus standard care, disease‐modifying agents, a restrictive versus a liberal transfusion strategy and long‐term RBC transfusions versus transfusions to treat complications. All reviews were of high quality according to AMSTAR quality assessment, however, the quality of the included trials was highly variable across outcomes. Trials were downgraded according to GRADE methodology for risk of bias, indirectness (most trials were conducted in children with HbSS), and imprecision (outcomes had wide confidence intervals). </p> <p>In all four reviews and all comparisons there was little or no difference in the risk of death (very low‐quality evidence). There were either no deaths or death was a rare event. </p> <p><b>Short‐term RBC transfusion versus standard care</b> (one review: two trials, 434 participants, GRADE very low‐ to low‐quality evidence)<br/> In people undergoing low‐ to medium‐risk surgery, RBC transfusions may decrease the risk of acute chest syndrome (ACS) in people with African haplotypes compared to standard care (low‐quality evidence), but there was little or no difference in people with the Arabic haplotype (very‐low quality evidence). There was also little or no difference in the risk of other SCD‐related or transfusion‐related complications (very‐low quality evidence). </p> <p><b>Long‐term RBC transfusion versus standard care</b> (two reviews: three trials, 405 participants, very low‐ to moderate‐quality evidence)<br/> In children and adolescents at high risk of stroke (abnormal transcranial doppler (TCD) velocities or silent cerebral infarct (SCI)), long‐term RBC transfusions probably decrease the risk of stroke (moderate‐quality evidence) and may decrease the risk of ACS and painful crisis compared to standard care (low‐quality evidence). Long‐term RBC transfusions may also decrease the risk of SCI in children with abnormal TCD velocities (low‐quality evidence), but there may be little or no difference in the risk of SCI in children with normal TCD velocities and previous SCI (low‐quality evidence). </p> <p>In children and adolescents already receiving long‐term RBC transfusions for preventing stroke, in comparison to standard care, continuing long‐term RBC transfusions may reduce the risk of SCI (low‐quality evidence) but we do not know whether there is a difference in the risk of stroke (very‐low quality evidence). In children with normal TCD velocities and SCI there was little or no difference in the risk of alloimmunisation or transfusion reactions, but RBC transfusions may increase the risk of iron overload (low‐quality evidence). </p> <p><b>Long‐term RBC transfusion versus RBC transfusion to treat complications</b> (one review: one trial, 72 participants, very low‐ to low‐quality evidence)<br/> In pregnant women, long‐term RBC transfusions may decrease the risk of painful crisis compared to transfusion for complications (low‐quality evidence); but there may be little or no difference in the risk of other SCD‐related complications or transfusion reactions (very‐low quality evidence). </p> <p><b>RBC transfusion versus disease‐modifying agents (hydroxyurea)</b> (two reviews: two trials; 254 participants, very low‐ to low‐quality evidence)<br/> For primary prevention of stroke in children, with abnormal TCD and no severe vasculopathy on magnetic resonance imaging/magnetic resonance angiography (MRI/MRA), who have received at least one year of RBC transfusions, we do not know whether there is a difference between RBC transfusion and disease‐modifying agents in the risk of stroke; SCI; ACS; or painful crisis (very‐low quality evidence). There may be little or no difference in the risk of iron overload (low‐quality evidence). </p> <p>Similarly, for secondary prevention of stroke in children and adolescents, we do not know whether there is a difference between these interventions in the risk of stroke; SCI; or ACS (very‐low quality evidence); but hydroxyurea with phlebotomy may increase the risk of painful crisis and global SCD serious adverse events compared to RBC transfusion (low‐quality evidence). There may be little or no difference in the risk of iron overload (low‐quality evidence). </p> <p><b>Restrictive versus liberal RBC transfusion strategy</b> (one review: one trial; 230 participants, very low‐quality evidence)<br/> In people undergoing cholecystectomy, there was little or no difference between strategies in the risk of SCD‐related or transfusion‐related complications (very‐low quality evidence). </p> </section> <section id="CD012082-sec-0005"> <h3 class="title" id="CD012082-sec-0005">Authors' conclusions</h3> <p>This overview provides support from two high‐quality Cochrane Reviews for the use of RBC transfusions in preventing stroke in children and adolescents at high risk of stroke (abnormal TCDs or SCI) and evidence that it may decrease the risk of SCI in children with abnormal TCD velocities. In addition RBC transfusions may reduce the risk of ACS and painful crisis in this population. </p> <p>This overview highlights the lack of high‐quality evidence in adults with SCD and the number of reviews that have no evidence for the use of RBC transfusions across a spectrum of SCD complications. Also of concern is the variable and often incomplete reporting of patient‐relevant outcomes in the included trials such as SCD‐related serious adverse events and quality of life. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012082-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012082-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012082-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012082-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012082-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012082-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012082-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012082-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012082-abs-0004" lang="en"> <h3>An overview of Cochrane Reviews on red blood cell transfusions to treat or prevent sickle cell disease‐related complications </h3> <p><b>Review question</b> </p> <p>To summarize the evidence in Cochrane Reviews of the effectiveness and safety of red blood cell (RBC) transfusions for treating or preventing complications experienced by people with sickle cell disease (SCD). </p> <p><b>Background</b> </p> <p>SCD is a serious inherited blood disorder where the RBCs, which carry oxygen around the body, develop abnormally. Normal RBCs are flexible and disc‐shaped, but in SCD they can become rigid and crescent shaped. Sickled cells are not only less flexible than healthy RBCs, they are also stickier. This can lead to the blockage of blood vessels, resulting in tissue and organ damage and episodes of severe pain. The abnormal RBCs are more fragile and break apart, which leads to fewer of them, known as anaemia. </p> <p><b>Overview characteristics</b> </p> <p>We searched for Cochrane Reviews that analysed the data from randomised controlled trials (RCT; experiments that randomly allocate participants to one of two or more treatment groups), which looked at the effectiveness of RBC transfusions to prevent or treat SCD complications. This overview summarises the results of these reviews. </p> <p><b>Key results</b> </p> <p>15 reviews met the inclusion criteria for this overview. However, only four reviews (which included nine RCTs and 1052 participants) looked at the effects of RBCtransfusion and had results that could be reported. In the four reviews there was no difference in the risk of death with any comparison. We found that long‐term RBC transfusions compared to standard care, probably decrease the risk of stroke in children and adolescents at high risk of stroke (abnormal transcranial doppler (TCD) ultrasound (high blood flow to the brain) or a previous silent stroke (a stroke with no outward symptoms and where a person is typically unaware they have suffered a stroke)) and may also decrease their risk of painful crisis and acute chest syndrome. Red blood cell transfusions may also decrease the risk of silent stroke in children with abnormal TCD ultrasound when compared to standard care. </p> <p>We found there was a lack of evidence for treating adults with SCD‐related complications and that important outcomes, including quality of life were often not measured or reported. </p> <p><b>Quality of the reviews and evidence within reviews</b> </p> <p>All reviews included in this review were of high quality and met Cochrane standards for systematic reviews. </p> <p>However, the quality of the trials included in the reviews was variable across the trials and in relation to the outcomes. The quality of the evidence within the trials was downgraded because trials had a high risk of bias, outcomes had imprecise measurements and much of the evidence applied only to children with HbSS disease. </p> <p>People with SCD are living longer and we need more high‐quality evidence on treating adults with SCD; as well as on the best treatment options, including the role of RBC transfusions, to treat SCD complications. We also need to improve and standardise the reporting of outcomes across trials. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012082-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012082-sec-0087"></div> <section id="CD012082-sec-0088"> <p> <h5 class="title">Implications for practice</h5> <section id="CD012082-sec-0089"> <p>This overview provides support from two high‐quality Cochrane Reviews for the use of red blood cell (RBC) transfusions for preventing strokes in children and adolescents with sickle cell disease (SCD) at a high risk of stroke (abnormal transcranial dopplers (TCDs) or silent cerebral infarcts (SCI)) and evidence that it may decrease the risk of SCI in children with abnormal TCD velocities. In addition RBC transfusions may reduce the risk of acute chest syndrome and painful crisis in this population. </p> <p>It also highlights the lack of high‐quality evidence in adults with SCD and the number of reviews that have no evidence for the use of RBC transfusions across a spectrum of chronic SCD complications. </p> </section> </p> <p> <h5 class="title">Implications for research</h5> <section id="CD012082-sec-0090"> <p>This overview provides a concise summary of where high‐quality evidence is lacking for the use of RBC transfusions to treat several SCD related‐complications as evidenced by the number of reviews with an RBC transfusion intervention or with no trials that met the reviews' inclusion criteria. Of particular concern is the lack of trials in adults with SCD given that people are living longer and may experience more of the chronic complications of SCD. Also of concern is the variable and often incomplete reporting of patient‐relevant outcomes such as SCD‐related serious adverse events and quality of life. Although it is acknowledged that recruitment to an RBC transfusion intervention in a trial is often slow and difficult, as the number of people in the population with chronic complications of SCD increases, it is an imperative to have a better understanding of the comparative benefits and harms of RBC transfusions and other interventions across the spectrum of SCD complications. Well‐designed trials are also needed that report on patient‐relevant outcomes as well as quality of life using validated scales in people receiving short‐ or long‐term RBC transfusions. Two trials suggest that quality of life is improved with both short‐ and long‐term RBC transfusion therapy and more robust measurements could provide data that may not only increase compliance with therapy but improve the lives of people living with SCD and facilitate recruitment to trials. </p> <p>We also need to consider including non‐randomised studies within future reviews to further assess adverse events (<a href="./references#CD012082-bbs2-0086" title="ZorzelaL , LokeYK , IoannidisJP , GolderS , SantaguidaP , AltmanDG , et al. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ2016;352:i157. ">Zorzela 2016</a>). </p> </section> </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012082-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012082-sec-0016"></div> <section id="CD012082-sec-0017"> <h3 class="title" id="CD012082-sec-0017">Description of the condition</h3> <p>Sickle cell disease (SCD) is an inherited blood disorder, which can lead to life‐threatening complications. People with SCD experience episodes of severe pain, and other complications including anaemia, end‐organ damage, pulmonary complications, kidney disease, and increased susceptibility to infections and stroke (<a href="./references#CD012082-bbs2-0060" title="PleasantsS . Epidemiology: a moving target. Nature2014;515(7526):S2‐3. ">Pleasants 2014</a>). It is one of the most common severe monogenic disorders in the world, due to the inheritance of two abnormal haemoglobin (beta globin) genes (<a href="./references#CD012082-bbs2-0062" title="ReesDC , WilliamsTN , GladwinMT . Sickle‐cell disease. Lancet2010;376(9757):2018‐31. ">Rees 2010</a>). Populations originating from sub‐Saharan Africa, the western hemisphere (South America, the Caribbean, and Central America), the Middle East, India and parts of the Mediterranean are predominantly affected. Reductions in infant and child mortality and increasing migration from highly affected countries have made this a worldwide problem (<a href="./references#CD012082-bbs2-0057" title="PielFB , PatilAP , HowesRE , NyangiriOA , GethingPW , DewiM , et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model‐based map and population estimates. Lancet2012;381(9861):142‐51. ">Piel 2012</a>). Over 12,500 people in the UK and 100,000 in the USA are estimated suffer from the disease (<a href="./references#CD012082-bbs2-0055" title="NICE (National Institute for Health and Care Excellence). Sickle cell disease. http://cks.nice.org.uk/sickle‐cell‐disease#!backgroundsub:3. London: NICE, (accessed 01 August 2015). ">NICE 2010</a>; <a href="./references#CD012082-bbs2-0060" title="PleasantsS . Epidemiology: a moving target. Nature2014;515(7526):S2‐3. ">Pleasants 2014</a>). A recent study estimated that approximately 305,800 babies were born with SCD in 2010, of which two thirds were born in Africa, and this could increase by 25% to approximately 404,200 by 2050 (<a href="./references#CD012082-bbs2-0057" title="PielFB , PatilAP , HowesRE , NyangiriOA , GethingPW , DewiM , et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model‐based map and population estimates. Lancet2012;381(9861):142‐51. ">Piel 2012</a>). </p> <p>The term 'sickle cell disease' refers to all genotypes that cause the clinical syndrome. There are three main types of SCD. Sickle cell anaemia is the most common form of the disease (up to 70% of cases of SCD in people of African origin) and is due to the inheritance of two beta globin S (βS) alleles (haemoglobin (Hb)SS). The second most common genotype (up to 30% of cases in people of African origin) is haemoglobin SC disease (HbSC disease) it is due to the co‐inheritance of the βS and βC alleles and tends to be a more moderate form of the disease. The third major type of SCD occurs when βS is inherited with a β‐thalassaemia allele, causing HbS/β‐thalassaemia. (<a href="./references#CD012082-bbs2-0062" title="ReesDC , WilliamsTN , GladwinMT . Sickle‐cell disease. Lancet2010;376(9757):2018‐31. ">Rees 2010</a>). People who have inherited a thalassaemia null mutation (HbSβ°) have a disease that is clinically indistinguishable from sickle cell anaemia, whereas people with HbSβ<sup>+</sup> thalassaemia have a milder disorder. In high‐income nations, people with SCD are expected to live into their 40's, 50's and beyond, whereas in low‐income countries including some African nations it is estimated that between 50% to 90% of children born with HbSS die before their fifth birthday (<a href="./references#CD012082-bbs2-0043" title="GravitzL , PincockS . Sickle‐cell disease. Nature2014;515(7526):S1. ">Gravitz 2014</a>; <a href="./references#CD012082-bbs2-0044" title="GrosseSD , OdameI , AtrashHK , AmendahDD , PielFB , WilliamsTN . Sickle cell disease in Africa. A neglected cause of early childhood mortality. American Journal of Preventive Medicine2011;41(6S4):S398‐S405. ">Grosse 2011</a>). </p> <p>People with SCD experience low oxygen levels, acidity and cellular dehydration, which cause the HbS molecules polymerise and begin to distort the red blood cells (RBCs) taking on the appearance of sickle‐shaped cells. The main determinant of disease severity is the rate and extent of this HbS polymerisation (<a href="./references#CD012082-bbs2-0062" title="ReesDC , WilliamsTN , GladwinMT . Sickle‐cell disease. Lancet2010;376(9757):2018‐31. ">Rees 2010</a>). This is exemplified by co‐inheritance of genetic factors that affect the intracellular HbS or fetal haemoglobin concentration, e.g., the protective effects of co‐inherited α‐thalassaemia (<a href="./references#CD012082-bbs2-0064" title="RumaneyMB , Ngo BitounguiVJ , VorsterAA , RamesarR , KengneAP , NgogangJ , et al. The co‐inheritance of alpha‐thalassemia and sickle cell anemia is associated with better hematological indices and lower consultations rate in Cameroonian patients and could improve their survival. PLoS ONE2014;9(6):e100516. ">Rumaney 2014</a>; <a href="./references#CD012082-bbs2-0073" title="SteinbergMH , SebastiniP . Genetic modifiers of sickle cell disease. American Journal of Hematology2012;87(8):795‐803. ">Steinberg 2012</a>) or hereditary persistence of fetal haemoglobin (<a href="./references#CD012082-bbs2-0030" title="AkinsheyeI , AlsultanA , SolovieffN , NgoD , BaldwinCT , SebastianiP , et al. Fetal hemoglobin in sickle cell anemia. Blood2011;118(1):19‐27. ">Akinsheye 2011</a>; <a href="./references#CD012082-bbs2-0073" title="SteinbergMH , SebastiniP . Genetic modifiers of sickle cell disease. American Journal of Hematology2012;87(8):795‐803. ">Steinberg 2012</a>). Sickling of RBCs results in two main events: blockage of blood flow resulting in organ and tissue ischaemia; and haemolytic anaemia (<a href="./references#CD012082-bbs2-0072" title="SparkenbaughE , PawlinskiR . Interplay between coagulation and vascular inflammation in sickle cell disease. British Journal of Haematology2013;162(1):3‐14. ">Sparkenbaugh 2013</a>). Both of these processes are thought to lead to increased inflammation and an increased tendency to develop a clot (<a href="./references#CD012082-bbs2-0042" title="FrenettePS , AtwehGF . Sickle cell disease: old discoveries, new concepts and future promise. Journal of Clinical Investigation2007;117(4):850‐8. ">Frenette 2007</a>; <a href="./references#CD012082-bbs2-0062" title="ReesDC , WilliamsTN , GladwinMT . Sickle‐cell disease. Lancet2010;376(9757):2018‐31. ">Rees 2010</a>). Blockage of blood flow is mediated via a dynamic interaction between sticky HbS containing red cells, the vessel wall, and white cells (<a href="./references#CD012082-bbs2-0062" title="ReesDC , WilliamsTN , GladwinMT . Sickle‐cell disease. Lancet2010;376(9757):2018‐31. ">Rees 2010</a>). Sickled RBCs also have a shorter lifespan of 10 to 12 days versus 120 days for normal RBCs due to intravascular and extravascular haemolysis, leading to anaemia (<a href="./references#CD012082-bbs2-0049" title="KatoGJ , McGowanV , MachadoRF , LittleJA , MorrisCR , et al. Lactate dehydrogenase as a biomarker of hemolysis‐associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood2006;107(6):2279‐85. ">Kato 2006a</a>). Chronic intravascular haemolysis leads to decreased levels of nitric oxide within the blood, development of pulmonary hypertension and ischaemic strokes (<a href="./references#CD012082-bbs2-0049" title="KatoGJ , McGowanV , MachadoRF , LittleJA , MorrisCR , et al. Lactate dehydrogenase as a biomarker of hemolysis‐associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood2006;107(6):2279‐85. ">Kato 2006a</a>; <a href="./references#CD012082-bbs2-0050" title="KatoGJ , HsiehM , MachadoR , TaylorJ 6th , LittleJ , ButmanJA , et al. Cerebrovascular disease associated with sickle cell pulmonary hypertension. American Journal of Hematology2006;81(7):503‐10. ">Kato 2006b</a>). </p> </section> <section id="CD012082-sec-0018"> <h3 class="title" id="CD012082-sec-0018">Description of the interventions</h3> <p>Individuals with SCD experience a variety of both acute and chronic complications as a result of the disease. Complications may be quite severe and include acute chest syndrome (ACS), acute cerebrovascular accident (CVA), acute and chronic pain, ocular or renal complications, chronic leg ulcers, priapism, avascular necrosis, pulmonary hypertension, and chronic respiratory and hepatobiliary complications (<a href="./references#CD012082-bbs2-0040" title="US Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute Expert Panel Report 2014. Evidence‐based management of sickle cell disease: Expert Panel Report, 2014. http://www.nhlbi.nih.gov/health‐pro/guidelines/sickle‐cell‐disease‐guidelines (accessed 01 August 2015). ">Expert Panel Report 2014</a>). The course of the disease is highly variable with some people having a relatively mild course with fewer complications and longer survival and others having frequent severe complications and shortened survival. RBC transfusions are a mainstay of treatment in SCD and 90% of adults will have received at least one RBC transfusion (<a href="./references#CD012082-bbs2-0037" title="ChouST . Transfusion therapy for sickle cell disease: a balancing act. Hematology2013;2013:439‐46. ">Chou 2013a</a>). </p> <p>RBC transfusions can be given to treat complications of SCD, e.g. ACS (this often involves a single transfusion episode), or they can be part of a regular long‐term transfusion programme to prevent complications of SCD (<a href="./references#CD012082-bbs2-0085" title="YawnBP , BuchananGR , Afenyi‐AnnanAN , BallasSK , HasselKL , JamesAH , et al. Management of sickle cell disease: summary of the 2014 evidence‐based report by expert panel members. JAMA2014;312(10):1033‐48. ">Yawn 2014</a>). People with SCD can be placed on a long‐term transfusion programme to prevent recurrence of a complication they have already experienced or to prevent the first episode of a complication, e.g. stroke in children with abnormal transcranial dopplers (<a href="./references#CD012082-bbs2-0028" title="AdamsRJ , McKieVC , HsuL , FilesB , VichinskyE , PegelowC , et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. New England Journal of Medicine1998;339(1):5‐11. ">Adams 1998</a>). Both a single transfusion episode or long‐term transfusion programmes can use either a simple transfusion regimen or an exchange transfusion regimen (<a href="./references#CD012082-bbs2-0048" title="JosephsonCD , SuLL , HillyerKL , HillyerCD . Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfusion Medicine Reviews2007;21(2):118‐32. ">Josephson 2007</a>). In addition to restrictive (to increase the total haemoglobin) or liberal (to decrease the haemoglobin S level below a specified percentage) RBC transfusions, other therapies may include drug therapy as an alternative to RBC transfusions such as hydroxyurea for anaemia, pain and ACS; or adjuvant RBC transfusion therapies such as analgesics for pain, oxygen for chest complications and fluid replacement for pain crisis. </p> <p>RBC transfusions have reduced complications and improved the quality of life in people with SCD (<a href="./references#CD012082-bbs2-0083" title="WareRE , deMontalembertM , TshiloloL , AbboudMR . Sickle cell disease. Lancet2017;390:311‐23. ">Ware 2017</a>); however, they can also cause adverse events (AEs) that are sometimes serious (<a href="./references#CD012082-bbs2-0048" title="JosephsonCD , SuLL , HillyerKL , HillyerCD . Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfusion Medicine Reviews2007;21(2):118‐32. ">Josephson 2007</a>). The benefits of transfusion therapy must be balanced against risks including infections, iron overload, alloimmunisation, and acute or delayed haemolytic transfusion reactions (<a href="./references#CD012082-bbs2-0037" title="ChouST . Transfusion therapy for sickle cell disease: a balancing act. Hematology2013;2013:439‐46. ">Chou 2013a</a>, <a href="./references#CD012082-bbs2-0038" title="ChouST , JacksonT , VegeS , Smith‐WhiteleyK , FriedmanDF , WesthoffCM . High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh‐matched minority donors. Blood2013;122(6):1062‐71. ">Chou 2013b</a>; <a href="./references#CD012082-bbs2-0061" title="PorterJ , GarbowskiM . Consequences and management of iron overload in sickle cell disease. ASH Education Program Book2013;1:447‐56. ">Porter 2013</a>; <a href="./references#CD012082-bbs2-0065" title="ScheunemannLP , AtagaKI . Delayed hemolytic transfusion reaction in sickle cell disease. American Journal of the Medical Sciences2010;339(3):266‐9. ">Scheunemann 2010</a>; <a href="./references#CD012082-bbs2-0076" title="UbesieA , EmodiI , IkefunaA , IlechukwuG , IlechukwuG . Prevalence of human immunodeficiency virus transmission among transfused children with sickle cell anemia in Enugu Nigeria. Annals of Medical and Health Sciences Research2012;2(2):109‐13. ">Ubesie 2012</a>). </p> </section> <section id="CD012082-sec-0019"> <h3 class="title" id="CD012082-sec-0019">How the intervention might work</h3> <p>Transfusing normal RBCs to people with SCD who are anaemic, can increase the oxygen carrying capacity of the blood (<a href="./references#CD012082-bbs2-0075" title="SwerdlowPS . Red cell exchange in sickle cell disease. Hematology2006;2006:48‐53. ">Swerdlow 2006</a>; <a href="./references#CD012082-bbs2-0078" title="WagnerMH , BerryRB . A patient with sickle cell disease and a low baseline sleeping oxygen saturation. Journal of Clinical Sleep Medicine2007;3(3):313‐5. ">Wagner 2007</a>). </p> <p>Sickled RBCs increase blood viscosity (resistance to flow) through intrinsic properties of the sickled cells, as well as through abnormal interactions of these cells with white cells, platelets, the vessel wall, and clotting factors. Transfusion of normal donor RBCs is used to mitigate these effects (<a href="./references#CD012082-bbs2-0085" title="YawnBP , BuchananGR , Afenyi‐AnnanAN , BallasSK , HasselKL , JamesAH , et al. Management of sickle cell disease: summary of the 2014 evidence‐based report by expert panel members. JAMA2014;312(10):1033‐48. ">Yawn 2014</a>) and several regimens are used in current clinical practice. These include 'simple' transfusion in which normal RBCs are given to decrease anaemia without removal of the individual's blood. In people with SCD who do not have severe anaemia simple RBC transfusions can cause hyperviscosity syndrome because they raise the haemoglobin, but only marginally lower the HbS percentage (<a href="./references#CD012082-bbs2-0066" title="SchmalzerEA , LeeJO , BrownAK , UsamiS , ChienS . Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels. Implications for transfusion. Transfusion1987;27(3):228‐33. ">Schmalzer 1987</a>). </p> <p>Exchange transfusion involves removing some of the individual's own blood and transfusing allogeneic blood, thereby lowering the concentration of HbS through dilution. This reduces the effects of a given haemoglobin level on blood viscosity. A full exchange transfusion involves a full blood volume exchange by manual or automated apheresis, this allows for rapid lowering of the HbS level to 30% or less, and correction of anaemia. A partial (limited) exchange transfusion refers to manual removal of some of the individual's own blood, this is less effective in lowering the HbS level but is more easily performed when automated exchange is not available. In order to lower the HbS below 30%, repeat partial exchange transfusions may be necessary. </p> <p>A restrictive (conservative) transfusion policy involves giving a simple transfusion to reach a pre‐specified target haemoglobin. </p> <p>A liberal (aggressive) transfusion policy involves giving a transfusion to reduce HbS percentage below a pre‐specified threshold. In people with SCD with severe anaemia simple blood transfusions can lead to a significant reduction in HbS percentage without the need for an exchange transfusion. In a trial of people with SCD due to have an operation, 36% of participants randomised to the aggressive transfusion arm (to reduce HbS to 30% or below) were treated with a simple transfusion pre‐operatively (<a href="./references#CD012082-bbs2-0077" title="VichinskyEP , HaberkernCM , NeumayrL , EarlesAN , BlackD , KoshyM , et al. A comparison of conservative and aggressive transfusion regimes in the perioperative management of sickle cell disease. New England Journal of Medicine1995;333(4):206‐13. ">Vichinsky 1995</a>). </p> </section> <section id="CD012082-sec-0020"> <h3 class="title" id="CD012082-sec-0020">Why it is important to do this overview</h3> <p>For people with SCD, RBC transfusions can reduce end‐organ damage and be life saving by treating or preventing life‐threatening complications (e.g. treating acute aplastic crisis or preventing strokes in children), but it may also be associated with serious complications. There are many indications for transfusion therapy in SCD; however, because of the inherent risks, an understanding of the evidence for its use for specific SCD complications is required. There is also wide variation in transfusion practices in SCD and some indications for transfusion therapy have been studied in randomised controlled trials (RCTs) and others based on observational studies or anecdotal evidence (<a href="./references#CD012082-bbs2-0048" title="JosephsonCD , SuLL , HillyerKL , HillyerCD . Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfusion Medicine Reviews2007;21(2):118‐32. ">Josephson 2007</a>). Several Cochrane Reviews addressing SCD complications such as stroke (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>), ACS (<a href="./references#CD012082-bbs2-0017" title="AlhashimiD , FedorowiczZ , AlhashimiF , DastgiriS . Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD007843.pub2] ">Alhashimi 2010</a>), chronic chest complications (<a href="./references#CD012082-bbs2-0003" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , HambletonIR , ChoG . Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD008360.pub4; CD008360] ">Estcourt 2016a</a>), and preoperative transfusions (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>) have been published. Providing an overview of these reviews will make the information more accessible for people with SCD and healthcare professionals. </p> <p>In this overview we identified gaps in the evidence base to inform recommendations for new systematic reviews and clinical trials research. We also summarized evidence on reported outcomes to make recommendations for standardizing outcomes for new research and reviews. We appraised the reviews and summarized their quality and strength of evidence and considered both common indications for transfusion as well as indications where transfusion is not commonly indicated but may be occasionally used. We also considered the type of transfusion, restrictive or liberal, that may be most appropriate for a particular complication and whether transfusions are intermittent or long‐term and used for prevention or treatment. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012082-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012082-sec-0021"></div> <p>To summarize the evidence in Cochrane Reviews of the effectiveness and safety of RBC transfusions versus no transfusion, or restrictive (to increase the total haemoglobin) versus liberal (to decrease the haemoglobin S level below a specified percentage) transfusion, for treating or preventing complications experienced by people with SCD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012082-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012082-sec-0022"></div> <section id="CD012082-sec-0023"> <h3 class="title">Criteria for considering reviews for inclusion</h3> <section id="CD012082-sec-0024"> <h4 class="title">Types of reviews</h4> <p>We included Cochrane Reviews of RCTs or quasi‐RCTs published in the <i>Cochrane Database of Systematic Reviews</i> part of the Cochrane Library<i>,</i> that reviewed the use of RBC transfusions for treatment or prevention of the various complications of SCD such as stroke, ACS, chronic chest complications. </p> </section> <section id="CD012082-sec-0025"> <h4 class="title">Participants</h4> <p>We included Cochrane Reviews of people of all ages with known SCD.</p> </section> <section id="CD012082-sec-0026"> <h4 class="title">Interventions</h4> <p>We included Cochrane Reviews that compare the following.</p> <p> <ol id="CD012082-list-0001"> <li> <p>RBC transfusions versus no RBC transfusions</p> </li> <li> <p>RBC transfusions plus standard care versus standard care (e.g. analgesia, intravenous fluids, oxygen) </p> </li> <li> <p>RBC transfusions versus disease‐modifying drug therapy (e.g. hydroxyurea)</p> </li> <li> <p>Restrictive (to increase the total haemoglobin) versus liberal (to decrease the haemoglobin S level below a specified percentage) RBC transfusion strategy </p> </li> </ol> </p> <section id="CD012082-sec-0027"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012082-list-0002"> <li> <p>Mortality from any cause</p> </li> <li> <p>Serious AEs (SAEs) as a result of SCD‐related complications (e.g. neurological, ophthalmological, respiratory, orthopaedic, vascular, hepatic or renal complications, vaso‐occlusive pain crisis, priapism, infections). We reported a summary count of total SAEs related to SCD‐related complications, as well as reporting the types of complications that make up this summary measure (SAE defined in <a href="#CD012082-sec-0100">Published notes</a>). </p> </li> <li> <p>AEs (serious and non‐serious) associated with transfusions (e.g. acute and delayed transfusion reactions, transfusion‐related acute lung injury, transfusion‐associated circulatory overload, transfusion‐associated dyspnoea, alloimmunisation, iron overload, problems of venous access). We reported a summary count of all adverse events related to transfusions, as well as reporting the types of complications that make up this summary measure. </p> </li> </ol> </p> </section> <section id="CD012082-sec-0028"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012082-list-0003"> <li> <p>Other AEs as a result of SCD‐related complications</p> </li> <li> <p>RBC transfusion requirement (number of units or mL required or number of RBC transfusion episodes) </p> </li> <li> <p>Quality of life (using validated instruments)</p> </li> <li> <p>Hospital length of stay including length of stay in critical care and hospital readmissions</p> </li> </ol> </p> </section> </section> </section> <section id="CD012082-sec-0029"> <h3 class="title">Search methods for identification of reviews</h3> <p>We performed a search of the <i>Cochrane Database of Systematic Reviews</i> (<a href="http://www.cochranelibrary.com/cochrane-database-of-systematic-reviews/table-of-contents-cdsr.html" target="_blank">http://www.cochranelibrary.com/cochrane‐database‐of‐systematic‐reviews/table‐of‐contents‐cdsr.html</a>) to 04 February 2017. We used the text words: sickle cell disease, and blood transfusion in the title, abstract and keywords. We also used MeSH descriptors such as,'anemia. sickle cell', 'erythrocyte transfusion'. We focused on retrieving all relevant published systematic reviews and identified published protocols (<i>see</i><a href="./appendices#CD012082-sec-0093">Appendix 1</a> for <i>Cochrane Database of Systematic Reviews</i> search strategy). </p> </section> <section id="CD012082-sec-0030"> <h3 class="title" id="CD012082-sec-0030">Data collection and analysis</h3> <section id="CD012082-sec-0031"> <h4 class="title">Selection of reviews</h4> <p>Two authors independently evaluated all reviews retrieved in the search for eligibility using the criteria listed in the <a href="#CD012082-sec-0023">Criteria for considering reviews for inclusion</a> in the above section. We resolved conflicts through discussion to arrive at a consensus. </p> </section> <section id="CD012082-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>Two overview authors (LE, PF) independently extracted data. We extracted data on forms designed to summarise key characteristics of each review. We abstracted data on the objectives of each review, any diagnostic criteria, inclusion criteria (e.g. participants, details of intervention, comparison, outcomes, type of trials and length of follow‐up), date of last search, frequency of updates, number of included trials, number of participants for each comparison and statistical outcome data. We also included narrative text of the results if meta‐analyses using the Review Manager software were not available (<a href="./references#CD012082-bbs2-0063" title="The Nordic Cochrane Centre. Review Manager (RevMan). Version Version 5.3. Copenhagen: The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p>We extracted data from included reviews where possible, but we would have contacted the review authors or extracted data from the relevant trials ourselves if information was missing or unclear. Data obtained from authors or trials would have been integrated with data obtained from the review and the source of the data would have been highlighted. We contacted the relevant Cochrane review group when information was unclear. </p> <p>We reported these data in a series of tables including 'Characteristics of included reviews' tables (<a href="#CD012082-tbl-0001">Table 1</a>; <a href="#CD012082-tbl-0002">Table 2</a>; <a href="#CD012082-tbl-0003">Table 3</a>). We reported details of the quality assessment of individual reviews using AMSTAR in tables (<a href="#CD012082-tbl-0004">Table 4</a>; <a href="#CD012082-tbl-0005">Table 5</a>; <a href="#CD012082-tbl-0006">Table 6</a>) as recommended in chapter 22 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012082-bbs2-0046" title="HigginsJPT , GreenS (editors) . Chapter 22: Overviews of reviews. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). We also reported primary outcomes in a summary of findings overview table (<a href="#CD012082-fig-0001">Figure 1</a>); and summary of findings tables based on the Grade assessments in the reviews (<a href="#CD012082-tbl-0007">Table 7</a>; <a href="#CD012082-tbl-0008">Table 8</a>; <a href="#CD012082-tbl-0009">Table 9</a>). </p> <div class="figure" id="CD012082-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD012082-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012082.pub2/media/CDSR/CD012082/image_n/nCD012082-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <div class="table" id="CD012082-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of reviews with an RBC transfusion intervention</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review</b> </p> <p><b>(Included trials)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objectives</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Date assessed as up to date / Date of last search</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study Population</b> </p> <p><b>Number of participants / type of SCD / age of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of included trials / study design / location of studies / duration of follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review outcomes for which data are reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review outcomes for which data are not reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a> </p> <p><b>Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease</b> </p> <p>(SIT (<a href="./references#CD012082-bbs2-0039" title="DeBaunMR , MGordon , RCMcKinstry , MJNoetzel , DAWhite , SASarnaik , et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. New England Journal of Medicine2014;371(8):699‐710. ">DeBaun 2014</a><b>)</b>; STOP (<a href="./references#CD012082-bbs2-0028" title="AdamsRJ , McKieVC , HsuL , FilesB , VichinskyE , PegelowC , et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. New England Journal of Medicine1998;339(1):5‐11. ">Adams 1998</a><b>)</b>; STOP2 (<a href="./references#CD012082-bbs2-0029" title="AdamsRJ , BrambillaD . Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. New England Journal of Medicine2005;353(26):2769‐78. ">Adams 2005</a><b>)</b>; SWITCH (<a href="./references#CD012082-bbs2-0081" title="WareRE , HelmsRW , SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood2012;119(17):3925‐32. ">Ware 2012</a><b>)</b>; TWITCH (<a href="./references#CD012082-bbs2-0082" title="WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia ‐ TCD with Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open‐label, phase 3, non‐inferiority trial. Lancet2016;387(10019):661‐70. ">Ware 2016</a><b>)</b>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To determine whether chronic blood transfusion in people with SCD:</p> <p>1. reduce occurrence of stroke (primary prevention);</p> <p>2. reduce recurrence of stroke (secondary prevention;</p> <p>3. reduce mortality;</p> <p>4. reduce other complications of SCD including pain crises, ACS and splenic sequestration;</p> <p>5. are associated with unacceptable adverse events or costs.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>04 April 2016 / 04 April 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chronic blood transfusion regimens to maintain HbS level &lt; 30% (+/‐ iron chelation)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Standard care</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 405 participants</p> <p>N = 130 children with abnormal TCD velocities and previous history of TIA or stroke (STOP) </p> <p>N= 79 children with normalised TCD velocities (STOP 2)</p> <p>N = 196 children with SCIs and normal TCD velocities (SIT)</p> <p>All 3 trials enrolled children with HbSS or Hb Sβº</p> <p>% with either 1 not clear majority HbSS</p> <p><b>Mean (SD) age (years)</b>: </p> <p>STOP: 8.3 (3.3);</p> <p>STOP 2: 8.6 (1.2);</p> <p>SIT: 8 (3).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 multicentre trials</p> <p>conducted in USA and Canada (STOP; STOP 2)</p> <p>Mean (SD) length of follow‐up: transfusion arm: 21.0 (5.7) months; standard care: 18.3 (7.0) months (STOP). </p> <p>Median time from randomisation to an end‐point event was 3.2 months (range, 2.1 to 10.1), and the mean (SD) was 4.5 (2.6) months (STOP 2). </p> <p>Both studies were stopped early due to safety concerns.</p> <p>1 multicentre trial conducted in USA, Canada, France and UK (SIT)</p> <p>Children were followed for a median of 3 years.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> <p>· Incidence of clinical stroke</p> <p>· Mortality</p> <p>· Transfusion‐related complications</p> <p><b>Secondary outcomes</b> </p> <p>· Incidence of TIA</p> <p>· Haemoglobin level and haemoglobin S percentage</p> <p>· Measure of neurological impairment</p> <p>· Incidence of other sickle cell complications</p> <p>· QoL, inpatient stay, immobility and disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measures of organ damage</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chronic blood transfusion regimens to maintain HbS level &lt; 30% (+/‐ iron chelation)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hydroxyurea with phlebotomy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 254 participants</p> <p>N = 133 history of stroke, chronic transfusion treatment and iron overload (SWiTCH)</p> <p>N = 121 children with abnormal TCD velocities but no severe vasculopathy on MRI/MRA, who have received at least 1 year of RBC transfusions (TWITCH) </p> <p><b>HbSS:</b> </p> <p>SWITCH: transfusion: 100% hydroxyurea : 99%</p> <p>TWITCH: transfusion: 97% hydroxyurea: 100%</p> <p><b>Mean (SD) age (years)</b>: SWITCH: transfusion: 13.3 (3.8); hydroxyurea: 13.0 (4.0); TWITCH: transfusion: 9.5 (0.68); hydroxyurea: 9.7 (3.2). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 multicentre trials with 254 participants</p> <p>Conducted in USA and Canada</p> <p>Total duration of study treatment was: 30 months after randomisation, with a final study visit scheduled 6 months after discontinuation of study treatments (SWiTCH); 24 months after randomisation with a 6‐month visit after completing exit studies (TWITCH). </p> <p>Both studies were stopped early, 1 for futility (SWITCH) and 1 for non‐inferiority (TWITCH). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> <p>· Mortality</p> <p>· Incidence of clinical stroke</p> <p>· Transfusion‐related complications</p> <p><b>Secondary outcomes</b> </p> <p>· Incidence of TIA or silent infarction</p> <p>· Haemoglobin level and haemoglobin S percentage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measure of neurological impairment</p> <p>Incidence of other SCD complications</p> <p>QoL</p> <p>Inpatient stay</p> <p>Immobility and disability</p> <p>Measures of organ damage</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a> </p> <p><b>Interventions for preventing silent cerebral infarcts in people with sickle cell disease </b> </p> <p>(SIT (<a href="./references#CD012082-bbs2-0039" title="DeBaunMR , MGordon , RCMcKinstry , MJNoetzel , DAWhite , SASarnaik , et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. New England Journal of Medicine2014;371(8):699‐710. ">DeBaun 2014</a><b>)</b>; STOP (<a href="./references#CD012082-bbs2-0028" title="AdamsRJ , McKieVC , HsuL , FilesB , VichinskyE , PegelowC , et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. New England Journal of Medicine1998;339(1):5‐11. ">Adams 1998</a><b>)</b>; STOP2 (<a href="./references#CD012082-bbs2-0029" title="AdamsRJ , BrambillaD . Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. New England Journal of Medicine2005;353(26):2769‐78. ">Adams 2005</a><b>)</b>; SWITCH (<a href="./references#CD012082-bbs2-0081" title="WareRE , HelmsRW , SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood2012;119(17):3925‐32. ">Ware 2012</a><b>)</b>; TWITCH (<a href="./references#CD012082-bbs2-0082" title="WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia ‐ TCD with Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open‐label, phase 3, non‐inferiority trial. Lancet2016;387(10019):661‐70. ">Ware 2016</a><b>)</b>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>To assess the effectiveness of red blood transfusions and hydroxyurea alone or in combination and HSCT to reduce or prevent SCI in people with SCD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>19 September 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chronic blood transfusion regimens to maintain HbS level &lt; 30% (+/‐ iron chelation)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Standard care</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 405 participants</p> <p>N = 130 children with abnormal TCD velocities and previous history of TIA or stroke (STOP) </p> <p>N= 79 children with normalised TCD velocities (STOP 2)</p> <p>N = 196 children with SCI and normal TCD velocities (SIT)</p> <p>All 3 trials enrolled children with <b>HbSS or Hb Sβº</b> </p> <p>% with either 1 not clear majority HbSS</p> <p><b>Mean (SD) age (years)</b>: STOP: 8.3 (3.3); STOP 2: 8.6 (1.2); SIT: 8 (3). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 multicentre trials</p> <p>conducted in USA and Canada</p> <p>(STOP, STOP 2)</p> <p>Mean (SD) length of follow‐up: transfusion arm: 21.0 (5.7) months; Standard care: 18.3 (7.0) months (STOP) </p> <p>Median time from randomisation to an end‐point event was 3.2 months (range, 2.1 to 10.1), and the mean (SD) was 4.5 (2.6) months (STOP 2). </p> <p>Both studies terminated early.</p> <p>1 multicentre trial conducted in USA, Canada, France and UK (SIT)</p> <p>Children were followed for a median of 3 years.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> <p>· Proportion of participants developing new or progressive SCI lesions on MRI</p> <p>· All‐cause mortality</p> <p>· SAEs associated with different therapies or SCD</p> <p><b>Secondary outcomes</b> </p> <p>· Clinical stroke (according to short‐, medium‐, and long‐term outcomes)</p> <p>· Cognitive function as assessed by validated scales (such as Wechsler scales) from baseline and at various time intervals as reported in studies (at least 6 months) </p> <p>· QoL as assessed by validated scales (at least 6 months)</p> <p>· Any AEs associated with different therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL and</p> <p>Cognitive function were not reported in STOP and STOP 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chronic blood transfusion regimens to maintain HbS level &lt; 30% (+/‐ iron chelation)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hydroxyurea with phlebotomy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 254 participants</p> <p>N = 133 history of stroke, chronic transfusion treatment and iron overload (SWiTCH)</p> <p>N = 121 children with abnormal TCD velocities but no severe vasculopathy on MRI/MRA, who have received at least 1 year of RBC transfusions (TWITCH) </p> <p><b>HbSS</b>: </p> <p>SWITCH: transfusion: 100% hydroxyurea : 99%</p> <p>TWITCH: 97% transfusion: 97% hydroxyurea: 100%</p> <p><b>Mean (SD) age (years)</b>: SWITCH: transfusion: 13.3 (3.8); hydroxyurea: 13.0 (4.0); TWITCH: transfusion: 9.5 (2.68); hydroxyurea: 9.7 (3.2). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 multicentre trials with 254 participants</p> <p>Conducted in USA and Canada</p> <p>Total duration of study treatment was:</p> <p>30 months after randomisation, with a final study visit scheduled 6 months after discontinuation of study treatments (SWiTCH); </p> <p>24 months after randomisation with a 6 month visit after completing exit studies (TWITCH).</p> <p>Both studies terminated early.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> <p>· Proportion of participants developing new or progressive SCI lesions on MRI</p> <p>· All‐cause mortality</p> <p>· SAEs associated with different therapies or SCD</p> <p><b>Secondary outcomes</b> </p> <p>· Clinical stroke (according to short‐, medium‐, and long‐term outcomes)</p> <p>· Any AEs associated with different therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive function as assessed by validated scales (such as Wechsler scales) from baseline and at various time intervals as reported in studies (at least 6 months) </p> <p>QoL as assessed by validated scales (at least 6 months)</p> <p>SWiTCH did not report any AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>Preoperative blood transfusions for sickle cell disease </p> <p>(<a href="./references#CD012082-bbs2-0032" title="Al‐JaouniSK , Al‐MuhayawiSM , QariMH , NawasMA , Al‐MazrooaA . Randomized clinical trial to evaluate the safety of avoiding pre‐operative transfusion in sickle cell anemia. Bahrain Medical Bulletin2006;28(4):164‐7. [] ">Al‐Jaouni 2006</a><b>; </b><a href="./references#CD012082-bbs2-0047" title="HowardJ , MalfroyM , LlewelynC , ChooL , HodgeR , JohnsonT , et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet2013;381:930‐8. ">Howard 2013</a><b>; </b><a href="./references#CD012082-bbs2-0077" title="VichinskyEP , HaberkernCM , NeumayrL , EarlesAN , BlackD , KoshyM , et al. A comparison of conservative and aggressive transfusion regimes in the perioperative management of sickle cell disease. New England Journal of Medicine1995;333(4):206‐13. ">Vichinsky 1995</a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>To determine whether there is evidence that preoperative blood transfusion in elective or emergency surgery: </p> <p>a. reduces mortality;</p> <p>b. reduces complications directly related to the surgical procedure, such as local infection and bleeding; </p> <p>c. reduces serious perioperative complications including pain, ACS and the postoperative frequency and severity of infections; </p> <p>d. is associated with severe AEs (as reported in the included studies).</p> <p>2. To compare the effectiveness of different transfusion regimens (aggressive or conservative) if preoperative transfusions </p> <p>are indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9 July 2015 / 17 March 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aggressive, designed to decrease the haemoglobin S level to less than 30%</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conservative, designed to increase the haemoglobin level to 100 g/L</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 551 participants</p> <p><b>HbSS</b>: 551 (100%) </p> <p>75% aged &lt; 20 years; 25% aged 20 years or older.</p> <p>Review reports on cholecystectomy (N = 230) and tonsillectomy/ adenoidectomy (N = 107) subgroups only due to unit of analysis issues with re‐randomisation in the trial. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 parallel RCT in USA</p> <p>30‐day follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> <p>· Perioperative mortality (all‐cause)</p> <p>· Serious complications related to:</p> <p>§ sickle cell disease</p> <p>§ surgery</p> <p>§ transfusion</p> <p><b>Secondary outcomes</b> </p> <p>· Other transfusion‐related complications</p> <p>· Haemoglobin level and haemoglobin S percentage</p> <p>· Number of units or volume (mL) of RBCs infused and, where known for exchange transfusions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>· Length of stay</p> <p>· QoL</p> <p>· Measures of organ damage</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Simple or exchange transfusion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No preoperative transfusion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 436 participants (2 re‐randomised)</p> <p>HbSS = 337 (77%)</p> <p>HbSβº = 76 (17%)</p> <p>HbSβ<sup>+</sup> = 14 (4%) </p> <p>HbSC = 9 (2%)</p> <p>247 children (57%) (aged up to 16 or 18 years)</p> <p>189 adults (43%) (only 6 (1%) aged 40 years or older)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 parallel RCTs:</p> <p>1 multinational (22 centres in Canada, Ireland, Netherlands and the UK); 1 in Saudi Arabia. </p> <p>1 study reports a 30‐day follow‐up the other does not report study duration.</p> <p>Multinational study stopped early before full enrolment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> <p>· Perioperative mortality (all‐cause)</p> <p>· Serious complications related to:</p> <p>§ sickle cell disease</p> <p>§ surgery</p> <p>§ transfusion</p> <p><b>Secondary outcomes</b> </p> <p>· Other transfusion‐related complications</p> <p>· Length of stay (reported in one trial only)</p> <p>· QoL</p> <p>(reported in 1 trial only)</p> <p>· Haemoglobin level and haemoglobin S percentage (reported in 1 trial only)</p> <p>· Number of units or volume (mL) of RBCs infused and, where known for exchange transfusions (reported in 1 trial only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>· Measures of organ damage</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy </p> <p><b>(</b><a href="./references#CD012082-bbs2-0051" title="KoshyM , BurdL , WallaceD , MoawadA , BaronJ . Prophylactic red‐cell transfusions in pregnant patients with sickle cell disease. New England Journal of Medicine1988;319:1447–52. ">Koshy 1988</a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the benefits and harms of a policy of prophylactic versus</p> <p>selective blood transfusion in pregnant women with SCD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 May 2016 /30 May 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prophylactic transfusion:</b> </p> <p><b>to optimise Hb concentration to a specified level</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Selective (emergency) transfusion:</b> </p> <p><b>when indicated by specific complication or a critically low level of Hb concentration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 72</p> <p>pregnant women with sickle cell anaemia (genotype HbSS) before 28 weeks of gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 multicentre study conducted in 6 secondary and university hospitals in the USA.</p> <p>Final evaluation conducted 6 weeks postpartum.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> <p>· Maternal death</p> <p>· Severe maternal morbidity (e.g. organ failure, pulmonary embolism, fat embolism, stroke, intensive care unit admission; or as defined by trial authors) </p> <p>· Perinatal death</p> <p><b>Secondary outcomes</b> </p> <p><b>Mother</b> </p> <p>· Sickle cell crisis (due to vaso‐occlusion, sequestration or</p> <p>· haemolysis)</p> <p>· Total units of blood transfused</p> <p>· Blood transfusion reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mother</b> </p> <p>· Iron overload</p> <p>· postpartum haemorrhage</p> <p>· Cumulative duration of hospital stay</p> <p><b>Infant</b> · </p> <p>· Admission to neonatal intensive care</p> <p>· Haemolytic disease of the newborn</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0002" title="DastgiriS , DolatkhahR . Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD007843.pub3; CD007843] ">Dastgiri 2016</a> </p> <p><b>Blood transfusions for treating acute chest syndrome in people with Sickle cell disease</b> </p> <p>(PROACTIVE (<a href="./references#CD012082-bbs2-0074" title="StylesL , WagerCG , LabotkaRJ , Smith‐WhitleyK , ThompsonAA , LanePA , et al. Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE).. British Journal of Haematology2012;157(5):627‐36. ">Styles 2012</a><b>))</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the effectiveness of blood transfusions, simple and exchange, for treating ACS by comparing improvement in symptoms and clinical outcomes against standard care. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 July 2016/ 25 April 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>· Confirmed diagnosis of SCD: SS; SC; Sβº; Sβ<sup>+</sup> </p> <p>· Male or female</p> <p>· All ages</p> <p>· Any setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>· RBC transfusions (simple or exchange)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>· Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study met the inclusion criteria but no study results reported as out of 237 enrolled only 10 were randomised – the rest observational. </p> <p>In the study publication they report 0/4 in transfusion arm no ACS and 2/6 in standard care arm with ACS. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dastigiri 2016 Blood transfusions for treating ACS in people with SCD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the effectiveness of blood transfusions, simple and exchange, for treating ACS by comparing improvement in symptoms and clinical outcomes against standard care. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACS: acute chest syndrome<br/> AEs: adverse events<br/> Hb: haemoglobin<br/> MRI/MRA: magnetic resonance imaging/magnetic resonance angiography<br/> QoL: quality of life<br/> RBC: red blood cell<br/> SAEs: serious adverse events<br/> SCD: sickle cell disease<br/> SCI: silent cerebral infarcts<br/> SD: standard deviation<br/> TCD: transcranial doppler<br/> TIA: transient ischaemic attack </p> </div> </div> <div class="table" id="CD012082-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of reviews with other interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review</b> </p> <p><b>(Included trials)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objectives</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Date assessed as up to date / Date of last search</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study Population</b> </p> <p><b>Number of participants/ type of sickle cell/ age of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of included trials/study design/location of studies/duration of follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0015" title="RoyNB , FortinPM , BullKR , DoreeC , TrivellaM , HopewellS , et al. Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database of Systematic Reviews 201, Issue 7. [DOI: 10.1002/14651858.CD012380; CD012380] ">Roy 2017</a> </p> <p><b>Interventions to treat chronic kidney disease in people with Sickle cell disease</b> </p> <p>(BABYHUG (<a href="./references#CD012082-bbs2-0080" title="WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663‐72. ">Wang 2011</a>); <a href="./references#CD012082-bbs2-0041" title="FoucanL , BourhisV , BangouJ , MeraultL , Etienne‐JulanM , SalmiRL . A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. American Journal of Medicine1998;104(4):339‐42. ">Foucan 1998</a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the effectiveness of any intervention in preventing or reducing kidney complications or CKD in people with SCD </p> <p>(including RBC transfusions, hydroxyurea and ACEi (either alone or in combination with each other) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>/07 October 2026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with all types of SCD of all ages and either gender</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0004"> <li> <p>RBCl transfusion</p> </li> <li> <p>Hydroxyurea</p> </li> <li> <p>ACEi</p> </li> <li> <p>In combination with each other</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0005"> <li> <p>Compared to each other</p> </li> <li> <p>Placebo</p> </li> <li> <p>Standard care</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two studies met the inclusion criteria: one study compared hydroxyurea to placebo and the other study compared angiotensin converting enzyme inhibitors to placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0001" title="ChinegwundohFI , AnieKA . Treatments for priapism in boys and men with sickle cell disease. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD004198.pub2; CD004198] ">Chinegwundoh 2004</a>Treatments for priapism in boys and men with sickle cell disease </p> <p>(<a href="./references#CD012082-bbs2-0069" title="SerjeantGR , deCeulaerK , MaudeGH . Stilboestrol and stuttering priapism in homozygous sickle‐cell disease. Lancet1985;2(8467):1274‐6. ">Serjeant 1985</a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the benefits and risks of the different treatments for both</p> <p>stuttering and fulminant priapism in SCD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 August 2010 / 22 July 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0006"> <li> <p>SCD: SS; SC; Sβº; Sβ⁺</p> </li> <li> <p>Males</p> </li> <li> <p>Priapism, fulminant or stuttering</p> </li> <li> <p>All ages</p> </li> <li> <p>Any race</p> </li> <li> <p>Any ethnic origin</p> </li> <li> <p>Any setting</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0007"> <li> <p>Any treatment for priapism in SCD</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0008"> <li> <p>Placebo;</p> </li> <li> <p>No treatment;</p> </li> <li> <p>Any other intervention</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study comparing Stilboestrol 5 mg daily versus placebo.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0008" title="Martí‐CarvajalAJ , Knight‐MaddenJM , Martinez‐ZapataMJ . Interventions for treating leg ulcers in people with sickle cell disease. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD008394.pub3; CD008394] ">Martí‐Carvajal 2014</a>Interventions for treating leg ulcers in people with sickle cell disease </p> <p>(<a href="./references#CD012082-bbs2-0036" title="BaumKF , MacFarlaneDE , MaudeGH , SerjeantGR . Topical antibiotics in chronic sickle cell leg ulcers. Transactions of the Royal Society of Tropical Medicine and Hygiene1987;81(5):847‐9. ">Baum 1987</a><b>; </b><a href="./references#CD012082-bbs2-0052" title="LaGrenadeL , ThomasPW , SerjeantGR . A randomized controlled trial of solcoseryl and duoderm in chronic sickle cell ulcers. West Indian Medical Journal1993;42(3):121‐3. ">La Grenade 1993</a><b>; </b><a href="./references#CD012082-bbs2-0053" title="McMahonL , TamaryH , AskinM , Adams‐GravesP , EberhardtRT , SuttonM , et al. A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers. British Journal of Haematology2010;151(5):526‐24. ">McMahon 2010</a><b>; </b><a href="./references#CD012082-bbs2-0068" title="SerjeantGR , HowardC . Isoxsuprine hydrochloride in the therapy of sickle cell leg ulceration. West Indian Medical Journal1977;26(3):164‐6. ">Serjeant 1977</a><b>; </b><a href="./references#CD012082-bbs2-0070" title="SerjeantBE , HarrisJ , ThomasP , SerjeantGR . Propionyl‐L‐carnitine in chronic leg ulcers of homozygous sickle cell disease: a pilot study. Journal of the American Academy of Dermatology1997;37:491‐3. ">Serjeant 1997</a><b>; </b><a href="./references#CD012082-bbs2-0084" title="WethersDL , RamirezGM , KoshyM , SteinbergMH , PhillipsGJr , SiegelRS , et al. Accelerated healing of chronic sickle‐cell leg ulcers treated with RGD peptide matrix. RGD Study Group. Blood1994;84(6):1775‐9. ">Wethers 1994</a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To determine whether any clinical interventions (used either alone or in combination) are effective and safe when treating leg ulcers in people with SCD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 October 2014 / 18 September 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0009"> <li> <p>Any SCD</p> </li> <li> <p>Diagnosed with a leg ulcer</p> </li> <li> <p>Treated in community, hospital or both</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systemic interventions</b> </p> <p> <ul id="CD012082-list-0010"> <li> <p>Vascular drugs</p> </li> <li> <p>Antioxidant agents</p> </li> <li> <p>Recombinant agents growth factors</p> </li> <li> <p>Pharmacologic stimulation of HbF synthesis</p> </li> <li> <p>Oral zinc sulphate</p> </li> </ul> </p> <p><b>Topical interventions</b> </p> <p> <ul id="CD012082-list-0011"> <li> <p>Antibiotics and antiseptics</p> </li> <li> <p>Growth factors and related</p> </li> <li> <p>Steroids</p> </li> <li> <p>Dressing;</p> </li> <li> <p>Debriding agents;</p> </li> <li> <p>Ccompression; miscellaneous (such as topical opioids)</p> </li> </ul> </p> <p><b>Non‐pharmaceutical interventions</b> </p> <p> <ul id="CD012082-list-0012"> <li> <p>Reconstructive surgery</p> </li> <li> <p>Cell therapy</p> </li> <li> <p>Laser therapy miscellaneous</p> </li> <li> <p>conventional care another treatment</p> </li> <li> <p>regimen for leg ulcers in people with SCD</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0013"> <li> <p>Conventional care</p> </li> <li> <p>Another treatment regimen for leg ulcers in people with SCD</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six studies met the review’s inclusion criteria:</p> <p>Interventions included:</p> <p>· Topical antibiotics</p> <p>· Solcoseryl® and Duo Derm</p> <p>· Arginine butyrate</p> <p>· Propionyl‐L‐carnitine</p> <p>· RGD peptide matrix</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0010" title="Martí‐CarvajalAJ , SolàI , Agreda‐PérezLH . Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD004344.pub6; CD004344] ">Martí‐Carvajal 2016</a>Treatment for avascular necrosis of bone in people with sickle cell disease </p> <p>(NOTSCA (<a href="./references#CD012082-bbs2-0054" title="NeumayrLD , AguilarC , EarlesAN , JergesenHE , HaberkernCM , KammenBF , et al. Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. Journal of Bone and Joint Surgery2006;88(12):2573‐82. ">Neumayr 2006</a><b>))</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To determine if the following treatments have any impact on avascular necrosis of bone in people with SCD in both the </p> <p>short‐ and the long‐term (efficacy, safety, and adverse events): any surgical versus non‐surgical intervention, including combinations of surgical and non‐surgical treatment. Also, address the following: </p> <p>1. the role of decompression;</p> <p>2. the relative effectiveness of surgical approaches (for studies comparing 2 surgical approaches); </p> <p>3. types of prosthesis (glued or not, with or without bone grafts etc.)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 July 2014 / 17 March 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0014"> <li> <p>Confirmed diagnosis of SCD (trial included HbSS; SC; Sβ⁰)</p> </li> <li> <p>Any SCD ‐related avascular necrosis</p> </li> <li> <p>All ages</p> </li> <li> <p>Male or female</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Surgical treatment:</b> </p> <p> <ul id="CD012082-list-0015"> <li> <p>Joint reconstruction (femoral head replacement, cup arthroplasty, articular surface replacement, total hip replacement); </p> </li> <li> <p>Nucleus decompression;</p> </li> <li> <p>Bone graft;</p> </li> <li> <p>Vascularized bone grafts;</p> </li> <li> <p>Osteotomy</p> </li> </ul> </p> <p><b>Non‐surgical treatment:</b> </p> <p> <ul id="CD012082-list-0016"> <li> <p>Observation;</p> </li> <li> <p>Analgesic drugs;</p> </li> <li> <p>Electrical stimulation;</p> </li> <li> <p>Physiotherapy;</p> </li> <li> <p>Resting of the joint;</p> </li> <li> <p>RBC transfusion;</p> </li> <li> <p>Stem cell transplant;</p> </li> <li> <p>Treatment to prevent sickling;</p> </li> <li> <p>Bisphosphonates</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0017"> <li> <p>1 surgical approach compared to another, or to a non‐surgical approach,</p> </li> <li> <p>2 non‐surgical approaches compared</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study: NOTSCA 2006</p> <p>Randomised open‐label</p> <p>Hip core decompression and physical therapy (N = 17) versus physical therapy alone (N = 21) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0012" title="OniyangiO , CohallDH . Phytomedicines (medicines derived from plants) for sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.CD004448.pub5; CD004448] ">Oniyangi 2015</a>Phytomedicines (medicines derived from plants) for sickle cell disease </p> <p>(<a href="./references#CD012082-bbs2-0031" title="AkinsulieAO , TemiyeEO , AkanmuAS , LesiFEA , WhyteCO . Clinical evaluation of extract of Cajanuscajan (Ciklavit) in sickle cell anaemia. Journal of Tropical Paediatrics2005;51(4):200‐5. ">Akinsulie 2005</a><b>; </b><a href="./references#CD012082-bbs2-0079" title="WambebeC , KhamofuH , MomohJAF , EkpeyongM , AuduBS , NjokuOS , et al. Double‐blind, placebo controlled,randomised cross‐over clinical trial of NIPRISAN in patients with sickle cell disorder. Phytomedicine2001;8(4):252‐61. ">Wambebe 2001</a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the benefits and risks of phytomedicines in people with SCD of all types, of any age, in any setting. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 January 2015 / 26 March 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0018"> <li> <p>People of all ages</p> </li> <li> <p>SCD of any genotype in any geographic setting such as: homozygous (HbSS) and compound heterozygotes </p> </li> <li> <p>Including SC disease (HbSC) and β‐ thalassaemia (Sβ0/</p> </li> <li> <p>Sβ⁺)</p> </li> <li> <p>Proven by electrophoresis with family studies or DNA tests as appropriate</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0019"> <li> <p>Administration (by any mode: topical; oral; or parenteral) of phytomedicines (defined as a remedy derived directly from plants or plant material and not synthesised). </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0020"> <li> <p>Placebo</p> </li> <li> <p>Conventional treatment, including blood transfusion and hydroxyurea</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two studies met the inclusion criteria: one study compared Niprisan versus placebo or conventional treatment (blood transfusions not reported) </p> <p>The second study compared Ciklavit versus placebo or conventional treatment (blood transfusions not reported). </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACEi: angiotensin‐converting enzyme inhibitors<br/> ACS: acute chest syndrome<br/> CKD: chronic kidney disease<br/> SCD: sickle cell disease<br/> SD: standard deviation<br/> TCD: transcranial doppler<br/> TIA: transient ischaemic attack </p> </div> </div> <div class="table" id="CD012082-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of reviews with no studies that met inclusion criteria</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objectives</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Date assessed as up to date / Date of last search</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study Population</b> </p> <p><b>Number of participants/ type of sickle cell/ age of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison Interventions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0003" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , HambletonIR , ChoG . Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD008360.pub4; CD008360] ">Estcourt 2016a</a> </p> <p><b>Regular long‐term red blood cell transfusions for managing chronic chest complication in sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Whether long‐term blood transfusions show differences in the</p> <p>following: incidence of chronic chest complications; ’severity’ or progression of established chronic chest complications; mortality associated with chronic chest complications; unacceptable adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 May 2016 / 25 April 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any SCD:</p> <p> <ul id="CD012082-list-0021"> <li> <p>Confirmed diagnosis of SCD: SS; SC; Sβº; Sβ⁺</p> </li> <li> <p>Male or female</p> </li> <li> <p>All ages</p> </li> <li> <p>Positive or negative for a history of chronic or acute chest complications</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0022"> <li> <p>Regular RBC transfusions (simple top‐up or exchange)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0023"> <li> <p>Alternative treatment;</p> </li> <li> <p>No treatment</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0007" title="Martí‐CarvajalAJ , Peña‐MartíGE , Comunián‐CarrascoG , Martí‐PeñaAJ . Interventions for treating painful sickle cell crisis during pregnancy. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006786.pub2; CD006786] ">Martí‐Carvajal 2009</a> </p> <p><b>Intervention for treating painful sickle cell crisis during pregnancy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the effectiveness and safety of different regimens of</p> <p>packed red cell transfusion, oxygen therapy, fluid replacement</p> <p>therapy, analgesic drugs, and steroids for the treatment of painful sickle cell crisis during pregnancy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 December 2009 / December 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0024"> <li> <p>Pregnant women with SCD (all types)</p> </li> <li> <p>Any age</p> </li> <li> <p>Excluded sickle cell trait</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0025"> <li> <p>RBC transfusion</p> </li> <li> <p>Oxygen therapy</p> </li> <li> <p>Fluid replacement therapy</p> </li> <li> <p>Analgesia (nonsteroidal</p> </li> <li> <p>aAnti‐inflammatory agents or opiates agents)</p> </li> <li> <p>Steroids (prednisone, dexamethasone, or methylprednisolone)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0026"> <li> <p>Each other</p> </li> <li> <p>Placebo</p> </li> <li> <p>Standard care</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0009" title="Martí‐CarvajalAJ , Simancas‐RacinesD . Interventions for treating intrahepatic cholestasis in people with sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD010985.pub2; CD010985] ">Martí‐Carvajal 2015a</a> </p> <p><b>Intervention for treating intrahepatic cholestasis in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the benefits and harms of the interventions for treating</p> <p>intrahepatic cholestasis in people with SCD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 March 2015 /10 October 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0027"> <li> <p>SCD with intrahepatic cholestasis</p> </li> <li> <p>Any age</p> </li> <li> <p>Male or female</p> </li> <li> <p>Hospital or community setting</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0028"> <li> <p>Simple RBC transfusion</p> </li> <li> <p>Exchange transfusion</p> </li> <li> <p>Liver transplant</p> </li> <li> <p>Bile acid binding resins (cholestyramine colestipol)</p> </li> <li> <p>Rifampin</p> </li> <li> <p>Opiate antagonists (naltrexone, nalmefene)</p> </li> <li> <p>Sertraline</p> </li> <li> <p>Dexamethasone</p> </li> <li> <p>Guar gum</p> </li> <li> <p>Activated charcoal</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0029"> <li> <p>Conventional care</p> </li> <li> <p>Each other</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0013" title="OringanjeC , NemecekE , OniyangiO . Hematopoietic stem cell transplantation for people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD007001.pub4; CD007001] ">Oringanje 2016</a> </p> <p><b>Hematopoietic stem cell transplantation for people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To determine whether stem cell transplantation can improve survival and prevent symptoms and complications associated with SCD. To examine the risks of stem cell transplantation against the potential long‐term gain for people with SCD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 March 2016 / 11 December 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0030"> <li> <p>Children and adults with SCD of all phenotypes, either gender and in all settings</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0031"> <li> <p>Methods of stem cell transplantation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0032"> <li> <p>Methods of stem cell transplantation compared with each other</p> </li> <li> <p>Ssupportive care (e.g. periodic transfusion, use of hydroxyurea,</p> </li> <li> <p>Antibiotics, pain relievers, supplemental oxygen)</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0014" title="Owusu‐OforiS , RemmingtonT . Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD003425.pub3; CD003425] ">Owusu‐Ofori 2015</a> </p> <p><b>Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess whether splenectomy (total or partial), to prevent acute splenic sequestration crises in people with SCD, improved survival and decreased morbidity in people with SCD, as compared with regular blood transfusions. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 July 2015 / 10 June 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any SCD:</p> <p> <ul id="CD012082-list-0033"> <li> <p>Confirmed diagnosis of SCD: SS; SC; Sβº; Sβ⁺</p> </li> <li> <p>Experienced at least one acute splenic sequestration crisis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0034"> <li> <p>Full or partial splenectomy</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0035"> <li> <p>Conservative management</p> </li> <li> <p>No treatment</p> </li> <li> <p>Rregimen of regular RBC transfusions (e.g. 4‐weekly)</p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>RBC: red blood cell<br/> SCD: sickle cell disease </p> </div> </div> <div class="table" id="CD012082-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">AMSTAR quality assessment: Reviews with an RBC transfusion intervention</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AMSTAR Criteria<sup>1, 2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a> </p> <p><b>Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a> </p> <p><b>Interventions for preventing silent cerebral infarcts in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a> </p> <p><b>Preoperative blood transfusions for sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a> </p> <p><b>Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0002" title="DastgiriS , DolatkhahR . Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD007843.pub3; CD007843] ">Dastgiri 2016</a> </p> <p><b>Blood transfusions for treating acute chest syndrome in people with sickle cell disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><sup>1</sup> We applied a modified AMSTAR based on the univariable questions developed for the overview by Pollock 2014. See <a href="./appendices#CD012082-sec-0094">Appendix 2</a> AMSTAR Checklist </p> <p><sup>2</sup> Modified AMSTAR answers are reported as: Y = yes; N = no; U = unsure; NA = not applicable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1. Was an ’a priori’ design provided</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available ‐ objectives, participants, interventions and comparisons and primary and secondary outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available ‐ objectives, participants, interventions and comparisons and primary and secondary outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available ‐ objectives, participants, interventions and comparisons and primary and secondary outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available ‐ objectives, participants, interventions and comparisons, and primary and secondary outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol first published: Issue 2, 2009.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2. Was there duplicate study selection and data extraction?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two independent review screened all electronically‐derived citations and abstracts of papers identified in the search for relevance. We excluded trials that were clearly irrelevant at this stage based on a review of the abstract. </p> <p>Two independent review authors formally assessed the full texts of all potentially‐relevant trials for eligibility against the criteria outlined above. We resolved all disagreements by discussion without the need for a third review author. </p> <p>Two review authors conducted the data extraction according to the guidelines proposed by Cochrane. We resolved disagreements between the review authors by consensus. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two independent review authors screened all electronically‐derived citations and abstracts of papers identified by the review search strategy for relevance. </p> <p>Two independent review authors (LE, PF) formally assessed the full texts of all potentially relevant trials for eligibility against the criteria outlined above. We requested additional information from study authors as necessary. </p> <p>The two review authors discussed the results of study selection and resolved our discrepancies.</p> <p>Two review authors conducted the data extraction according to the guidelines proposed by the Cochrane Collaboration. Disagreements were resolved by consensus. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two independent review authors screened all electronically‐derived citations and abstracts of papers identified by the review search strategy for relevance. </p> <p>Two independent review authors (PF, LE) formally assessed the full texts of all potentially‐relevant trials for eligibility against the criteria outlined above. </p> <p> We resolved all disagreements by discussion without the need for a third review author.</p> <p>Two review authors conducted the data extraction according to the guidelines proposed by the Cochrane Collaboration. Disagreements were resolved by consensus. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two review authors independently assessed for inclusion all the potential studies identified as a result of the search strategy. </p> <p>For eligible studies, both review authors independently extracted the data using the agreed form. We resolved discrepancies through discussion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two authors independently assessed the abstracts of trials identified from the searches. The two review authors independently assessed the full text papers independently and resolved any disagreement on their eligibility for this review through discussion and consensus; or if necessary through a third party. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3. Was a comprehensive literature search performed?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Searched Haemoglobinopathies Trials Register. We also searched the following databases for RCTs and SRs on April 4 2016: </p> <p>The Cochrane Library (CENTRAL &amp; DARE) – issue 4, 2016; issue 2, 2015 respectively MEDLINE (OvidSP, 1946 to April 4 2016) EMBASE (OvidSP, last 6 months to April 4 2016) CINAHL (EBSCOHost, to April 4 2016) PubMed (e publications only to April 4 2016) Transfusion Evidence Library (1950 to April 4 2016) LILACS (1982 to April 4 2016) IndMed (1986 to April 4 2016) KoreaMed (1997 to April 4 2016) Web of Science (Conference Proceedings Citation Index‐ Science (CPCI‐S) ‐1990 to April 4 2016) We also searched the following trial databases for ongoing trials on 4 April 2016: ClinicalTrials.gov; WHO International Clinical Trials Registry Platform (ICTRP). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Searched haemoglobinopathies trials register and the following databases for RCTs on 19 September 2016. </p> <p>The Cochrane Library (CENTRAL, DARE, HTA, NHSEED) MEDLINE (OvidSP, Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE Daily and </p> <p>Ovid MEDLINE, 1946 to 19 September 2016) PubMed (Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Embase (OvidSP) CINAHL (EBSCOHost, 1937 to 19 September 2016)Transfusion Evidence Library (1950 to 19 September 2016) LILACS (1982 to 19 September 2016) Web of Science (Conference Proceedings Citation Index‐ Science (CPCI‐S) ‐ 1990 to 19 September 2016) We also searched the following trial databases for ongoing trials on 19 Sepetember 2016. </p> <p>ClinicalTrials.gov</p> <p>WHO International Clinical Trials Registry Platform (ICTRP).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Searched haemoglobinopathies trials register and supplemented searches with a search of current MEDLINE, Embase, clinical trial registries, included mesh terms, key words and dates. Search strategies in appendix. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>The Cochrane Pregnancy and Childbirth Group’s Trials Register which includes at least 2 major databases – and handsearches was searched 30 May 2016. </p> <p>Provided Mesh terms but no key words. Trial registries were not searched.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We conducted searches in the Cochrane Cystic Fibrosis and Genetic</p> <p>Disorders Group’s Haemoglobinopathies Trials Register using the terms: sickle cell AND acute chest syndrome. We also searched the (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>) database to identify any additional relevant clinical studies and registered clinical trials of the same topic. Regarding the relatively high prevalence of hereditary sickle cell disease (SS) and others associated disorders in south provinces of Iran (Zandian 2012), we tried to find any additional RCT studies registered in Iranian Registry of </p> <p>Clinical Trials (<a href="http://www.irct.ir" target="_blank">www.irct.ir</a>). Other databases and trial sites not search such as EMBASE and ICSTR. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4. Was the status of publication</b> </p> <p><b>(i.e. grey literature) used as an Inclusion criterion?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>no limits on language or publication status.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Searches for unpublished work included in search of the Register. No language restrictions.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Searches for unpublished work included in search of the Register. No language restrictions.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Searches for unpublished work included in search of the Register. No language restrictions.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We contacted the trial authors of the PROACTIVE trial for further data and information, but to date have received no. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5. Was a list of studies (included</b> </p> <p><b>and excluded) provided?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Includes study flow diagram.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Includes a flow diagram.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Includes a flow diagram.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Includes study flow diagram.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> <p>No study flow diagram provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6. Were the characteristics of the included studies provided?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Detailed descriptions of participants interventions and outcomes of included studies provided </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Detailed descriptions of participants interventions and outcomes of included studies provided. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Detailed descriptions of participants interventions and outcomes of included studies provided. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Detailed descriptions of participants interventions and outcomes of included studies provided. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Detailed descriptions of participants interventions and outcomes provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7. Was the scientific quality of the Included studies assessed and documented?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Assessed by two authors independently with Cochrane Risk of Bias tool, and Summary of findings table included and documented. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Assessed by two authors independently with Cochrane Risk of Bias tool and Summary of findings table included and documented. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Assessed by two authors independently with Cochrane Risk of Bias tool and Summary of findings table included and documented. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Assessed by two authors independently with Cochrane Risk of Bias tool, and Summary of findings table included and documented. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Not applicable</b>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8. Was the scientific quality of the Included studies used appropriately in formulating conclusions?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>The quality of the evidence was very low to moderate across different outcomes according to GRADE methodology. This was due to the trials being at a high risk of bias due to lack of blinding, indirectness and imprecise outcome estimates. Due to lack of evidence this review cannot comment on management for adults with HbSS disease or children and adults with HbSβ<sup>0</sup>, HbSC or HbSβ<sup>+</sup> disease. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>The quality of the evidence was very low to moderate across different outcomes according to GRADE methodology. This was due to: trials being at high risk of bias because they were unblinded; indirectness (the available evidence was for children with HbSS); and imprecise outcome estimates. There is low‐quality evidence that long‐term RBC transfusions may reduce the incidence of SCI in children with abnormal TCD velocities but have little or no effect on children with normal TCD velocities. In children who are at higher risk of stroke and have not had previous long‐term transfusions, there is moderate‐quality evidence that long‐term RBC transfusions. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Overall, the quality of the evidence was rated as low to very low across different outcomes according to GRADE methodology. This was due to two of the studies being at high </p> <p>or unclear risk of bias, and many of the outcome estimates being imprecise.</p> <p>Due to lack of evidence this review cannot comment on management for people with HbSC or HbSβ⁺ disease or patients with high baseline haemoglobin concentrations, or management of patients undergoing low risk surgery. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Evidence from one small trial of very low quality suggests that prophylactic blood transfusion to pregnant women with sickle cell </p> <p>anaemia (HbSS) confers no clear clinical benefits when compared with selective transfusion. Currently, there is no evidence from randomised or quasi‐randomised trials to provide reliable advice on the optimal blood transfusion policy for women with other variants of sickle cell disease (i.e. HbSC and HbS_Thal). The available data and quality of evidence on this subject are insufficient to advocate for a change in existing clinical practice and policy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Not applicable</b>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9. Were the methods used to combine the findings of studies</b> </p> <p><b>appropriate?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Risk ratio reported and Peto odds ratio reported for outcomes with low event rates all confidence intervals included. Heterogeneity defined, There was no statistical heterogeneity, but if statistical heterogeneity was found to be above 75%, we would identify a reason for clinical heterogeneity and not perform a meta‐analysis but comment instead on the results as a narrative. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Risk ratio reported and Peto odds ratio reported for outcomes with low event rates all confidence intervals included. Heterogeneity defined, There was no statistical heterogeneity, but if statistical heterogeneity was found to be above 75%, we would identify a reason for clinical heterogeneity and not perform a meta‐analysis but comment instead on the results as a narrative. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Risk ratio reported and Peto odds ratio reported for outcomes with low event rates all confidence intervals included. Heterogeneity defined, identified and reported. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>For dichotomous data, we presented results as summary risk ratio with 95% confidence intervals. No continuous data were analysed in this review. In future updates, if appropriate, we will use the mean difference if outcomes are measured in the same way between trials.We will use the standardised mean difference to combine trials that measure the same outcome, but use different methods. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Not applicable</b>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10. Was the likelihood of publication bias assessed?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Mentioned that too few studies to assess publication bias.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Mentioned that too few studies to assess publication bias.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Mentioned that too few studies to assess publication bias.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Mentioned that too few studies to assess publication bias.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Not applicable</b>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11. Was the conflict of interest</b> </p> <p><b>stated?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Lise Estcourt is partly funded by an NIHR Cochrane Programme Grant. Patricia Fortin is funded by an NIHR Cochrane Programme Grant. Sally Hopwell is partly funded by an NIHR Programme Grant. Marialena Trivella is partly funded by an NIHR Programme Grant. Winfred Wang was a PI on several of the included trials. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Lise Estcourt is partly funded by an NIHR Cochrane Programme Grant.</p> <p>Carolyn Doree: none to declare. Patricia Fortin is funded by an NIHR Cochrane Programme Grant. </p> <p>Sally Hopwell is partly funded by an NIHR Programme Grant.</p> <p>Marialena Trivella is partly funded by an NIHR Programme Grant.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Lise Estcourt is partly funded by an NIHR Cochrane Programme Grant.</p> <p>Carolyn Doree: none to declare. Patricia Fortin is funded by an NIHR Cochrane Programme Grant. </p> <p>Sally Hopwell is partly funded by an NIHR Programme Grant.</p> <p>Marialena Trivella is partly funded by an NIHR Programme Grant.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>None known.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>There are no financial conflicts of interest and the review authors declare that they do not have any associations with any parties who may have vested interests in the results of this review. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NIHR: National Institute for Health Research<br/> PI: principal investigator<br/> TCD: transcranial doppler </p> </div> </div> <div class="table" id="CD012082-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">AMSTAR quality assessment: Reviews with other interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AMSTAR</b> </p> <p><b>Criteria<sup>1, 2, 3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0001" title="ChinegwundohFI , AnieKA . Treatments for priapism in boys and men with sickle cell disease. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD004198.pub2; CD004198] ">Chinegwundoh 2004</a> </p> <p><b>Treatments for priapism in boys and men with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0008" title="Martí‐CarvajalAJ , Knight‐MaddenJM , Martinez‐ZapataMJ . Interventions for treating leg ulcers in people with sickle cell disease. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD008394.pub3; CD008394] ">Martí‐Carvajal 2014</a> </p> <p><b>Interventions for treating leg ulcers in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0010" title="Martí‐CarvajalAJ , SolàI , Agreda‐PérezLH . Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD004344.pub6; CD004344] ">Martí‐Carvajal 2016</a> </p> <p><b>Treatment for avascular necrosis of bone in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0015" title="RoyNB , FortinPM , BullKR , DoreeC , TrivellaM , HopewellS , et al. Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database of Systematic Reviews 201, Issue 7. [DOI: 10.1002/14651858.CD012380; CD012380] ">Roy 2017</a> </p> <p><b>Interventions for chronic kidney disease in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0012" title="OniyangiO , CohallDH . Phytomedicines (medicines derived from plants) for sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.CD004448.pub5; CD004448] ">Oniyangi 2015</a> </p> <p><b>Phytomedicines (medicines derived from plants) for sickle cell disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><sup>1</sup> We applied a modified AMSTAR based on the univariable questions developed for the overview by Pollock 2014. See <a href="./appendices#CD012082-sec-0094">Appendix 2</a> modified AMSTAR questions </p> <p><sup>2</sup> Modified AMSTAR answers are reported as: Y = yes; N = no; U = unsure; NA = not applicable </p> <p><sup>3</sup> Items 5 ‐ 10 of AMSTAR were not assessed in the quality appraisal as the reviews did not include any studies with a red cell transfusion comparison </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1. Was an ’a priori’ design provided</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2. Was there duplicate study selection and data extraction?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Each author independently identified potentially relevant trials. Each author independently extracted data. No disagreement occurred, so no other expert in the field was invited to make an independent assessment based on the selection criteria. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two authors independently selected studies for inclusion, and extracted data. A third author was always included when two authors disagreed, all disagreements resolved by group discussion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>The authors screened the search results for potentially relevant trials and independently assessed them. Each author used this form to extract data from each relevant study. We independently extracted information from the papers. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two independent review authors screened all citations and abstracts of papers identified by the search strategy for relevance. </p> <p>Two review authors independently and formally assessed the full texts of all</p> <p>potentially relevant trials for eligibility. Two review authors conducted the data extraction. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two authors (OO, DC) independently selected the trials for inclusion in the review using pre‐defined inclusion criteria. two authors (NC, OO) had independently </p> <p>extracted the data and resolved differences by referring to the original trial. The process was repeated for this update by both authors. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3. Was a comprehensive literature search performed?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Studies identified in the Group’s Haemoglobinopathies Trials Register. Searched Embase (1974 to 2003) (<a href="./appendices#CD012082-sec-0093">Appendix 1</a>) and the Internet (December 2003). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We identified relevant trials from the Group’s Haemoglobinopathies Trials Register. Also searched– LILACS and several other databases and websites. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>U</b> </p> <p>Trials were identified from the Group’s Haemoglobinopathies Trials Register.</p> <p>No Embase or trial registry search.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We identified trials from the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register. In addition to this we searched the following databases for RCTs on 05 April 2016. CENTRAL, the Cochrane Library (current issue) MEDLINE (Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE Daily and Ovid </p> <p>MEDLINE, Embase CINAHL PubMed;Transfusion Evidence Library LILACS; IndMed; KoreaMed;</p> <p>PakMediNet; Web of Science;</p> <p>ClinicalTrials.gov; WHO International Clinical Trials Registry Platform (ICTRP).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Relevant trials were identified from the Group’s Haemoglobinopathies Trials Register. Relevant trials were also identified from the International Standard Randomised </p> <p>Controlled Trial Number Registry (ISCTN). An additional search of the Allied and Complimentary Medicine </p> <p>(AMED) bibliographic database.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4. Was the status of publication (i.e. grey literature) used as an Inclusion criterion?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Attempts were also made to identify any unpublished trials through contact with experts in the field and personal communication </p> <p>with known authors.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We searched for trials, irrespective of publication status (trials may be unpublished or published as an article, an abstract, or a letter), language or country. No limit was applied with respect to the period of follow‐up. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>U</b> </p> <p>Did not mention if any language restrictions.</p> <p>Stated that bibliographic references of all retrieved literature were reviewed for additional reports of trials. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We did not limit searches by language, year</p> <p>of publication or publication type.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>U</b> </p> <p>The bibliographic references of all retrieved trials and reviews were assessed for additional reports of trials; lead authors were to be contacted if necessary. </p> <p>No mention of limitation by language.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11. Was the conflict of interest stated?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>None known.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>In 2004 Arturo Martí‐Carvajal was employed by Eli Lilly to run a four‐hour workshop on ’How to critically appraise clinical trials. In 2007 Arturo Martí‐Carvajal was employed by Merck to run a four‐hour workshop on ’How to critically appraise clinical trials. Jennifer Knight‐Madden and María José Martínez‐Zapata: none known. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> <p>None known.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Noemi Roy: none known.</p> <p>Patricia Fortin: funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components. </p> <p>Katherine Bull: none known.</p> <p>Carolyn Doree: none known.</p> <p>Sally Hopewell: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components. Marialena Trivella: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components. </p> <p>Lise Estcourt: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>None known.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NIHR: National Institute for Health Research</p> </div> </div> <div class="table" id="CD012082-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">AMSTAR quality assessment: Reviews with no studies identified</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AMSTAR</b> </p> <p><b>Criteria<sup>1, 2, 3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0003" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , HambletonIR , ChoG . Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD008360.pub4; CD008360] ">Estcourt 2016a</a> </p> <p><b>Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0007" title="Martí‐CarvajalAJ , Peña‐MartíGE , Comunián‐CarrascoG , Martí‐PeñaAJ . Interventions for treating painful sickle cell crisis during pregnancy. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006786.pub2; CD006786] ">Martí‐Carvajal 2009</a> </p> <p><b>Interventions for treating painful sickle cell crisis during pregnancy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0009" title="Martí‐CarvajalAJ , Simancas‐RacinesD . Interventions for treating intrahepatic cholestasis in people with sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD010985.pub2; CD010985] ">Martí‐Carvajal 2015a</a> </p> <p><b>Interventions for treating intrahepatic cholestasis in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0013" title="OringanjeC , NemecekE , OniyangiO . Hematopoietic stem cell transplantation for people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD007001.pub4; CD007001] ">Oringanje 2016</a> </p> <p><b>Hematopoietic stem cell transplantation for people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0014" title="Owusu‐OforiS , RemmingtonT . Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD003425.pub3; CD003425] ">Owusu‐Ofori 2015</a> </p> <p><b>Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><sup>1</sup> We applied a modified AMSTAR based on the univariable questions developed for the overview by Pollock 2014. See appendix xx modified AMSTAR questions </p> <p><sup>2</sup> Modified AMSTAR answers are reported as: Y = yes; N = no; U = unsure; NA = not applicable </p> <p><sup>3</sup> Items 5 ‐ 10 of AMSTAR were not assessed in the quality appraisal as the reviews did not include any studies with a red cell transfusion comparison </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1. Was an ’a priori’ design provided</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2. Was there duplicate study selection and data extraction?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two review authors independently screened all the remaining references for relevance against the full eligibility criteria. We retrieved full‐text articles for all references for which a decision on eligibility could not be made from title and abstract alone. The two review authors discussed the results of study selection and resolved any disagreements on trial inclusions by consensus. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We planned to screen the results of our search strategy for potentially relevant trials, and independently assess them. We will independently extract the data. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two authors will screen the search results for potentially relevant trials and independently assess them. One author will extract data from the included trials using a spreadsheet data extraction form and one author will check the data entered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two authors independently screened the ten trials found by the initial search of all the databases and reference lists to identify papers with potential relevance to the review. We obtained the full text of selected articles. Two authors independently selected trials for inclusion by applying the inclusion </p> <p>criteria to all potential trials.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We did not apply the process described below, as we were not able to identify any trials eligible for inclusion. However, if we include any trials in future updates of this review, we will apply the following methods. The two authors will independently identify potentially relevant </p> <p>trials from the results of the searches. Each author will independently extract data on trial information. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3. Was a comprehensive literature search performed?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Potentially relevant trials were identified from the Group’s haemoglobinopathies Trials Register We also searched for RCTs in the following databases: </p> <p>CENTRAL &amp; DARE; MEDLINE); Embase; CINAHL; Pubmed; Transfusion Evidence Library; LILACS(BIREME/PAHO/WHO); KoreaMed; IndMed; PakMediNet; Web of Science; ClinicalTrials.gov; The WHO International Clinical Trials Registry (ICTRP); the ISRCTN Register EU Clinical Trials Register and the Hong Kong Clinical Trials Register. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Searched the Cochrane Pregnancy and Childbirth Group’s Trials Register. In addition, we searched using the terms using the terms sickle cell AND pregnancy: Cystic Fibrosis and Genetic Disorders Group’s Trials Register (October 2007); <i>LILACS</i> database (1982 to Dec 5 2007); ClinicalTrials.gov <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Relevant studies from Disorders Group’s Haemoglobinopathies Trials Register using the terms: </p> <p>Also searched LILACS; Epistemonikos; WHO International Clinical Trials Registry.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>U</b> </p> <p>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Group’s Haemoglobinopathies Trials Register. We searched the Meetings of the American society for Blood and </p> <p>Marrow Transplantation; Center for the International Blood and Marrow Transplant Research; and European Group for Blood and Marrow </p> <p>Transplantation .</p> <p>No additional databases or clinical trials sites searched.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Relevant trials were identified from Relevant trials were identified from the Group’s Haemoglobinopathies Trials Register. In addition to the above, further subject specific electronic searched of MEDLINE and Embase. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4. Was the status of publication (i.e. grey literature) used as an Inclusion criterion?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We did not limit searches by language or publication</p> <p>status.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>U</b> </p> <p>Did not mention if any language restrictions</p> <p>Stated that bibliographic references of all retrieved literature were reviewed for additional reports of trials. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We did not adopt any language or publication restrictions.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>U</b> </p> <p>All randomised controlled and quasi‐randomised studies.</p> <p>Not stated if any language or publication status limitations.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>A comprehensive search strategy was formulated in an attempt to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11. Was the conflict of interest stated?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Lise Estcourt: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components. </p> <p>Patricia Fortin: funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components. Sally Hopewell: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components. Marialena Trivella: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components. Ian Hambleton: none declared. </p> <p>Gavin Cho: none declared.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> <p>None known.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>In 2004 Arturo Martí‐Carvajal was employed by Eli Lilly to run a four‐hour workshop on ’How to critically appraise clinical trials </p> <p>In 2007 Arturo Martí‐Carvajal was employed by Merck to run a four‐hour workshop on ’How to critically appraise clinical trials </p> <p>Daniel Simancas‐Racines: none known.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Chioma Oringanje: none known.</p> <p>Eneida Nemecek: none known.</p> <p>Oluseyi Oniyangi: none known.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Dr Shirley Owusu‐Ofori: none known.</p> <p>Tracey Remmington: Managing Editor of the Cochrane Cystic Fibrosis and Genetic Disorders Group. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NIHR: National Institute for Health Research</p> </div> </div> <div class="table" id="CD012082-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Mortality: Summary of findings</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N Participants </b> </p> <p><b>(N RCTs)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect estimate (95% confidence interval)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GRADE quality rating</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interpretation </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a> </p> <p><b>Primary and secondary stroke</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Long‐term RBC transfusions versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children with no previous long‐term RBC transfusions</p> <p>(Follow‐up 18 to 36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether long‐term RBC transfusions decrease mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children and adolescents with previous long‐term RBC transfusions</p> <p>(Follow‐up 18 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 8.0 (0.16 to 404.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether long‐term RBC transfusions decrease mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RBC transfusion versus disease‐modifying agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary prevention</p> <p>Children with abnormal TCD velocities but no severe vasculopathy on MRI/MRA, who have received at least one year of RBC transfusions </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether hydroxyurea and phlebotomy decreases mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary prevention</p> <p>Children and adolescents with previous stroke, at least 18 months of RBC transfusions, and evidence of iron overload </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.98 (0.06 to 15.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether hydroxyurea and phlebotomy decreases mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a> </p> <p><b>Silent cerebral infarcts</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Long‐term RBC transfusions versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children or adolescents with abnormal TCD velocities 18 to 21 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether long‐term RBC transfusions decrease mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children or adolescents with normalised TCD velocities 18 months of follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 8.00 (0.16 to 404.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether long‐term RBC transfusions decrease mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children with normal TCD velocities and silent stroke</p> <p>(median 3 years follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether long‐term RBC transfusions decrease mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RBC transfusion versus disease‐modifying agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary prevention</p> <p>Children with abnormal TCD velocities but no severe vasculopathy on MRI/MRA, who have received at least one year of red cell transfusions </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether hydroxyurea and phlebotomy decreases mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary prevention</p> <p>Children and adolescents with previous stroke, at least 18 months of RBC transfusions, and evidence of iron overload </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 1.02 (0.06 to 16.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether hydroxyurea with phlebotomy decreases mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a> </p> <p><b>Preoperative blood transfusions for sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Restrictive (to increase the total haemoglobin) versus liberal (to decrease the haemoglobin S level below a specified percentage) RBC transfusion strategy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with SCD undergoing cholecystectomy</p> <p>(Follow‐up: 30 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> <p>(1 RCT)<sup>a</sup> cholecystectomy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions decrease mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term RBC transfusion versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with SCD undergoing low to medium risk surgery or any surgery other than cardiac surgery </p> <p>(Follow‐up 30 days in one trial; not stated in 1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>434</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions decrease mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a> </p> <p><b>Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Long‐term RBC transfusions versus RBC transfusions to treat complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pregnant women with SCD</p> <p>(Follow‐up for 21.5 to 24.5 weeks of prenatal care)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether prophylactic RBC transfusions decrease maternal mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (76 births)</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.85 (0.61 to 13.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether prophylactic RBC transfusions decrease perinatal mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><sup>1</sup> High Risk of bias in one or more domains using the Cochrane Risk of Bias tool </p> <p><sup>2</sup> Indirectness as specific population or procedure reported may not be generalisable to review question </p> <p><sup>3</sup> Imprecision as effect has wide confidence intervals and/or study has small number of people or low event rates </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>MRI/MRA: magnetic resonance imaging/magnetic resonance angiography <br/> RBC: red blood cell<br/> RCT: randomised controlled trial<br/> SCD: sickle cell disease<br/> TCD: transcranial doppler </p> </div> </div> <div class="table" id="CD012082-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">SCD‐related SAEs: Summary of findings</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>GRADE summary of findings for SCD‐related serious adverse events<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systematic Review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population</b> </p> <p><b>(Follow‐up)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N Participants (N RCTs)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reported outcomes and time points</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect estimate (95% confidence interval)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GRADE quality rating</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interpretation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="13" valign="top"> <p><a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a> </p> <p><b>Primary and secondary stroke</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Long‐term RBC transfusions versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Children with no previous long‐term RBC transfusions</p> <p>(Follow‐up 18 to 36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.12<br/> (0.03 to 0.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions probably reduce the risk of stroke</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.24<br/> (0.12 to 0.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may reduce the incidence of ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Painful crises</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.62 (0.46 to 0.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may reduce the incidence of painful crisis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Children and adolescents with previous long‐term RBC transfusions</p> <p>(Follow‐up 18 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.22 (0.01 to 4.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether continuing long‐term red cell transfusions reduces the incidence of clinical stroke </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>_</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>_</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>RBC transfusion versus disease‐modifying agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Primary prevention</p> <p>Children with abnormal TCD velocities but no severe vasculopathy on MRI/MRA, who have received at least one year of red cell transfusions </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No stroke occurred in either arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on the risk of stroke </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.03</p> <p>(0.39 to 10.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.08</p> <p>(0.61 to 42.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on pain crisis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Secondary prevention</p> <p>Children and adolescents with previous stroke, at least 18 months of RBC transfusions, and evidence of iron overload </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 14.78<br/> (0.86 to 253.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>2.3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on the risk of stroke </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global SCD SAEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.10 (1.42 to 6.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switching to hydroxyurea and phlebotomy may increase the risk of SCD related serious adverse events </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33 (0.04 to 3.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very uncertain whether switching to hydroxyurea and phlebotomy has any effect on the risk of ACS </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.15 (1.23 to 8.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switching to hydroxyurea and phlebotomy may increase the risk of painful crisis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p><a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a> </p> <p><b>Silent cerebral infarcts</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>Long‐term RBC transfusions versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Children and adolescents with abnormal TCD velocities</p> <p>(18 – 21 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New or progressive SCI lesions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.11 (0.02 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>1, 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may reduce the incidence of SCIs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.30</p> <p>(0.11 to 0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may reduce the incidence of ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90</p> <p>(0.44 to 1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may be no different than standard care in reducing the incidence of pain crisis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Children and adolescents with normalised TCD velocities</p> <p>(18 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New or progressive SCI lesions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.29</p> <p>(0.09 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>1, 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuing RBC transfusions may reduce the incidence of SCIs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Children with normal TCD velocities and silent stroke</p> <p>(median 3 years follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New or progressive SCI lesions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70</p> <p>(0.23 to</p> <p>2.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may be no different than standard care in reducing the incidence of SCIs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute chest syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.20</p> <p>(0.08 to 0.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may reduce the incidence of ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.56</p> <p>(0.40 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may reduce the incidence of pain crisis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>RBC transfusion versus disease‐modifying agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Primary prevention</p> <p>Children with abnormal TCD velocities but no severe vasculopathy on MR/MRA, who have received at least one year of red cell transfusions </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New or progressive SCI lesions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No SCIs occurred in either study arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on SCIs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global SCD SAEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.52 (0.58 to 4.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if switching to hydroxyurea and phlebotomy has any effect on total SAEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.03</p> <p>(0.39 to 10.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.08</p> <p>(0.61 to 42.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on pain crisis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Secondary prevention</p> <p>Children and adolescents with previous stroke, at least 18 months of RBC transfusions, and evidence of iron overload </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New or progressive SCI lesions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 7.28</p> <p>(0.14 to</p> <p>366.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on SCIs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33</p> <p>(0.04 to</p> <p>3.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.15</p> <p>(1.23 to</p> <p>8.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>1, 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switching to hydroxyurea and phlebotomy may increase the risk of pain crisis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p><a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a> </p> <p><b>Preoperative blood transfusions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Restrictive (to increase the total haemoglobin) versus liberal (to decrease the haemoglobin S level below a specified percentage) RBC transfusion strategy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>People undergoing cholecystectomy</p> <p>(Follow‐up: 30 days)</p> <p>(results for the tonsillectomy / adenoidectomy groups are similar)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> <p>No effect estimate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions reduce the risk of acute stroke</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.84</p> <p>(0.38 to 1.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions reduce the risk of ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Painful crises</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.30</p> <p>(0.09 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions reduce the risk of painful crisis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> <p>No effect estimate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions reduce the risk of renal complications</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.75 (0.59 to 5.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions reduce the risk of serious infection</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Short‐term RBC transfusion versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>People undergoing low‐to medium‐risk surgery or any surgery other than cardiac surgery</p> <p>(Follow‐up 30 days in 1 trial; not stated in 1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>434 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 7.22 (1.24 to 41.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions increase the risk of neurological complications (no events in no preoperative transfusion group) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.11 (0.01 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Preoperative RBC transfusions may reduce the risk of ACS the population of African haplotypes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369 (1)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.81 (0.23 to 99.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions increase the risk of ACS (no events in control group) in the population of Arabic haplotypes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>434 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Painful crises</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 1.91 (0.61 to 6.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions reduce the risk of painful crisis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> <p>No effect estimate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions reduce the risk of renal complications (no events) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>434 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 1.29 (0.29 to 5.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions reduce the risk of serious infection</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a> </p> <p><b>Prophylactic vs selective blood transfusion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Long‐term RBC transfusions versus RBC transfusions to treat complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Pregnant women with SCD</p> <p>(Follow‐up for 21.5‐24.5 weeks of prenatal care)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.67</p> <p>(0.12 to 3.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether prophylactic RBC transfusions reduce the risk of ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Painful crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.28 (0.12 to 0.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic RBC transfusions may reduce the risk of painful crisis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (0.07 to 15.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether prophylactic RBC transfusions reduce the risk of renal complications</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (0.07 to 15.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether prophylactic RBC transfusions reduce the risk of serious infection</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><sup>a</sup> Sickle cell serious adverse events include: neurological, ophthalmological, respiratory, orthopaedic, vascular, hepatic or renal complications, vaso‐occlusive pain crisis, priapism, infections </p> <p><sup>b</sup> Rated down by 2 for very serious risk of bias </p> <p><sup>1</sup> High Risk of bias in one or more domains using the Cochrane Risk of Bias tool </p> <p><sup>2</sup> Indirectness as specific population or procedure reported may not be generalisable to review question </p> <p><sup>3</sup> Imprecision as effect has wide confidence intervals and/or study has small number of people or low event rates </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACS: acute chest syndrome<br/> MRI/MRA: magnetic resonance imaging/magnetic resonance angiography<br/> OR: odds ratio<br/> RBC: red blood cell<br/> RCT: randomised controlled trial<br/> RR: risk ratio<br/> SAEs: serious adverse events<br/> SCI: silent cerebral infarct<br/> TCD: transcranial doppler </p> </div> </div> <div class="table" id="CD012082-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Transfusion‐related AEs (serious and non‐serious): Summary of findings</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Table: Transfusion related adverse events (serious and non‐serious)<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systematic Review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population </b> </p> <p><b>(Follow‐up)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N Participants (N RCTs)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reported outcomes and </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect estimate</b> </p> <p><b>(95% confidence interval)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GRADE quality rating </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interpretation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a> </p> <p><b>Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Long‐term RBC transfusions versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Children with no previous long‐term RBC transfusions</p> <p>(Follow‐up 18 to 36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.16 (0.18 to 57.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if long‐term RBC transfusions increase the risk of alloimmunisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.17 (0.71 to 37.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if long‐term RBC transfusions increase the risk of transfusion reactions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron overload (serum ferritin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased in children receiving long‐term RBC transfusions, incidence rate ratio 14.42 (5.41 to 875.17 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may increase the risk of iron overload</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Children and adolescents with previous long‐term RBC transfusions</p> <p>(Follow‐up 18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participant who was in the continuing transfusion arm developed an alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 participants in the continuing transfusion arm had 9 reactions to transfusions. 1 required hospitalisation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RBC Transfusion versus disease‐modifying agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary prevention</p> <p>Children with abnormal TCD velocities but no severe vasculopathy on MRI/MRA, who have received at least one year of red cell transfusions </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver iron concentrations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐1.80 (‐5.16 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switching to hydroxyurea and phlebotomy may have little or no effect on liver iron concentrations </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary prevention</p> <p>Children and adolescents with previous stroke, at least 18 months of RBC transfusions, and evidence of iron overload </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver iron concentrations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea: 17.3 mg Fe/g dry weight iron, (IQR 10.0 to 30.6); transfusion: 17.3 mg Fe/g dry weight iron, (IQR 8.8 to 30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switching to hydroxyurea and phlebotomy may have little or no effect on liver iron concentrations </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign="top"> <p><a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a> </p> <p><b>Interventions for preventing silent cerebral infarcts in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>Long‐term RBC transfusions versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Children or adolescents with abnormal TCD velocities</p> <p>(18 to 21 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 participants in the transfusion arm developed an alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 participants in the transfusion arm had 16 mild reactions to blood products or transfusion </p> <p>procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron overload</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron overload developed faster than anticipated in children receiving transfusion, with mean (SD) </p> <p>serum ferritin rising to and 2509 μg/L (974 μg/L) at 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Children and adolescents with normalised TCD velocities</p> <p>(18 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participant who was in the continuing transfusion arm developed an alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 participants in the continuing transfusion arm had 9 reactions to transfusions. 1 required hospitalisation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Children with normal TCD velocities and silent stroke</p> <p>(median 3 years follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.16 (0.18 to 57.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very Low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if long‐term RBC transfusions increase the risk of alloimmunisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.17 (0.71 to 37.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if long‐term RBC transfusions increase the risk of transfusion reactions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron overload (serum ferritin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased in children receiving long‐term RBC transfusions, incidence rate ratio 14.42 (5.41 to 875.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>2.3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may increase the risk of iron overload</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RBC transfusion versus disease‐modifying agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary prevention</p> <p>Children with abnormal TCD velocities but no severe vasculopathy on MRI/MRA, who have received at least one year of red cell transfusions </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver iron concentrations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐1.80 (‐5.16 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switching to hydroxyurea and phlebotomy may have little or no effect on liver iron concentrations </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary prevention</p> <p>Children and adolescents with previous stroke, at least 18 months of RBC transfusions, and evidence of iron overload </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver iron concentrations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea: 17.3 mg Fe/g dry weight iron, IQR 10.0 to 30.6; transfusion: 17.3 mg Fe/g dry </p> <p>weight iron, IQR 8.8 to 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switching to hydroxyurea and phlebotomy may have little or no effect on liver iron concentrations </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a> </p> <p><b>Preoperative blood transfusions for sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Restrictive (to increase the total haemoglobin) versus liberal (to decrease the haemoglobin S level below a specified percentage) RBC transfusion strategy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>People with SCD undergoing cholecystectomy</p> <p>(Follow‐up: 30 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.05 (1.14 to 8.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions increase the risk of alloimmunisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.18 (0.77 to 6.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions increase the risk of transfusion reactions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any transfusion complication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.85 (0.89 to 3.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions increase the risk of transfusion complications </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Short‐term RBC transfusion versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>People with SCD undergoing low to medium risk surgery or any surgery other than cardiac surgery </p> <p>(Follow‐up for 30 days in 1 trial; not stated in 1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>434 (2)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious transfusion complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events in 1 trial, circulatory overload reported in the preoperative transfusion group in 1 trial </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions increase the risk of serious transfusion complications </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (1)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 7.17 (0.14 to 361.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions increase the risk of alloimmunisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>434 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events in 1 trial; 2 reactions reported in the preoperative transfusion group in 1 trial </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions increase the risk of transfusion reactions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a> </p> <p><b>Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions versus RBC transfusions to treat complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pregnant women with SCD</p> <p>(Follow‐up for 21.5‐24.5 weeks of prenatal care)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.00 (0.54 to 7.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether prophylactic RBC transfusions increase the risk of transfusion reactions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><sup>a</sup> Serious and non‐serious transfusion related adverse events can include: acute and delayed transfusion reactions, transfusion‐related acute lung injury, transfusion‐associated circulatory overload, transfusion‐associated dyspnoea, alloimmunisation, iron overload, problems of venous access) </p> <p><sup>b</sup> Rated down by 1 for serious risk of bias and rated down by 2 for very serious risk of bias </p> <p><sup>1</sup> High Risk of bias in one or more domains using the Cochrane Risk of Bias tool </p> <p><sup>2</sup> Indirectness as specific population or procedure reported may not be generalisable to review question </p> <p><sup>3</sup> Imprecision as effect has wide CIs and/or study has small number of people or low event rates </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/> IQR: inter‐quartile range<br/> OR: odds ratio<br/> MRI/MRA: magnetic resonance imaging/magnetic resonance angiography<br/> RBC: red blood cell<br/> RCT: randomised controlled trial<br/> RR: risk ratio<br/> SAEs: serious adverse events<br/> SCD: sickle cell disease<br/> TCD: transcranial doppler </p> </div> </div> </section> <section id="CD012082-sec-0033"> <h4 class="title">Assessment of methodological quality of included reviews</h4> <section id="CD012082-sec-0034"> <h5 class="title">Methodological quality of included reviews</h5> <p>Two overview authors (LE, PF) assessed the methodological quality of the included reviews using the 11 domains in AMSTAR (<a href="./references#CD012082-bbs2-0071" title="SheaBJ , GrimshawJM , WellsGA , BoersM , AnderssonN , HamelC , et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology2007; Vol. 7, issue 10. ">Shea 2007</a>; <a href="./appendices#CD012082-sec-0094">Appendix 2</a>) and used these domains to interpret the results of the review. We resolved any differences through discussion or third party adjudication (SH). Rather than providing a numerical summary of the ratings we provided a judgement or copied text from the review for each domain to support the quality rating of the included reviews. We did not exclude reviews based on their methodological quality. We did not conduct sensitivity analyses to explore the consequences of combining reviews of varying methodological quality because all included reviews are Cochrane Reviews, we did not expect significant overlap between comparisons. A recent systematic review of the measurement properties of AMSTAR found that the interrater reliability of AMSTAR was very satisfactory (<a href="./references#CD012082-bbs2-0059" title="PieperD , BuechterRB , LiL , PredigerB , EikermannM . Systematic review found AMSTAR, but not R(evised)‐AMSTAR to have good measurement properties. Journal of Clinical Epidemiology2015;68:574‐583. ">Pieper 2015</a>). As more guidance is provided for its use, and additional validity studies that link systematic review methodological quality to the strength of conclusions (<a href="./references#CD012082-bbs2-0059" title="PieperD , BuechterRB , LiL , PredigerB , EikermannM . Systematic review found AMSTAR, but not R(evised)‐AMSTAR to have good measurement properties. Journal of Clinical Epidemiology2015;68:574‐583. ">Pieper 2015</a>), we will use AMSTAR in future updates of this overview until a more reliable tool becomes available. AMSTAR domains include: </p> <p> <ol id="CD012082-list-0036"> <li> <p>an a priori design;</p> </li> <li> <p>duplicate review and data abstraction;</p> </li> <li> <p>a comprehensive search was performed;</p> </li> <li> <p>status of publication used as an inclusion criteria;</p> </li> <li> <p>a list of included and excluded studies provided;</p> </li> <li> <p>characteristics of included studies provided;</p> </li> <li> <p>scientific quality was assessed and documented;</p> </li> <li> <p>scientific quality was used appropriately in formulating conclusions;</p> </li> <li> <p>appropriate methods were used to combine the findings of trials;</p> </li> <li> <p>publication bias was assessed;</p> </li> <li> <p>conflict of interest included.</p> </li> </ol> </p> </section> <section id="CD012082-sec-0035"> <h5 class="title">Quality of evidence in included reviews</h5> <p>Two overview authors (LE, PF) assessed and summarized the quality of evidence included in the summary of findings tables and the risk of bias tables according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and recommendations in the <i>Cochrane Handbook of Systematic Reviews of Interventions</i>, respectively (<a href="./references#CD012082-bbs2-0035" title="BalshemH , HelfandM , SchunemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE Guidelines 3. rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. ">Balshem 2011</a>; <a href="./references#CD012082-bbs2-0045" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>; <a href="./references#CD012082-bbs2-0067" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>). Assessments included information on outcomes across studies and based on trial design, directness of evidence, precision and consistency of results, and publication bias. Where possible we graded the outcomes based on assessments provided in the original reviews. We resolved any differences through discussion or third party adjudication (SH). </p> </section> </section> <section id="CD012082-sec-0036"> <h4 class="title">Data synthesis</h4> <p>Our unit of analysis was the included systematic reviews. We presented all statistical outcome data if available, if this was not possible we presented data as a narrative synthesis. We reported the evidence for each intervention from the reviews using the GRADE approach (<a href="./references#CD012082-bbs2-0035" title="BalshemH , HelfandM , SchunemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE Guidelines 3. rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. ">Balshem 2011</a>; <a href="./references#CD012082-bbs2-0067" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>). The data available in the reviews, determined the comparisons presented. </p> <p>We included a Summary of findings overview table (<a href="#CD012082-fig-0001">Figure 1</a>); and summary of findings tables for the three primary outcomes in this overview, for each intervention (<a href="#CD012082-tbl-0007">Table 7</a>; <a href="#CD012082-tbl-0008">Table 8</a>; <a href="#CD012082-tbl-0009">Table 9</a>). These are in a format similar to the 'Summary of findings' table as recommended in chapter 22 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012082-bbs2-0046" title="HigginsJPT , GreenS (editors) . Chapter 22: Overviews of reviews. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). </p> <p>Where possible, we classified data from reviews into subgroups based on:</p> <p> <ul id="CD012082-list-0037"> <li> <p>the indication for RBC transfusions for preventing or treating SCD complications;</p> </li> <li> <p>acute or chronic RBC transfusions;</p> </li> <li> <p>restrictive (to increase the total haemoglobin) or liberal (to decrease the haemoglobin S level below a specified percentage) transfusion; </p> </li> <li> <p>by age of participants (children, adolescents, adults);</p> </li> <li> <p>participant characteristics (i.e. pregnant, undergoing surgery, type of SCD).</p> </li> </ul> </p> <p>As planned, we did not conduct any indirect comparisons or network meta‐analyses.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012082-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012082-sec-0037"></div> <section id="CD012082-sec-0038"> <h3 class="title" id="CD012082-sec-0038">Results of the search</h3> <p>We searched the Cochrane Database of Systematic Reviews on 04 February 2017 and retrieved 127 reviews. Two review authors (LE, PF) excluded 100 reviews that were not relevant. We examined the full text of 27 Cochrane Reviews and excluded another 12 reviews: </p> <p> <ul id="CD012082-list-0038"> <li> <p>Nine reviews did not include RBC transfusion as an intervention or comparator (<a href="./references#CD012082-bbs2-0016" title="Al HajeriA , FedorowiczZ . Piracetam for reducing the incidence of painful sickle cell disease crises. Cochrane Database of Systematic Reviews2016, Issue 2. [DOI: 10.1002/14651858.CD006111.pub2] ">Al Hajeri 2016</a>; <a href="./references#CD012082-bbs2-0017" title="AlhashimiD , FedorowiczZ , AlhashimiF , DastgiriS . Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD007843.pub2] ">Alhashimi 2010</a>; <a href="./references#CD012082-bbs2-0020" title="JonesAP , DaviesSC , OlujohungbeA . Hydroxyurea for sickle cell disease. Cochrane Database of Systematic Reviews2001, Issue 2. [DOI: 10.1002/14651858.CD002202] ">Jones 2001;</a><a href="./references#CD012082-bbs2-0021" title="Knight‐MaddenJM , HambletonIR . Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD003733.pub3] ">Knight‐Madden 2014</a>; <a href="./references#CD012082-bbs2-0022" title="Martí‐CarvajalAJ , ConternoLO . Antibiotics for treating community acquired pneumonia in people with sickle cell disease. Cochrane Database of Systematic Reviews2012, Issue 10. [DOI: 10.1002/14651858.CD005598.pub3] ">Martí‐Carvajal 2012</a>; <a href="./references#CD012082-bbs2-0023" title="Martí‐CarvajalAJ , ConternoLO , Knight‐MaddenJM . Antibiotics for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD006110.pub4] ">Martí‐Carvajal 2015b</a>; <a href="./references#CD012082-bbs2-0025" title="NagallaS , BallasSK . Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD003426.pub4] ">Nagalla 2012</a>; <a href="./references#CD012082-bbs2-0026" title="OkomoU , MeremikwuMM . Fluid replacement therapy for acute episodes of pain in people with sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD005406.pub4] ">Okomo 2015;</a><a href="./references#CD012082-bbs2-0027" title="vanZuurenEJ , FedorowiczZ . Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD010155.pub2] ">van Zuuren 2013</a>) </p> </li> <li> <p>Three reviews did not include people with SCD (<a href="./references#CD012082-bbs2-0018" title="CarsonJL , CarlessPA , HebertPC . Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD002042.pub4] ">Carson 2012</a>; <a href="./references#CD012082-bbs2-0019" title="DoddJM , DareMR , MiddletonP . Treatment for women with postpartum iron deficiency anaemia. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD004222.pub2] ">Dodd 2004</a>; <a href="./references#CD012082-bbs2-0024" title="MeremikwuMM , SmithHJ . Blood transfusion for treating malarial anaemia. Cochrane Database of Systematic Reviews1999, Issue 4. [DOI: 10.1002/14651858.CD001475] ">Meremikwu 1999</a>). </p> </li> </ul> </p> <p>We included 15 reviews that addressed various SCD complications and where RBC transfusion was an intervention or comparator (<a href="./references#CD012082-bbs2-0001" title="ChinegwundohFI , AnieKA . Treatments for priapism in boys and men with sickle cell disease. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD004198.pub2; CD004198] ">Chinegwundoh 2004</a>; <a href="./references#CD012082-bbs2-0002" title="DastgiriS , DolatkhahR . Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD007843.pub3; CD007843] ">Dastgiri 2016</a>; <a href="./references#CD012082-bbs2-0003" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , HambletonIR , ChoG . Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD008360.pub4; CD008360] ">Estcourt 2016a</a>; <a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>; <a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>; <a href="./references#CD012082-bbs2-0007" title="Martí‐CarvajalAJ , Peña‐MartíGE , Comunián‐CarrascoG , Martí‐PeñaAJ . Interventions for treating painful sickle cell crisis during pregnancy. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006786.pub2; CD006786] ">Martí‐Carvajal 2009</a>; <a href="./references#CD012082-bbs2-0008" title="Martí‐CarvajalAJ , Knight‐MaddenJM , Martinez‐ZapataMJ . Interventions for treating leg ulcers in people with sickle cell disease. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD008394.pub3; CD008394] ">Martí‐Carvajal 2014</a>; <a href="./references#CD012082-bbs2-0009" title="Martí‐CarvajalAJ , Simancas‐RacinesD . Interventions for treating intrahepatic cholestasis in people with sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD010985.pub2; CD010985] ">Martí‐Carvajal 2015a</a>; <a href="./references#CD012082-bbs2-0010" title="Martí‐CarvajalAJ , SolàI , Agreda‐PérezLH . Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD004344.pub6; CD004344] ">Martí‐Carvajal 2016</a>; <a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>; <a href="./references#CD012082-bbs2-0012" title="OniyangiO , CohallDH . Phytomedicines (medicines derived from plants) for sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.CD004448.pub5; CD004448] ">Oniyangi 2015</a>; <a href="./references#CD012082-bbs2-0013" title="OringanjeC , NemecekE , OniyangiO . Hematopoietic stem cell transplantation for people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD007001.pub4; CD007001] ">Oringanje 2016</a>; <a href="./references#CD012082-bbs2-0014" title="Owusu‐OforiS , RemmingtonT . Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD003425.pub3; CD003425] ">Owusu‐Ofori 2015</a>; <a href="./references#CD012082-bbs2-0015" title="RoyNB , FortinPM , BullKR , DoreeC , TrivellaM , HopewellS , et al. Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database of Systematic Reviews 201, Issue 7. [DOI: 10.1002/14651858.CD012380; CD012380] ">Roy 2017</a>). </p> <p>Five reviews included RCTs with an RBC transfusion intervention for the following complications: primary and secondary stroke (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>); silent cerebral infarcts (SCI) (<a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>); preoperative transfusion (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>); prevention of SCD complications in pregnancy (<a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>); and ACS (<a href="./references#CD012082-bbs2-0002" title="DastgiriS , DolatkhahR . Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD007843.pub3; CD007843] ">Dastgiri 2016</a>) (<a href="#CD012082-tbl-0001">Table 1</a>). </p> <p>10 reviews had no RCTs with an RBC transfusion intervention. Five of these reviews included RCTs with other interventions for the following complications: chronic kidney disease (<a href="./references#CD012082-bbs2-0015" title="RoyNB , FortinPM , BullKR , DoreeC , TrivellaM , HopewellS , et al. Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database of Systematic Reviews 201, Issue 7. [DOI: 10.1002/14651858.CD012380; CD012380] ">Roy 2017</a>); priapism (<a href="./references#CD012082-bbs2-0001" title="ChinegwundohFI , AnieKA . Treatments for priapism in boys and men with sickle cell disease. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD004198.pub2; CD004198] ">Chinegwundoh 2004</a>); leg ulcers (<a href="./references#CD012082-bbs2-0008" title="Martí‐CarvajalAJ , Knight‐MaddenJM , Martinez‐ZapataMJ . Interventions for treating leg ulcers in people with sickle cell disease. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD008394.pub3; CD008394] ">Martí‐Carvajal 2014</a>); avascular necrosis (<a href="./references#CD012082-bbs2-0010" title="Martí‐CarvajalAJ , SolàI , Agreda‐PérezLH . Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD004344.pub6; CD004344] ">Martí‐Carvajal 2016</a>); and phytomedicines (<a href="./references#CD012082-bbs2-0012" title="OniyangiO , CohallDH . Phytomedicines (medicines derived from plants) for sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.CD004448.pub5; CD004448] ">Oniyangi 2015</a>) (<a href="#CD012082-tbl-0002">Table 2</a>). Five reviews contained no RCTs that met the inclusion criteria for the following complications: chronic chest complications (<a href="./references#CD012082-bbs2-0003" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , HambletonIR , ChoG . Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD008360.pub4; CD008360] ">Estcourt 2016a</a>); painful crisis in pregnancy (<a href="./references#CD012082-bbs2-0007" title="Martí‐CarvajalAJ , Peña‐MartíGE , Comunián‐CarrascoG , Martí‐PeñaAJ . Interventions for treating painful sickle cell crisis during pregnancy. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006786.pub2; CD006786] ">Martí‐Carvajal 2009</a>); intrahepatic cholestasis (<a href="./references#CD012082-bbs2-0009" title="Martí‐CarvajalAJ , Simancas‐RacinesD . Interventions for treating intrahepatic cholestasis in people with sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD010985.pub2; CD010985] ">Martí‐Carvajal 2015a</a>); hematopoietic stem cell transplantation (<a href="./references#CD012082-bbs2-0013" title="OringanjeC , NemecekE , OniyangiO . Hematopoietic stem cell transplantation for people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD007001.pub4; CD007001] ">Oringanje 2016</a>); and acute splenic sequestration crisis (<a href="./references#CD012082-bbs2-0014" title="Owusu‐OforiS , RemmingtonT . Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD003425.pub3; CD003425] ">Owusu‐Ofori 2015</a>) (<a href="#CD012082-tbl-0003">Table 3</a>). </p> </section> <section id="CD012082-sec-0039"> <h3 class="title" id="CD012082-sec-0039">Description of included reviews</h3> <p>The 15 reviews were published between 2004 to 2017. Three were new reviews (<a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>; <a href="./references#CD012082-bbs2-0009" title="Martí‐CarvajalAJ , Simancas‐RacinesD . Interventions for treating intrahepatic cholestasis in people with sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD010985.pub2; CD010985] ">Martí‐Carvajal 2015a</a>; <a href="./references#CD012082-bbs2-0015" title="RoyNB , FortinPM , BullKR , DoreeC , TrivellaM , HopewellS , et al. Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database of Systematic Reviews 201, Issue 7. [DOI: 10.1002/14651858.CD012380; CD012380] ">Roy 2017</a>), and the remainder were updated reviews. </p> <p>In this overview we have focused on describing the five reviews that included RCTs with an intervention of RBC transfusion (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>; <a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>; <a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>; <a href="./references#CD012082-bbs2-0002" title="DastgiriS , DolatkhahR . Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD007843.pub3; CD007843] ">Dastgiri 2016</a>) (<a href="#CD012082-tbl-0001">Table 1</a>). </p> <p>We have presented the review characteristics of the remaining 10 reviews with no RBC transfusion intervention or no included trials in additional tables (<a href="#CD012082-tbl-0002">Table 2</a>; <a href="#CD012082-tbl-0003">Table 3</a>). We rated these 10 reviews as high quality according to AMSTAR quality assessment (<a href="#CD012082-tbl-0005">Table 5</a>, <a href="#CD012082-tbl-0006">Table 6</a>). </p> <section id="CD012082-sec-0040"> <h4 class="title">Study design</h4> <p>All five reviews included RCTs, one review also included quasi‐RCTs (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>). </p> <p>One review (on ACS) included one multicentre trial that enrolled 237 people, of which only 10 participants met the inclusion criteria for randomisation, the remaining 227 participants were recruited to an observational arm (<a href="./references#CD012082-bbs2-0002" title="DastgiriS , DolatkhahR . Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD007843.pub3; CD007843] ">Dastgiri 2016</a>). The review authors could not extract any data from the randomised participants in the trial. </p> <p>The other four reviews contained nine unique trials, of parallel group design, with two reviews reporting on the same trials (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>). In one review (surgery) containing three trials participant follow‐up was 30 days (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>). In the two reviews with the same five trials (participants at high risk of stroke or SCIs), follow‐up ranged from six months to a median of three years (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>); and the other review (in pregnant women), included one trial with a follow‐up of 21.5 to 24.5 weeks of prenatal care (<a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>). </p> </section> <section id="CD012082-sec-0041"> <h4 class="title">Included participants</h4> <p>A total of 1512 participants were included in the five reviews. Two reviews (on stroke and SCIs) included the same five trials with 659 participants (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>). In one review (surgery), one trial reported on 551 trial participants; however, the review authors report on subgroups of 230 participants undergoing cholecystectomy, and 107 participants undergoing tonsillectomy or adenoidectomy, the trial re‐randomised participants creating unit of analysis issues. The review authors did not combine the two subgroups as it was unknown if any of the participants had both surgeries. This review included three trials with 771 participants (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>). One review (on pregnancy) included one trial with 72 women (<a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>). One review (on ACS) included only 10 participants (<a href="./references#CD012082-bbs2-0002" title="DastgiriS , DolatkhahR . Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD007843.pub3; CD007843] ">Dastgiri 2016</a>). </p> <p>In two reviews, participants in the included trials were either children or children and adolescents (mean ages eight to nine years) (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>). Two reviews included trials with children and adults (<a href="./references#CD012082-bbs2-0002" title="DastgiriS , DolatkhahR . Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD007843.pub3; CD007843] ">Dastgiri 2016</a>; <a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>). One review included pregnant women who had a mean age of 23 years (<a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>). </p> <p>In two reviews, trials included only HbSS or HbSβº phenotypes and the majority of participants were HbSS phenotype (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>). In one review with three trials, participants in one trial were all diagnosed with HbSS disease; in another trial some participants were diagnosed with HbSβº but the majority of participants had HbSS; and in one trial, although the majority of participants had HbSS, a substantial number also had HbSβº (n = 74) and the trial also included a small proportion of participants with HbSβ+ and HbSC disease (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>). In the Okusanya review all women in the one trial had HbSS disease (<a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>). </p> </section> <section id="CD012082-sec-0042"> <h4 class="title">Interventions</h4> <p>All five reviews had an RBC transfusion group. Two reviews addressing stroke and SCI respectively, had an RBC transfusion arm versus standard care (n = 405) or hydroxyurea (n = 254) (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>). One review included an RBC transfusion arm versus standard care (n = 10) (<a href="./references#CD012082-bbs2-0002" title="DastgiriS , DolatkhahR . Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD007843.pub3; CD007843] ">Dastgiri 2016</a>). One review on preoperative RBC transfusions included 337 participants from one trial which compared a liberal RBC transfusion regimen, designed to decrease the haemoglobin S level to less than 30%, to a restrictive RBC transfusion regimen, designed to increase the haemoglobin level to 100 g/L. This review also included two trials with 434 participants which compared a preoperative RBC transfusion arm (simple or exchange) to standard care (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>). In one review with 72 pregnant women, long‐term RBC transfusions to optimise haemoglobin concentration to a specified level were compared to short‐term (emergency) RBC transfusions to treat specific complications or a critically low level of haemoglobin (<a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>). </p> </section> </section> <section id="CD012082-sec-0043"> <h3 class="title" id="CD012082-sec-0043">Methodological quality of included reviews</h3> <section id="CD012082-sec-0044"> <h4 class="title">Quality of included reviews (AMSTAR)</h4> <p>All five reviews that included an RBC transfusion group were high quality according to AMSTAR quality assessment (<a href="#CD012082-tbl-0004">Table 4</a>). The five reviews provided: an a priori design and published Cochrane Protocol; comprehensive searches of the relevant group's specialised registers and other databases and searches of clinical trials and grey literature. All reviews contained tables of included and excluded trials and review authors rated trial quality using the Cochrane Risk of Bias tool and included GRADE summary of findings tables ‐ except in the Dastgiri review, as there wereno data to report (<a href="./references#CD012082-bbs2-0002" title="DastgiriS , DolatkhahR . Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD007843.pub3; CD007843] ">Dastgiri 2016</a>). Discussion and conclusions were appropriate to the quality of evidence and the review authors used appropriate methods to combine findings, analyse data or provide a narrative review of outcomes. There were too few trials in the reviews to assess publication bias. </p> </section> <section id="CD012082-sec-0045"> <h4 class="title">Quality of evidence in included reviews (GRADE)</h4> <p>Review authors, in accordance with GRADE criteria, rated the quality of evidence as very‐low to moderate across different outcomes in two reviews (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>). In the Estcourt 2016 review, review authors rated the quality of evidence as very‐low to low across all outcomes, according to GRADE criteria (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>). In the Okusanya review, review authors rated the one included trial as very‐low quality evidence according to GRADE criteria (<a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>). In the Dastgiri review, review authors rated the risk of bias as unclear in all domains due to incomplete reporting and they could not include a summary of findings table as there were no data to extract (<a href="./references#CD012082-bbs2-0002" title="DastgiriS , DolatkhahR . Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD007843.pub3; CD007843] ">Dastgiri 2016</a>). </p> </section> </section> <section id="CD012082-sec-0046"> <h3 class="title" id="CD012082-sec-0046">Effect of interventions</h3> <p>See: summary of findings overview table (<a href="#CD012082-fig-0001">Figure 1</a>) </p> <p>In the Dastgiri review only 10 participants were included in the randomised part of the study and no data were reported on any of the review outcomes (<a href="./references#CD012082-bbs2-0002" title="DastgiriS , DolatkhahR . Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD007843.pub3; CD007843] ">Dastgiri 2016</a>). </p> <p>We have reported the outcomes for this overview, for the other four reviews which include 1502 participants and nine RCTs with an RBC intervention (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>; <a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>; <a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>). As well as a summary of findings overview table (<a href="#CD012082-fig-0001">Figure 1</a>), we have included detailed summary of findings tables for the following outcomes: mortality (<a href="#CD012082-tbl-0007">Table 7</a>); SCD‐related SAEs (<a href="#CD012082-tbl-0008">Table 8</a>); and transfusion‐related AEs (<a href="#CD012082-tbl-0009">Table 9</a>). </p> <section id="CD012082-sec-0047"> <h4 class="title">Primary outcomes</h4> <section id="CD012082-sec-0048"> <h5 class="title">1. Mortality from any cause</h5> <p>(see Mortality: summary of findings <a href="#CD012082-tbl-0007">Table 7</a>) </p> <p>Four reviews reported this outcome (nine trials; 1502 participants) (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>; <a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>; <a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>). </p> <section id="CD012082-sec-0049"> <h6 class="title">RBC transfusions versus standard care</h6> <p>All four reviews (six trials, 955 participants) compared short‐ or long‐term RBC transfusion to standard care (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>; <a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>; <a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>). There was little or no evidence of a difference in all‐cause mortality; however, this evidence was very low‐quality according to GRADE criteria. There were either no deaths (short‐term transfusion) or death was a rare event (long‐term transfusion) (<a href="#CD012082-tbl-0007">Table 7</a>). </p> </section> <section id="CD012082-sec-0050"> <h6 class="title">RBC transfusions versus disease‐modifying agents</h6> <p>Two reviews (two trials; 254 participants) compared RBC transfusion versus hydroxyurea for primary or secondary prevention of stroke in children or adolescents (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>). There was little or no evidence of a difference in all‐cause mortality; however, this evidence was very low‐quality according to GRADE criteria. There were either no deaths (primary prevention) or death was a rare event (secondary prevention) (<a href="#CD012082-tbl-0007">Table 7</a>). </p> </section> <section id="CD012082-sec-0051"> <h6 class="title">Restrictive (to increase the total haemoglobin) versus liberal (to decrease the haemoglobin S level below a specified percentage) RBC transfusion strategy </h6> <p>One review (one trial; 230 participants) compared a restrictive to a liberal RBC transfusion strategy in people undergoing cholecystectomy (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>). There was little or no evidence of a difference in all‐cause mortality, however, this evidence was very low‐quality according to GRADE criteria. There were no deaths (<a href="#CD012082-tbl-0007">Table 7</a>). </p> </section> </section> <section id="CD012082-sec-0052"> <h5 class="title">2. Serious adverse events as a result of SCD‐related complications</h5> <p>(see SCD‐related SAEs: summary of findings (<a href="#CD012082-tbl-0008">Table 8</a>) </p> <p>Four reviews reported this outcome (nine trials; 1502 participants) (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>; <a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>; <a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>). </p> <section id="CD012082-sec-0053"> <h6 class="title">RBC transfusions versus standard care</h6> <section id="CD012082-sec-0054"> <p><b>Short‐term</b></p> <p>One review (two trials, 434 participants) compared short‐term RBC transfusion versus standard care in people undergoing low‐ to medium‐risk surgery (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>). There was little or no difference in the risk of neurological complications; painful crises; serious infections; and renal complications; however, this evidence was very low‐quality according to GRADE criteria. RBC transfusions may decrease the risk of ACS in people with SCD and African haplotypes, RR 0.11 (95% CI 0.01 to 0.80) (one trial, 65 participants, GRADE low‐quality evidence); but there was little or no difference in the risk of ACS in individuals with Arabic haplotypes (one trial, 369 participants, GRADE very low‐quality evidence) (<a href="#CD012082-tbl-0008">Table 8</a>). </p> </section> <section id="CD012082-sec-0055"> <p><b>Long‐term</b></p> <p>Two reviews (three trials, 405 participants) compared long‐term RBC transfusion versus standard care in children and adolescents at high risk of stroke (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>). In children who have not previously received long‐term RBC transfusions and at high risk of stroke (abnormal TCDs or SCI; two trials; 326 participants), long‐term RBC transfusions decrease the risk of stroke, RR 0.12 (95% CI 0.03 to 0.49) (GRADE moderate‐quality evidence). RBC transfusion may also decrease the risk of ACS, RR 0.24 (95% CI 0.12 to 0.48) (GRADE low‐quality evidence); and painful crisis, RR 0.62 (95% CI 0.46 to 0.84) (GRADE low‐quality evidence) (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>) (<a href="#CD012082-tbl-0008">Table 8</a>). Long‐term RBC transfusions in children with abnormal TCD velocities, may also decrease the risk of SCIs, RR 0.11 (95% CI 0.02 to 0.86) (one trial,124 participants, GRADE low‐quality evidence) and the risk of ACS, RR 0.30 (95% CI 0.11 to 0.87) (one trial, 130 participants, GRADE low‐quality evidence), but there was little or no difference in children with normal TCD velocities on the risk of SCIs (one trial, 196 participants, GRADE low‐quality evidence) (<a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>) (<a href="#CD012082-tbl-0008">Table 8</a>). In children and adolescents who have received previous long‐term RBC transfusions (one trial, 79 participants), there was little or no difference in the risk of clinical stroke, but this evidence was graded as very low‐quality (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>). Continuing long‐term RBC transfusions (one trial, 77 participants) may reduce the incidence of SCI, RR 0.29 (95% CI 0.09 to 0.97) (GRADE low‐quality evidence) (<a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>) (<a href="#CD012082-tbl-0008">Table 8</a>). </p> <p>One review (one trial, 72 participants) compared long‐term RBC transfusions versus RBC transfusions to treat complications in pregnant women (<a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>). Long‐term RBC transfusions may decrease the risk of painful crisis, RR 0.28 (95% CI 0.12 to 0.67) (GRADE low‐quality evidence); but there was little or no difference on the risk of other SCD‐related complications (ACS; renal complications; serious infection); however, this evidence was very low‐quality according to GRADE criteria (<a href="#CD012082-tbl-0008">Table 8</a>). </p> </section> </section> <section id="CD012082-sec-0056"> <h6 class="title">RBC transfusions versus disease‐modifying agents</h6> <p>Two reviews (two trials; 254 participants) compared RBC transfusion versus hydroxyurea for primary or secondary prevention of stroke in children or adolescents (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>). </p> <p>For primary prevention of stroke in children with abnormal TCD velocities and no severe vasculopathy on MRI/MRA (one trial, 121 participants), there was little or no difference in the risk of SCD‐related complications (stroke; SCI; global SAEs; ACS; painful crisis); however, this evidence was very low‐quality according to GRADE criteria (<a href="#CD012082-tbl-0008">Table 8</a>). </p> <p>In secondary prevention (one trial, 133 participants), hydroxyurea and phlebotomy may increase the risk of painful crisis, RR 3.15 (95% CI 1.23 to 8.11) and global SCD SAEs, RR 3.10 (95% CI 1.42 to 6.75) (GRADE low‐quality evidence) (<a href="#CD012082-tbl-0008">Table 8</a>), but there was little or no difference in the risk of stroke, SCI or ACS (this evidence was very low‐quality according to GRADE criteria <a href="#CD012082-tbl-0008">Table 8</a>). </p> </section> <section id="CD012082-sec-0057"> <h6 class="title">Restrictive (to increase the total haemoglobin) versus liberal (to decrease the haemoglobin S level below a specified percentage) RBC transfusion strategy </h6> <p>One review (one trial; 230 participants) compared a restrictive to a liberal RBC transfusion strategy in people undergoing cholecystectomy (results for the tonsillectomy/adenoidectomy groups are similar) (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>). There was little or no difference on the risk of SCD‐related complications (neurological; renal; ACS; painful crisis; serious infection); however, this evidence was very low‐quality according to GRADE criteria (<a href="#CD012082-tbl-0008">Table 8</a>). </p> </section> </section> <section id="CD012082-sec-0058"> <h5 class="title">3. Adverse events (serious and non‐serious) associated with transfusions</h5> <p>(<b>see transfusion‐related AEs (serious and non‐serious): summary of findings</b> (<a href="#CD012082-tbl-0009">Table 9</a>) </p> <p>This outcome is reported in four reviews (nine trials; 1502 participants) (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>; <a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>; <a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>). </p> <section id="CD012082-sec-0059"> <h6 class="title">RBC transfusions versus standard care</h6> <section id="CD012082-sec-0060"> <p><b>Short‐term</b></p> <p>One review (two trials, 434 participants) compared short‐term RBC transfusion versus standard care in people undergoing low‐ to medium‐risk surgery (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>). There was little or no difference in the risk of transfusion‐related complications (alloimmunisation; serious transfusion complications; transfusion reactions); however, this evidence was very low‐quality according to GRADE criteria (<a href="#CD012082-tbl-0009">Table 9</a>). </p> </section> <section id="CD012082-sec-0061"> <p><b>Long‐term</b></p> <p>Two reviews (three trials, 405 participants) compared long‐term RBC transfusion versus standard care in children and adolescents at high risk of stroke (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>). In children with no previous long‐term RBC transfusions with normal TCD velocities and silent stroke (one trial, 121 participants), there was little or no difference in the risk of alloimmunisation or transfusion reactions; however, the evidence was very low‐quality according to GRADE criteria. However, RBC transfusions may increase the risk of iron overload, incidence rate ratio 14.42 (95% CI 5.41 to 875.17) (GRADE low‐quality evidence) (<a href="#CD012082-tbl-0009">Table 9</a>). In children and adolescents with abnormal or normalised TCD velocities (two trials, 209 participants) there is no effect estimate for alloimmunisation, transfusion reactions, and iron overload as no comparative numbers were provided. </p> <p>One review (one trial, 72 participants) compared long‐term RBC transfusions versus RBC transfusions to treat complications in pregnant women (<a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>) and there was little or no difference in the risk of transfusion reactions, however, this evidence was very low‐quality according to GRADE criteria (<a href="#CD012082-tbl-0009">Table 9</a>). </p> </section> </section> <section id="CD012082-sec-0062"> <h6 class="title">RBC transfusions versus disease‐modifying agents</h6> <p>Two reviews (two trials; 254 participants) compared RBC transfusion and chelation versus switching to hydroxyurea and phlebotomy used for primary or secondary prevention of stroke in children or adolescents (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>) and there was little or no difference in liver iron concentrations, this evidence was low‐quality according to GRADE criteria (<a href="#CD012082-tbl-0009">Table 9</a>). </p> </section> <section id="CD012082-sec-0063"> <h6 class="title">Restrictive (to increase the total haemoglobin) versus liberal (to decrease the haemoglobin S level below a specified percentage) RBC transfusion strategy </h6> <p>One review (one trial; 230 participants) compared a restrictive to a liberal RBC transfusion strategy in people undergoing cholecystectomy (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>). There was little or no difference in the risk of alloimmunisation; transfusion reactions; or any transfusion complication, however, this evidence was very low‐quality according to GRADE criteria (<a href="#CD012082-tbl-0009">Table 9</a>). </p> </section> </section> </section> <section id="CD012082-sec-0064"> <h4 class="title">Secondary outcomes</h4> <section id="CD012082-sec-0065"> <h5 class="title">1. Other adverse events as a result of SCD‐related complications</h5> <p>This outcome was not reported in the short‐term RBC transfusions and the restrictive transfusion versus liberal RBC transfusion comparisons; three reviews reported this outcome with 838 participants (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>; <a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>). </p> <section id="CD012082-sec-0066"> <h6 class="title">RBC transfusions versus standard care</h6> <section id="CD012082-sec-0067"> <p><b>Long‐term</b></p> <p>Two reviews (three trials, 405 participants) compared long‐term RBC transfusion versus standard care in children and adolescents at high risk of stroke (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>). In children with no previous long‐term RBC transfusions with normal TCD velocities and silent stroke, RBC transfusions may reduce the risk of priapism (incidence rate ratio 0.13 (95% CI 0.03 to 0.55) (one trial, 112 participants); symptomatic avascular necrosis of the hip (incidence rate ratio 0.22 (95% CI 0.05 to 0.85) (one trial, 196 participants) (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>). </p> <p>One review (one trial, 72 participants) compared long‐term RBC transfusions versus RBC transfusions to treat complications in pregnant women (<a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>) and there was little or no difference in the risk in the occurrence of splenic sequestration, RR 0.33 (95%CI 0.01 to 7.92) (GRADE low‐quality evidence). </p> </section> </section> <section id="CD012082-sec-0068"> <h6 class="title">RBC transfusions versus disease‐modifying agents</h6> <p>Two reviews (two trials; 254 participants) compared RBC transfusion versus hydroxyurea used for primary or secondary prevention of stroke in children or adolescents (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>) and there was little or no difference in the risk of TIA, however this evidence was very low‐quality according to GRADE criteria. </p> </section> </section> <section id="CD012082-sec-0069"> <h5 class="title">2. RBC transfusion requirement</h5> <p>RBC transfusion requirement was not reported in the RBC transfusion versus disease‐modifying agents comparison. Four reviews reported this outcome (five trials, 527 participants) (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>; <a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>; <a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>). </p> <section id="CD012082-sec-0070"> <h6 class="title">RBC transfusions versus standard care</h6> <p><i>Short‐term</i> </p> <p>One review (two trials, 434 participants) compared short‐term RBC transfusion versus standard care in people undergoing low to medium risk surgery (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>). </p> <p>In participants that received an intraoperative or postoperative transfusion (one trial, four participants transfusion; 12 participants no transfusion) there was little or no difference in the number of units administered per transfusion. </p> <p><i>Long‐term</i> </p> <p>Two reviews (three trials, 405 participants) compared long‐term RBC transfusion versus standard care in children and adolescents at high risk of stroke (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>). In children and adolescents with abnormal TCD velocities (one trial,130 participants),1521 transfusions were given; and children and adolescents with normalised TCD velocities and previous long‐term RBC transfusions (one trial, 79 participants) 1070 transfusions were given. </p> <p>One review (one trial, 72 participants) compared long‐term RBC transfusions versus RBC transfusions to treat complications in pregnant women (<a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>); 432 units (with mean of 12 units) were transfused in women receiving long‐term RBC transfusions and 108 units (with mean of 3 units) in women receiving RBC transfusions to treat complications. Women receiving long‐term RBC transfusions received more RBC units. </p> </section> <section id="CD012082-sec-0071"> <h6 class="title">Restrictive (to increase the total haemoglobin) versus liberal (to decrease the haemoglobin S level below a specified percentage) RBC transfusion strategy </h6> <p>In one review (one trial, 230 participants) (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>) in people undergoing cholecystectomy, there was an increase in the number of red cell units transfused in the liberal RBC transfusion arm, MD 2.70 units (95% CI 2.10 to 3.30); however, this evidence was very low‐quality according to GRADE criteria. </p> </section> </section> <section id="CD012082-sec-0072"> <h5 class="title">3. Quality of life</h5> <p>Quality of life was not reported for RBC transfusions versus disease‐modifying agents, for restrictive RBC transfusion versus liberal RBC transfusion, or for long‐term RBC transfusions versus RBC transfusions to treat complications. </p> <p>This outcome is reported in three reviews and includes 215 participants ( <a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>; <a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>). </p> <section id="CD012082-sec-0073"> <h6 class="title">RBC transfusions versus standard care</h6> <section id="CD012082-sec-0074"> <p><b>Short‐term</b></p> <p>One review (two trials, 434 participants) compared short‐term RBC transfusion versus standard care in people undergoing low‐ to medium‐risk surgery (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>), the mean health‐related quality of life scores were higher in the short‐term RBC transfusion group when controlling for baseline EQ‐5D, MD 0.024 (95% CI ‐0.093 to 0.141) (one trial,19 participants, included data on one re‐randomised participant, evidence not GRADE assessed in review), analysis performed by trial authors. </p> <p><i>Long‐term</i> </p> <p>Two reviews (three trials, 405 participants) compared long‐term RBC transfusion versus standard care in children and adolescents at high risk of stroke (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>). In children with normal TCD velocities and silent stroke, quality of life was measured on the Child Health Questionnaire Parent Form 50 (CHQ_PF50) completed at baseline and at the occurrence of an overt stroke or at trial exit at 36 months. It is not known what the minimal clinically important differences are for the CHQ_PF50. Long‐term RBC transfusions may increase the quality of life, MD ‐0.54 (95% CI ‐0.92 to ‐0.17) (one trial, 196 participants, GRADE low‐quality evidence) analysis performed by the trial authors. </p> </section> </section> </section> <section id="CD012082-sec-0075"> <h5 class="title">4. Hospital length of stay including length of stay in critical care and hospital readmissions </h5> <p>This outcome was reported in one review (one trial, 65 participants) (<a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>). In short‐term RBC transfusion versus standard care, in people undergoing low‐ to medium‐risk surgery, there may be little or no difference in the length of hospital stay, this evidence was low‐quality according to GRADE criteria. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012082-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012082-sec-0076"></div> <section id="CD012082-sec-0077"> <h3 class="title" id="CD012082-sec-0077">Summary of main results</h3> <p>We examined the evidence from published Cochrane Reviews for the use of RBC transfusions to treat or prevent complications in people with SCD. We included 15 reviews, however, in 10 of these reviews there was no RBC transfusion intervention (five reviews included other interventions and five reviews found no RCT evidence) (<a href="#CD012082-fig-0001">Figure 1</a>). We concentrated this overview on the five reviews which include an RBC transfusion intervention comparison; however, one of these reviews included only 10 randomised participants and had no data to report (<a href="./references#CD012082-bbs2-0002" title="DastgiriS , DolatkhahR . Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD007843.pub3; CD007843] ">Dastgiri 2016</a>). The four remaining reviews compared short‐ and long‐term RBC transfusions to standard care; long‐term RBC transfusions for preventing complications versus RBC transfusions to treat complications; restrictive versus liberal RBC transfusion strategy; and RBC transfusion versus disease‐modifying agents (hydroxyurea). One review included trials in both adults and children, however, the majority of participants were children and adolescents; one review included pregnant women; and two reviews included trials in children and adolescents. </p> <p>The key outcome findings of our review are as follows.</p> <p> <ul id="CD012082-list-0039"> <li> <p>In all four reviews and all comparisons there was little or no difference in the risk of death. </p> </li> </ul> </p> <section id="CD012082-sec-0078"> <h4 class="title">Short‐term RBC transfusion versus standard care</h4> <p> <ul id="CD012082-list-0040"> <li> <p>In people undergoing low‐ to medium‐risk surgery, compared to standard care, RBC transfusions may decrease the risk of ACS in people with African haplotypes, but there was little or no difference in people with the Arabic haplotype. There was little or no difference in the risk of other SCD‐related or transfusion‐related complications. </p> </li> </ul> </p> </section> <section id="CD012082-sec-0079"> <h4 class="title">Long‐term RBC transfusion versus standard care</h4> <p> <ul id="CD012082-list-0041"> <li> <p>In children and adolescents at high risk of stroke (abnormal TCDs or SCI), long‐term RBC transfusions probably decrease the risk of stroke and may decrease the risk of ACS and painful crisis compared to standard care. </p> </li> <li> <p>Compared to standard care, long‐term RBC transfusions may decrease the risk of SCI in children with abnormal TCD velocities, but there was little or no difference in the risk of SCI in children with normal TCD velocities and previous SCI. </p> </li> <li> <p>In children and adolescents already receiving long‐term RBC transfusions for prevention of stroke, we do not know whether there is a difference in the risk of stroke between long‐term RBC transfusion and standard care, but continuing long‐term RBC transfusions may reduce the risk of SCI. </p> </li> <li> <p>In children with normal TCD velocities and SCI there was little or no difference in the risk of alloimmunisation or transfusions reactions between treatment groups, but RBC transfusions may increase the risk of iron overload. </p> </li> </ul> </p> </section> <section id="CD012082-sec-0080"> <h4 class="title">Long‐term RBC transfusion versus RBC transfusion to treat complications</h4> <p> <ul id="CD012082-list-0042"> <li> <p>In pregnant women, long‐term RBC transfusions may decrease the risk of painful crisis when compared to transfusions for complications; but there was little or no difference in the risk of other SCD‐related complications or transfusion reactions. </p> </li> </ul> </p> </section> <section id="CD012082-sec-0081"> <h4 class="title">RBC transfusion versus disease‐modifying agents (hydroxyurea)</h4> <p> <ul id="CD012082-list-0043"> <li> <p>For primary prevention of stroke in children, with abnormal TCD and no severe vasculopathy on MRI/MRA, who have received at least one year of RBC transfusions, we do not know whether there is a difference in the risk of stroke; SCI; ACS; painful crisis; or iron overload when RBC transfusion is compared to disease‐modifying agents (hydroxyurea). </p> </li> <li> <p>For secondary prevention of stroke in children and adolescents, we do not know whether there is a difference in the risk of stroke; SCI; ACS; or iron overload when RBC transfusion is compared to disease‐modifying agents (hydroxyurea). However, hydroxyurea with phlebotomy may increase the risk of painful crisis and global SCD SAEs. </p> </li> </ul> </p> </section> <section id="CD012082-sec-0082"> <h4 class="title">Restrictive versus liberal RBC transfusion strategy</h4> <p> <ul id="CD012082-list-0044"> <li> <p>In people undergoing cholecystectomy, there was little or no difference in the risk of SCD‐related or transfusion‐related complications between transfusion strategies. </p> </li> </ul> </p> </section> </section> <section id="CD012082-sec-0083"> <h3 class="title" id="CD012082-sec-0083">Overall completeness and applicability of evidence</h3> <p>Although 15 reviews met the inclusion criteria, 10 of these reviews did not identify any trials with an RBC transfusion intervention, which demonstrates the striking lack of RCT evidence on the use of RBC transfusions to treat many SCD‐related complications in both adults and children. Also SCD‐ and transfusion‐related outcomes were often not measured or not reported in the trials which highlights the lack of evidence on overall effects of interventions on various disease and treatment outcomes. Both these issues are made transparent in a summary (<a href="#CD012082-fig-0001">Figure 1</a>). There were few trials in the reviews and several of them were stopped early which could also affect the effect estimate of the interventions. </p> <p>Some of the outcomes within the reviews were rare, such as death. This meant that because the reviews only contained a small number of participants the reviews would be unable to detect a difference in any rare outcome, even if one existed. </p> <p>Few of the trials within the reviews included adults, however, the number of people with SCD are living longer, and over the past 40 years, the observed median survival has increased to over 60 years of age (<a href="./references#CD012082-bbs2-0058" title="PielFB , SteinbergMH , ReesDC . Sickle Cell Disease. New England Journal of Medicine2017;376(16):1561‐73. ">Piel 2017</a>). There is a pressing and ongoing need for effective therapies (including blood transfusions) to treat acute and chronic complications of SCD as the population ages. Moreover, the trials primarily included children or adolescents with HbSS disease with no evidence for effects in other SCD genotypes (HbSβº, HbSC or HbSβ+). </p> <p>All of the reviews included trials that were conducted in high‐income countries (USA, Canada, France and the UK). The potential risks associated with transfusion therapy are increased in low‐income countries due to a lack of trained staff, modern equipment, sanitary conditions and clean, infection‐free blood products (<a href="./references#CD012082-bbs2-0033" title="AnsongD , AkotoA O , OclooD , Ohene‐FrempongK . Sickle cell disease: management options and challenges in developing countries. Mediterranean Journal of Hematology and Infectious Diseases2013;5(1):e2013062. ">Ansong 2013</a>; <a href="./references#CD012082-bbs2-0056" title="Ohene‐FrempongK . Sickle cell disease in the United Statesof America and Africa. Hematology (American Society of Hematology Education Program). American Society of Hematology1999:64‐72. ">Ohene‐Frempong 1999</a>). Therefore, the risk‐benefit ratio will be different in low‐income countries and the results compiled in this overview may not be generalisable to that setting. </p> </section> <section id="CD012082-sec-0084"> <h3 class="title" id="CD012082-sec-0084">Quality of the evidence</h3> <p>The quality of the included Cochrane Reviews was high based on AMSTAR criteria. The reviews were current, included comprehensive literature searches, reported the quality of outcomes using GRADE, and conclusions were appropriately based on the evidence. </p> <p>However, the quality of the trials included in the reviews was variable as a result many outcomes were considered very low to low quality according to GRADE. One outcome was rated as having moderate‐quality evidence of benefit (stroke in children and adolescents at high risk of stroke). The main sources of bias for individual outcomes in primary studies were lack of blinding and limitations in the methodological conduct of the trial (including: imbalance in baseline characteristics between treatment arms; cross‐over between trial arms; quasi‐randomisation; reporting outcomes as treated rather than intention‐to‐treat analysis), which led to the downgrading of the evidence. In two reviews, which included five trials (<a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>), four trials were stopped early (<a href="./references#CD012082-bbs2-0028" title="AdamsRJ , McKieVC , HsuL , FilesB , VichinskyE , PegelowC , et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. New England Journal of Medicine1998;339(1):5‐11. ">Adams 1998</a>; <a href="./references#CD012082-bbs2-0029" title="AdamsRJ , BrambillaD . Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. New England Journal of Medicine2005;353(26):2769‐78. ">Adams 2005</a>; <a href="./references#CD012082-bbs2-0081" title="WareRE , HelmsRW , SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood2012;119(17):3925‐32. ">Ware 2012</a>; <a href="./references#CD012082-bbs2-0082" title="WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia ‐ TCD with Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open‐label, phase 3, non‐inferiority trial. Lancet2016;387(10019):661‐70. ">Ware 2016</a>). Two were stopped for safety reasons (<a href="./references#CD012082-bbs2-0028" title="AdamsRJ , McKieVC , HsuL , FilesB , VichinskyE , PegelowC , et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. New England Journal of Medicine1998;339(1):5‐11. ">Adams 1998</a>; <a href="./references#CD012082-bbs2-0029" title="AdamsRJ , BrambillaD . Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. New England Journal of Medicine2005;353(26):2769‐78. ">Adams 2005</a>); one for futility (for the composite primary end point of stroke and liver iron concentration, the increased risk of stroke with hydroxyurea was acceptable and within the non‐inferiority stroke margin, hydroxyurea and phlebotomy was not superior to transfusion and chelation at reducing liver iron concentration) (<a href="./references#CD012082-bbs2-0081" title="WareRE , HelmsRW , SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood2012;119(17):3925‐32. ">Ware 2012</a>); and one for non‐inferiority (<a href="./references#CD012082-bbs2-0082" title="WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia ‐ TCD with Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open‐label, phase 3, non‐inferiority trial. Lancet2016;387(10019):661‐70. ">Ware 2016</a>). Other sources of bias which led to the downgrading of evidence included risk of bias (e.g. baseline imbalance in the number of participants with severe vasculopathy (<a href="./references#CD012082-bbs2-0081" title="WareRE , HelmsRW , SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood2012;119(17):3925‐32. ">Ware 2012</a>)) indirectness (most trials were only done in children); and imprecision as many of the outcomes had very wide CIs. </p> </section> <section id="CD012082-sec-0085"> <h3 class="title" id="CD012082-sec-0085">Potential biases in the overview process</h3> <p>To our knowledge our overview process was free of bias; however, we only included Cochrane Reviews and there could be other non‐Cochrane reviews which could impact on the findings of this overview. We undertook a thorough search of the <i>Cochrane Database of Systematic Reviews</i> and used Cochrane methods to select reviews, standard tools to assess the risk of bias and to extract data. We achieved consensus on any disagreements through discussion or by consulting a third overview author (SH). A potential bias in the overview process was that the authors of this overview were also authors of five included reviews (<a href="./references#CD012082-bbs2-0003" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , HambletonIR , ChoG . Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD008360.pub4; CD008360] ">Estcourt 2016a</a>; <a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>; <a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>; <a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a>; <a href="./references#CD012082-bbs2-0015" title="RoyNB , FortinPM , BullKR , DoreeC , TrivellaM , HopewellS , et al. Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database of Systematic Reviews 201, Issue 7. [DOI: 10.1002/14651858.CD012380; CD012380] ">Roy 2017</a>). The overview authors updated several reviews because they were out of date and did not provide GRADE assessments of the quality of the evidence (<a href="./references#CD012082-bbs2-0003" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , HambletonIR , ChoG . Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD008360.pub4; CD008360] ">Estcourt 2016a</a>; <a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>; <a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a>). This made sure that this overview conformed to Ballard's proposed checklist for overviews (<a href="./references#CD012082-bbs2-0034" title="BallardM , MontgomeryP . Risk of bias in overviews of reviews: a scoping review of methodological guidance and four‐item checklist. Research Synthesis Methods2017;8:92‐108. [DOI: 10.1002/jrsm.1229] ">Ballard 2017</a>). </p> </section> <section id="CD012082-sec-0086"> <h3 class="title" id="CD012082-sec-0086">Agreements and disagreements with other studies or reviews</h3> <p>We identified two reviews that summarised evidence for RBC transfusions to treat complications of SCD (<a href="./references#CD012082-bbs2-0040" title="US Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute Expert Panel Report 2014. Evidence‐based management of sickle cell disease: Expert Panel Report, 2014. http://www.nhlbi.nih.gov/health‐pro/guidelines/sickle‐cell‐disease‐guidelines (accessed 01 August 2015). ">Expert Panel Report 2014</a>; <a href="./references#CD012082-bbs2-0048" title="JosephsonCD , SuLL , HillyerKL , HillyerCD . Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfusion Medicine Reviews2007;21(2):118‐32. ">Josephson 2007</a>). Yawn (<a href="./references#CD012082-bbs2-0085" title="YawnBP , BuchananGR , Afenyi‐AnnanAN , BallasSK , HasselKL , JamesAH , et al. Management of sickle cell disease: summary of the 2014 evidence‐based report by expert panel members. JAMA2014;312(10):1033‐48. ">Yawn 2014</a>) summarises the Expert Panel Report from 2014 and makes a strong recommendation for the use of both hydroxyurea and RBC transfusion in many individuals with SCD (<a href="./references#CD012082-bbs2-0040" title="US Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute Expert Panel Report 2014. Evidence‐based management of sickle cell disease: Expert Panel Report, 2014. http://www.nhlbi.nih.gov/health‐pro/guidelines/sickle‐cell‐disease‐guidelines (accessed 01 August 2015). ">Expert Panel Report 2014</a>). The report assesses evidence from both RCTs and observational studies. Yawn acknowledges the lack of high quality evidence for treating chronic SCD complications in particular (<a href="./references#CD012082-bbs2-0085" title="YawnBP , BuchananGR , Afenyi‐AnnanAN , BallasSK , HasselKL , JamesAH , et al. Management of sickle cell disease: summary of the 2014 evidence‐based report by expert panel members. JAMA2014;312(10):1033‐48. ">Yawn 2014</a>). Josephson also reviews the evidence of RBC transfusion therapy to treat acute and chronic complications of SCD and acknowledges that many of the indications for RBC transfusion are based on anecdotal and observational studies (<a href="./references#CD012082-bbs2-0048" title="JosephsonCD , SuLL , HillyerKL , HillyerCD . Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfusion Medicine Reviews2007;21(2):118‐32. ">Josephson 2007</a>). The number of included reviews in this overview which have no RBC transfusion intervention or RCT evidence, also highlights the overall lack of evidence to treat specific complications. It also highlights the missing data or lack of reporting of important patient outcomes of SCD‐related SAEs and quality of life within trials, which makes it difficult to assess the benefit or harm of interventions. This overview provides the most current assessment of reviews of RCTs and includes two reviews that have assessed one of the largest and most recent trials in children with SCD (<a href="./references#CD012082-bbs2-0039" title="DeBaunMR , MGordon , RCMcKinstry , MJNoetzel , DAWhite , SASarnaik , et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. New England Journal of Medicine2014;371(8):699‐710. ">DeBaun 2014</a>) which adds to the evidence base for the use of RBC transfusions in children and adolescents for stroke and SCI prevention. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012082-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/media/CDSR/CD012082/urn:x-wiley:14651858:media:CD012082:CD012082-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/media/CDSR/CD012082/image_t/tCD012082-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD012082-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012082.pub2/media/CDSR/CD012082/image_n/nCD012082-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full#CD012082-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/media/CDSR/CD012082/image_n/nCD012082-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD012082-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of reviews with an RBC transfusion intervention</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review</b> </p> <p><b>(Included trials)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objectives</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Date assessed as up to date / Date of last search</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study Population</b> </p> <p><b>Number of participants / type of SCD / age of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of included trials / study design / location of studies / duration of follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review outcomes for which data are reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review outcomes for which data are not reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a> </p> <p><b>Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease</b> </p> <p>(SIT (<a href="./references#CD012082-bbs2-0039" title="DeBaunMR , MGordon , RCMcKinstry , MJNoetzel , DAWhite , SASarnaik , et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. New England Journal of Medicine2014;371(8):699‐710. ">DeBaun 2014</a><b>)</b>; STOP (<a href="./references#CD012082-bbs2-0028" title="AdamsRJ , McKieVC , HsuL , FilesB , VichinskyE , PegelowC , et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. New England Journal of Medicine1998;339(1):5‐11. ">Adams 1998</a><b>)</b>; STOP2 (<a href="./references#CD012082-bbs2-0029" title="AdamsRJ , BrambillaD . Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. New England Journal of Medicine2005;353(26):2769‐78. ">Adams 2005</a><b>)</b>; SWITCH (<a href="./references#CD012082-bbs2-0081" title="WareRE , HelmsRW , SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood2012;119(17):3925‐32. ">Ware 2012</a><b>)</b>; TWITCH (<a href="./references#CD012082-bbs2-0082" title="WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia ‐ TCD with Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open‐label, phase 3, non‐inferiority trial. Lancet2016;387(10019):661‐70. ">Ware 2016</a><b>)</b>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To determine whether chronic blood transfusion in people with SCD:</p> <p>1. reduce occurrence of stroke (primary prevention);</p> <p>2. reduce recurrence of stroke (secondary prevention;</p> <p>3. reduce mortality;</p> <p>4. reduce other complications of SCD including pain crises, ACS and splenic sequestration;</p> <p>5. are associated with unacceptable adverse events or costs.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>04 April 2016 / 04 April 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chronic blood transfusion regimens to maintain HbS level &lt; 30% (+/‐ iron chelation)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Standard care</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 405 participants</p> <p>N = 130 children with abnormal TCD velocities and previous history of TIA or stroke (STOP) </p> <p>N= 79 children with normalised TCD velocities (STOP 2)</p> <p>N = 196 children with SCIs and normal TCD velocities (SIT)</p> <p>All 3 trials enrolled children with HbSS or Hb Sβº</p> <p>% with either 1 not clear majority HbSS</p> <p><b>Mean (SD) age (years)</b>: </p> <p>STOP: 8.3 (3.3);</p> <p>STOP 2: 8.6 (1.2);</p> <p>SIT: 8 (3).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 multicentre trials</p> <p>conducted in USA and Canada (STOP; STOP 2)</p> <p>Mean (SD) length of follow‐up: transfusion arm: 21.0 (5.7) months; standard care: 18.3 (7.0) months (STOP). </p> <p>Median time from randomisation to an end‐point event was 3.2 months (range, 2.1 to 10.1), and the mean (SD) was 4.5 (2.6) months (STOP 2). </p> <p>Both studies were stopped early due to safety concerns.</p> <p>1 multicentre trial conducted in USA, Canada, France and UK (SIT)</p> <p>Children were followed for a median of 3 years.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> <p>· Incidence of clinical stroke</p> <p>· Mortality</p> <p>· Transfusion‐related complications</p> <p><b>Secondary outcomes</b> </p> <p>· Incidence of TIA</p> <p>· Haemoglobin level and haemoglobin S percentage</p> <p>· Measure of neurological impairment</p> <p>· Incidence of other sickle cell complications</p> <p>· QoL, inpatient stay, immobility and disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measures of organ damage</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chronic blood transfusion regimens to maintain HbS level &lt; 30% (+/‐ iron chelation)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hydroxyurea with phlebotomy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 254 participants</p> <p>N = 133 history of stroke, chronic transfusion treatment and iron overload (SWiTCH)</p> <p>N = 121 children with abnormal TCD velocities but no severe vasculopathy on MRI/MRA, who have received at least 1 year of RBC transfusions (TWITCH) </p> <p><b>HbSS:</b> </p> <p>SWITCH: transfusion: 100% hydroxyurea : 99%</p> <p>TWITCH: transfusion: 97% hydroxyurea: 100%</p> <p><b>Mean (SD) age (years)</b>: SWITCH: transfusion: 13.3 (3.8); hydroxyurea: 13.0 (4.0); TWITCH: transfusion: 9.5 (0.68); hydroxyurea: 9.7 (3.2). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 multicentre trials with 254 participants</p> <p>Conducted in USA and Canada</p> <p>Total duration of study treatment was: 30 months after randomisation, with a final study visit scheduled 6 months after discontinuation of study treatments (SWiTCH); 24 months after randomisation with a 6‐month visit after completing exit studies (TWITCH). </p> <p>Both studies were stopped early, 1 for futility (SWITCH) and 1 for non‐inferiority (TWITCH). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> <p>· Mortality</p> <p>· Incidence of clinical stroke</p> <p>· Transfusion‐related complications</p> <p><b>Secondary outcomes</b> </p> <p>· Incidence of TIA or silent infarction</p> <p>· Haemoglobin level and haemoglobin S percentage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measure of neurological impairment</p> <p>Incidence of other SCD complications</p> <p>QoL</p> <p>Inpatient stay</p> <p>Immobility and disability</p> <p>Measures of organ damage</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a> </p> <p><b>Interventions for preventing silent cerebral infarcts in people with sickle cell disease </b> </p> <p>(SIT (<a href="./references#CD012082-bbs2-0039" title="DeBaunMR , MGordon , RCMcKinstry , MJNoetzel , DAWhite , SASarnaik , et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. New England Journal of Medicine2014;371(8):699‐710. ">DeBaun 2014</a><b>)</b>; STOP (<a href="./references#CD012082-bbs2-0028" title="AdamsRJ , McKieVC , HsuL , FilesB , VichinskyE , PegelowC , et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. New England Journal of Medicine1998;339(1):5‐11. ">Adams 1998</a><b>)</b>; STOP2 (<a href="./references#CD012082-bbs2-0029" title="AdamsRJ , BrambillaD . Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. New England Journal of Medicine2005;353(26):2769‐78. ">Adams 2005</a><b>)</b>; SWITCH (<a href="./references#CD012082-bbs2-0081" title="WareRE , HelmsRW , SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood2012;119(17):3925‐32. ">Ware 2012</a><b>)</b>; TWITCH (<a href="./references#CD012082-bbs2-0082" title="WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia ‐ TCD with Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open‐label, phase 3, non‐inferiority trial. Lancet2016;387(10019):661‐70. ">Ware 2016</a><b>)</b>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>To assess the effectiveness of red blood transfusions and hydroxyurea alone or in combination and HSCT to reduce or prevent SCI in people with SCD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>19 September 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chronic blood transfusion regimens to maintain HbS level &lt; 30% (+/‐ iron chelation)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Standard care</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 405 participants</p> <p>N = 130 children with abnormal TCD velocities and previous history of TIA or stroke (STOP) </p> <p>N= 79 children with normalised TCD velocities (STOP 2)</p> <p>N = 196 children with SCI and normal TCD velocities (SIT)</p> <p>All 3 trials enrolled children with <b>HbSS or Hb Sβº</b> </p> <p>% with either 1 not clear majority HbSS</p> <p><b>Mean (SD) age (years)</b>: STOP: 8.3 (3.3); STOP 2: 8.6 (1.2); SIT: 8 (3). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 multicentre trials</p> <p>conducted in USA and Canada</p> <p>(STOP, STOP 2)</p> <p>Mean (SD) length of follow‐up: transfusion arm: 21.0 (5.7) months; Standard care: 18.3 (7.0) months (STOP) </p> <p>Median time from randomisation to an end‐point event was 3.2 months (range, 2.1 to 10.1), and the mean (SD) was 4.5 (2.6) months (STOP 2). </p> <p>Both studies terminated early.</p> <p>1 multicentre trial conducted in USA, Canada, France and UK (SIT)</p> <p>Children were followed for a median of 3 years.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> <p>· Proportion of participants developing new or progressive SCI lesions on MRI</p> <p>· All‐cause mortality</p> <p>· SAEs associated with different therapies or SCD</p> <p><b>Secondary outcomes</b> </p> <p>· Clinical stroke (according to short‐, medium‐, and long‐term outcomes)</p> <p>· Cognitive function as assessed by validated scales (such as Wechsler scales) from baseline and at various time intervals as reported in studies (at least 6 months) </p> <p>· QoL as assessed by validated scales (at least 6 months)</p> <p>· Any AEs associated with different therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL and</p> <p>Cognitive function were not reported in STOP and STOP 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chronic blood transfusion regimens to maintain HbS level &lt; 30% (+/‐ iron chelation)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hydroxyurea with phlebotomy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 254 participants</p> <p>N = 133 history of stroke, chronic transfusion treatment and iron overload (SWiTCH)</p> <p>N = 121 children with abnormal TCD velocities but no severe vasculopathy on MRI/MRA, who have received at least 1 year of RBC transfusions (TWITCH) </p> <p><b>HbSS</b>: </p> <p>SWITCH: transfusion: 100% hydroxyurea : 99%</p> <p>TWITCH: 97% transfusion: 97% hydroxyurea: 100%</p> <p><b>Mean (SD) age (years)</b>: SWITCH: transfusion: 13.3 (3.8); hydroxyurea: 13.0 (4.0); TWITCH: transfusion: 9.5 (2.68); hydroxyurea: 9.7 (3.2). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 multicentre trials with 254 participants</p> <p>Conducted in USA and Canada</p> <p>Total duration of study treatment was:</p> <p>30 months after randomisation, with a final study visit scheduled 6 months after discontinuation of study treatments (SWiTCH); </p> <p>24 months after randomisation with a 6 month visit after completing exit studies (TWITCH).</p> <p>Both studies terminated early.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> <p>· Proportion of participants developing new or progressive SCI lesions on MRI</p> <p>· All‐cause mortality</p> <p>· SAEs associated with different therapies or SCD</p> <p><b>Secondary outcomes</b> </p> <p>· Clinical stroke (according to short‐, medium‐, and long‐term outcomes)</p> <p>· Any AEs associated with different therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive function as assessed by validated scales (such as Wechsler scales) from baseline and at various time intervals as reported in studies (at least 6 months) </p> <p>QoL as assessed by validated scales (at least 6 months)</p> <p>SWiTCH did not report any AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a>Preoperative blood transfusions for sickle cell disease </p> <p>(<a href="./references#CD012082-bbs2-0032" title="Al‐JaouniSK , Al‐MuhayawiSM , QariMH , NawasMA , Al‐MazrooaA . Randomized clinical trial to evaluate the safety of avoiding pre‐operative transfusion in sickle cell anemia. Bahrain Medical Bulletin2006;28(4):164‐7. [] ">Al‐Jaouni 2006</a><b>; </b><a href="./references#CD012082-bbs2-0047" title="HowardJ , MalfroyM , LlewelynC , ChooL , HodgeR , JohnsonT , et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet2013;381:930‐8. ">Howard 2013</a><b>; </b><a href="./references#CD012082-bbs2-0077" title="VichinskyEP , HaberkernCM , NeumayrL , EarlesAN , BlackD , KoshyM , et al. A comparison of conservative and aggressive transfusion regimes in the perioperative management of sickle cell disease. New England Journal of Medicine1995;333(4):206‐13. ">Vichinsky 1995</a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>To determine whether there is evidence that preoperative blood transfusion in elective or emergency surgery: </p> <p>a. reduces mortality;</p> <p>b. reduces complications directly related to the surgical procedure, such as local infection and bleeding; </p> <p>c. reduces serious perioperative complications including pain, ACS and the postoperative frequency and severity of infections; </p> <p>d. is associated with severe AEs (as reported in the included studies).</p> <p>2. To compare the effectiveness of different transfusion regimens (aggressive or conservative) if preoperative transfusions </p> <p>are indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9 July 2015 / 17 March 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aggressive, designed to decrease the haemoglobin S level to less than 30%</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conservative, designed to increase the haemoglobin level to 100 g/L</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 551 participants</p> <p><b>HbSS</b>: 551 (100%) </p> <p>75% aged &lt; 20 years; 25% aged 20 years or older.</p> <p>Review reports on cholecystectomy (N = 230) and tonsillectomy/ adenoidectomy (N = 107) subgroups only due to unit of analysis issues with re‐randomisation in the trial. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 parallel RCT in USA</p> <p>30‐day follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> <p>· Perioperative mortality (all‐cause)</p> <p>· Serious complications related to:</p> <p>§ sickle cell disease</p> <p>§ surgery</p> <p>§ transfusion</p> <p><b>Secondary outcomes</b> </p> <p>· Other transfusion‐related complications</p> <p>· Haemoglobin level and haemoglobin S percentage</p> <p>· Number of units or volume (mL) of RBCs infused and, where known for exchange transfusions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>· Length of stay</p> <p>· QoL</p> <p>· Measures of organ damage</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Simple or exchange transfusion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No preoperative transfusion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 436 participants (2 re‐randomised)</p> <p>HbSS = 337 (77%)</p> <p>HbSβº = 76 (17%)</p> <p>HbSβ<sup>+</sup> = 14 (4%) </p> <p>HbSC = 9 (2%)</p> <p>247 children (57%) (aged up to 16 or 18 years)</p> <p>189 adults (43%) (only 6 (1%) aged 40 years or older)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 parallel RCTs:</p> <p>1 multinational (22 centres in Canada, Ireland, Netherlands and the UK); 1 in Saudi Arabia. </p> <p>1 study reports a 30‐day follow‐up the other does not report study duration.</p> <p>Multinational study stopped early before full enrolment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> <p>· Perioperative mortality (all‐cause)</p> <p>· Serious complications related to:</p> <p>§ sickle cell disease</p> <p>§ surgery</p> <p>§ transfusion</p> <p><b>Secondary outcomes</b> </p> <p>· Other transfusion‐related complications</p> <p>· Length of stay (reported in one trial only)</p> <p>· QoL</p> <p>(reported in 1 trial only)</p> <p>· Haemoglobin level and haemoglobin S percentage (reported in 1 trial only)</p> <p>· Number of units or volume (mL) of RBCs infused and, where known for exchange transfusions (reported in 1 trial only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>· Measures of organ damage</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a>Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy </p> <p><b>(</b><a href="./references#CD012082-bbs2-0051" title="KoshyM , BurdL , WallaceD , MoawadA , BaronJ . Prophylactic red‐cell transfusions in pregnant patients with sickle cell disease. New England Journal of Medicine1988;319:1447–52. ">Koshy 1988</a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the benefits and harms of a policy of prophylactic versus</p> <p>selective blood transfusion in pregnant women with SCD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 May 2016 /30 May 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prophylactic transfusion:</b> </p> <p><b>to optimise Hb concentration to a specified level</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Selective (emergency) transfusion:</b> </p> <p><b>when indicated by specific complication or a critically low level of Hb concentration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 72</p> <p>pregnant women with sickle cell anaemia (genotype HbSS) before 28 weeks of gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 multicentre study conducted in 6 secondary and university hospitals in the USA.</p> <p>Final evaluation conducted 6 weeks postpartum.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> <p>· Maternal death</p> <p>· Severe maternal morbidity (e.g. organ failure, pulmonary embolism, fat embolism, stroke, intensive care unit admission; or as defined by trial authors) </p> <p>· Perinatal death</p> <p><b>Secondary outcomes</b> </p> <p><b>Mother</b> </p> <p>· Sickle cell crisis (due to vaso‐occlusion, sequestration or</p> <p>· haemolysis)</p> <p>· Total units of blood transfused</p> <p>· Blood transfusion reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mother</b> </p> <p>· Iron overload</p> <p>· postpartum haemorrhage</p> <p>· Cumulative duration of hospital stay</p> <p><b>Infant</b> · </p> <p>· Admission to neonatal intensive care</p> <p>· Haemolytic disease of the newborn</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0002" title="DastgiriS , DolatkhahR . Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD007843.pub3; CD007843] ">Dastgiri 2016</a> </p> <p><b>Blood transfusions for treating acute chest syndrome in people with Sickle cell disease</b> </p> <p>(PROACTIVE (<a href="./references#CD012082-bbs2-0074" title="StylesL , WagerCG , LabotkaRJ , Smith‐WhitleyK , ThompsonAA , LanePA , et al. Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE).. British Journal of Haematology2012;157(5):627‐36. ">Styles 2012</a><b>))</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the effectiveness of blood transfusions, simple and exchange, for treating ACS by comparing improvement in symptoms and clinical outcomes against standard care. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 July 2016/ 25 April 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>· Confirmed diagnosis of SCD: SS; SC; Sβº; Sβ<sup>+</sup> </p> <p>· Male or female</p> <p>· All ages</p> <p>· Any setting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>· RBC transfusions (simple or exchange)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>· Standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study met the inclusion criteria but no study results reported as out of 237 enrolled only 10 were randomised – the rest observational. </p> <p>In the study publication they report 0/4 in transfusion arm no ACS and 2/6 in standard care arm with ACS. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dastigiri 2016 Blood transfusions for treating ACS in people with SCD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the effectiveness of blood transfusions, simple and exchange, for treating ACS by comparing improvement in symptoms and clinical outcomes against standard care. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>ACS: acute chest syndrome<br/> AEs: adverse events<br/> Hb: haemoglobin<br/> MRI/MRA: magnetic resonance imaging/magnetic resonance angiography<br/> QoL: quality of life<br/> RBC: red blood cell<br/> SAEs: serious adverse events<br/> SCD: sickle cell disease<br/> SCI: silent cerebral infarcts<br/> SD: standard deviation<br/> TCD: transcranial doppler<br/> TIA: transient ischaemic attack </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of reviews with an RBC transfusion intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full#CD012082-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012082-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of reviews with other interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review</b> </p> <p><b>(Included trials)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objectives</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Date assessed as up to date / Date of last search</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study Population</b> </p> <p><b>Number of participants/ type of sickle cell/ age of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of included trials/study design/location of studies/duration of follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0015" title="RoyNB , FortinPM , BullKR , DoreeC , TrivellaM , HopewellS , et al. Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database of Systematic Reviews 201, Issue 7. [DOI: 10.1002/14651858.CD012380; CD012380] ">Roy 2017</a> </p> <p><b>Interventions to treat chronic kidney disease in people with Sickle cell disease</b> </p> <p>(BABYHUG (<a href="./references#CD012082-bbs2-0080" title="WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663‐72. ">Wang 2011</a>); <a href="./references#CD012082-bbs2-0041" title="FoucanL , BourhisV , BangouJ , MeraultL , Etienne‐JulanM , SalmiRL . A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. American Journal of Medicine1998;104(4):339‐42. ">Foucan 1998</a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the effectiveness of any intervention in preventing or reducing kidney complications or CKD in people with SCD </p> <p>(including RBC transfusions, hydroxyurea and ACEi (either alone or in combination with each other) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>/07 October 2026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with all types of SCD of all ages and either gender</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0004"> <li> <p>RBCl transfusion</p> </li> <li> <p>Hydroxyurea</p> </li> <li> <p>ACEi</p> </li> <li> <p>In combination with each other</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0005"> <li> <p>Compared to each other</p> </li> <li> <p>Placebo</p> </li> <li> <p>Standard care</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two studies met the inclusion criteria: one study compared hydroxyurea to placebo and the other study compared angiotensin converting enzyme inhibitors to placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0001" title="ChinegwundohFI , AnieKA . Treatments for priapism in boys and men with sickle cell disease. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD004198.pub2; CD004198] ">Chinegwundoh 2004</a>Treatments for priapism in boys and men with sickle cell disease </p> <p>(<a href="./references#CD012082-bbs2-0069" title="SerjeantGR , deCeulaerK , MaudeGH . Stilboestrol and stuttering priapism in homozygous sickle‐cell disease. Lancet1985;2(8467):1274‐6. ">Serjeant 1985</a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the benefits and risks of the different treatments for both</p> <p>stuttering and fulminant priapism in SCD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 August 2010 / 22 July 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0006"> <li> <p>SCD: SS; SC; Sβº; Sβ⁺</p> </li> <li> <p>Males</p> </li> <li> <p>Priapism, fulminant or stuttering</p> </li> <li> <p>All ages</p> </li> <li> <p>Any race</p> </li> <li> <p>Any ethnic origin</p> </li> <li> <p>Any setting</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0007"> <li> <p>Any treatment for priapism in SCD</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0008"> <li> <p>Placebo;</p> </li> <li> <p>No treatment;</p> </li> <li> <p>Any other intervention</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study comparing Stilboestrol 5 mg daily versus placebo.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0008" title="Martí‐CarvajalAJ , Knight‐MaddenJM , Martinez‐ZapataMJ . Interventions for treating leg ulcers in people with sickle cell disease. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD008394.pub3; CD008394] ">Martí‐Carvajal 2014</a>Interventions for treating leg ulcers in people with sickle cell disease </p> <p>(<a href="./references#CD012082-bbs2-0036" title="BaumKF , MacFarlaneDE , MaudeGH , SerjeantGR . Topical antibiotics in chronic sickle cell leg ulcers. Transactions of the Royal Society of Tropical Medicine and Hygiene1987;81(5):847‐9. ">Baum 1987</a><b>; </b><a href="./references#CD012082-bbs2-0052" title="LaGrenadeL , ThomasPW , SerjeantGR . A randomized controlled trial of solcoseryl and duoderm in chronic sickle cell ulcers. West Indian Medical Journal1993;42(3):121‐3. ">La Grenade 1993</a><b>; </b><a href="./references#CD012082-bbs2-0053" title="McMahonL , TamaryH , AskinM , Adams‐GravesP , EberhardtRT , SuttonM , et al. A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers. British Journal of Haematology2010;151(5):526‐24. ">McMahon 2010</a><b>; </b><a href="./references#CD012082-bbs2-0068" title="SerjeantGR , HowardC . Isoxsuprine hydrochloride in the therapy of sickle cell leg ulceration. West Indian Medical Journal1977;26(3):164‐6. ">Serjeant 1977</a><b>; </b><a href="./references#CD012082-bbs2-0070" title="SerjeantBE , HarrisJ , ThomasP , SerjeantGR . Propionyl‐L‐carnitine in chronic leg ulcers of homozygous sickle cell disease: a pilot study. Journal of the American Academy of Dermatology1997;37:491‐3. ">Serjeant 1997</a><b>; </b><a href="./references#CD012082-bbs2-0084" title="WethersDL , RamirezGM , KoshyM , SteinbergMH , PhillipsGJr , SiegelRS , et al. Accelerated healing of chronic sickle‐cell leg ulcers treated with RGD peptide matrix. RGD Study Group. Blood1994;84(6):1775‐9. ">Wethers 1994</a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To determine whether any clinical interventions (used either alone or in combination) are effective and safe when treating leg ulcers in people with SCD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 October 2014 / 18 September 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0009"> <li> <p>Any SCD</p> </li> <li> <p>Diagnosed with a leg ulcer</p> </li> <li> <p>Treated in community, hospital or both</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systemic interventions</b> </p> <p> <ul id="CD012082-list-0010"> <li> <p>Vascular drugs</p> </li> <li> <p>Antioxidant agents</p> </li> <li> <p>Recombinant agents growth factors</p> </li> <li> <p>Pharmacologic stimulation of HbF synthesis</p> </li> <li> <p>Oral zinc sulphate</p> </li> </ul> </p> <p><b>Topical interventions</b> </p> <p> <ul id="CD012082-list-0011"> <li> <p>Antibiotics and antiseptics</p> </li> <li> <p>Growth factors and related</p> </li> <li> <p>Steroids</p> </li> <li> <p>Dressing;</p> </li> <li> <p>Debriding agents;</p> </li> <li> <p>Ccompression; miscellaneous (such as topical opioids)</p> </li> </ul> </p> <p><b>Non‐pharmaceutical interventions</b> </p> <p> <ul id="CD012082-list-0012"> <li> <p>Reconstructive surgery</p> </li> <li> <p>Cell therapy</p> </li> <li> <p>Laser therapy miscellaneous</p> </li> <li> <p>conventional care another treatment</p> </li> <li> <p>regimen for leg ulcers in people with SCD</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0013"> <li> <p>Conventional care</p> </li> <li> <p>Another treatment regimen for leg ulcers in people with SCD</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six studies met the review’s inclusion criteria:</p> <p>Interventions included:</p> <p>· Topical antibiotics</p> <p>· Solcoseryl® and Duo Derm</p> <p>· Arginine butyrate</p> <p>· Propionyl‐L‐carnitine</p> <p>· RGD peptide matrix</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0010" title="Martí‐CarvajalAJ , SolàI , Agreda‐PérezLH . Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD004344.pub6; CD004344] ">Martí‐Carvajal 2016</a>Treatment for avascular necrosis of bone in people with sickle cell disease </p> <p>(NOTSCA (<a href="./references#CD012082-bbs2-0054" title="NeumayrLD , AguilarC , EarlesAN , JergesenHE , HaberkernCM , KammenBF , et al. Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. Journal of Bone and Joint Surgery2006;88(12):2573‐82. ">Neumayr 2006</a><b>))</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To determine if the following treatments have any impact on avascular necrosis of bone in people with SCD in both the </p> <p>short‐ and the long‐term (efficacy, safety, and adverse events): any surgical versus non‐surgical intervention, including combinations of surgical and non‐surgical treatment. Also, address the following: </p> <p>1. the role of decompression;</p> <p>2. the relative effectiveness of surgical approaches (for studies comparing 2 surgical approaches); </p> <p>3. types of prosthesis (glued or not, with or without bone grafts etc.)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 July 2014 / 17 March 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0014"> <li> <p>Confirmed diagnosis of SCD (trial included HbSS; SC; Sβ⁰)</p> </li> <li> <p>Any SCD ‐related avascular necrosis</p> </li> <li> <p>All ages</p> </li> <li> <p>Male or female</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Surgical treatment:</b> </p> <p> <ul id="CD012082-list-0015"> <li> <p>Joint reconstruction (femoral head replacement, cup arthroplasty, articular surface replacement, total hip replacement); </p> </li> <li> <p>Nucleus decompression;</p> </li> <li> <p>Bone graft;</p> </li> <li> <p>Vascularized bone grafts;</p> </li> <li> <p>Osteotomy</p> </li> </ul> </p> <p><b>Non‐surgical treatment:</b> </p> <p> <ul id="CD012082-list-0016"> <li> <p>Observation;</p> </li> <li> <p>Analgesic drugs;</p> </li> <li> <p>Electrical stimulation;</p> </li> <li> <p>Physiotherapy;</p> </li> <li> <p>Resting of the joint;</p> </li> <li> <p>RBC transfusion;</p> </li> <li> <p>Stem cell transplant;</p> </li> <li> <p>Treatment to prevent sickling;</p> </li> <li> <p>Bisphosphonates</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0017"> <li> <p>1 surgical approach compared to another, or to a non‐surgical approach,</p> </li> <li> <p>2 non‐surgical approaches compared</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study: NOTSCA 2006</p> <p>Randomised open‐label</p> <p>Hip core decompression and physical therapy (N = 17) versus physical therapy alone (N = 21) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0012" title="OniyangiO , CohallDH . Phytomedicines (medicines derived from plants) for sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.CD004448.pub5; CD004448] ">Oniyangi 2015</a>Phytomedicines (medicines derived from plants) for sickle cell disease </p> <p>(<a href="./references#CD012082-bbs2-0031" title="AkinsulieAO , TemiyeEO , AkanmuAS , LesiFEA , WhyteCO . Clinical evaluation of extract of Cajanuscajan (Ciklavit) in sickle cell anaemia. Journal of Tropical Paediatrics2005;51(4):200‐5. ">Akinsulie 2005</a><b>; </b><a href="./references#CD012082-bbs2-0079" title="WambebeC , KhamofuH , MomohJAF , EkpeyongM , AuduBS , NjokuOS , et al. Double‐blind, placebo controlled,randomised cross‐over clinical trial of NIPRISAN in patients with sickle cell disorder. Phytomedicine2001;8(4):252‐61. ">Wambebe 2001</a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the benefits and risks of phytomedicines in people with SCD of all types, of any age, in any setting. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 January 2015 / 26 March 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0018"> <li> <p>People of all ages</p> </li> <li> <p>SCD of any genotype in any geographic setting such as: homozygous (HbSS) and compound heterozygotes </p> </li> <li> <p>Including SC disease (HbSC) and β‐ thalassaemia (Sβ0/</p> </li> <li> <p>Sβ⁺)</p> </li> <li> <p>Proven by electrophoresis with family studies or DNA tests as appropriate</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0019"> <li> <p>Administration (by any mode: topical; oral; or parenteral) of phytomedicines (defined as a remedy derived directly from plants or plant material and not synthesised). </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0020"> <li> <p>Placebo</p> </li> <li> <p>Conventional treatment, including blood transfusion and hydroxyurea</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two studies met the inclusion criteria: one study compared Niprisan versus placebo or conventional treatment (blood transfusions not reported) </p> <p>The second study compared Ciklavit versus placebo or conventional treatment (blood transfusions not reported). </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ACEi: angiotensin‐converting enzyme inhibitors<br/> ACS: acute chest syndrome<br/> CKD: chronic kidney disease<br/> SCD: sickle cell disease<br/> SD: standard deviation<br/> TCD: transcranial doppler<br/> TIA: transient ischaemic attack </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of reviews with other interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full#CD012082-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012082-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of reviews with no studies that met inclusion criteria</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objectives</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Date assessed as up to date / Date of last search</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study Population</b> </p> <p><b>Number of participants/ type of sickle cell/ age of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison Interventions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0003" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , HambletonIR , ChoG . Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD008360.pub4; CD008360] ">Estcourt 2016a</a> </p> <p><b>Regular long‐term red blood cell transfusions for managing chronic chest complication in sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Whether long‐term blood transfusions show differences in the</p> <p>following: incidence of chronic chest complications; ’severity’ or progression of established chronic chest complications; mortality associated with chronic chest complications; unacceptable adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 May 2016 / 25 April 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any SCD:</p> <p> <ul id="CD012082-list-0021"> <li> <p>Confirmed diagnosis of SCD: SS; SC; Sβº; Sβ⁺</p> </li> <li> <p>Male or female</p> </li> <li> <p>All ages</p> </li> <li> <p>Positive or negative for a history of chronic or acute chest complications</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0022"> <li> <p>Regular RBC transfusions (simple top‐up or exchange)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0023"> <li> <p>Alternative treatment;</p> </li> <li> <p>No treatment</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0007" title="Martí‐CarvajalAJ , Peña‐MartíGE , Comunián‐CarrascoG , Martí‐PeñaAJ . Interventions for treating painful sickle cell crisis during pregnancy. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006786.pub2; CD006786] ">Martí‐Carvajal 2009</a> </p> <p><b>Intervention for treating painful sickle cell crisis during pregnancy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the effectiveness and safety of different regimens of</p> <p>packed red cell transfusion, oxygen therapy, fluid replacement</p> <p>therapy, analgesic drugs, and steroids for the treatment of painful sickle cell crisis during pregnancy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 December 2009 / December 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0024"> <li> <p>Pregnant women with SCD (all types)</p> </li> <li> <p>Any age</p> </li> <li> <p>Excluded sickle cell trait</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0025"> <li> <p>RBC transfusion</p> </li> <li> <p>Oxygen therapy</p> </li> <li> <p>Fluid replacement therapy</p> </li> <li> <p>Analgesia (nonsteroidal</p> </li> <li> <p>aAnti‐inflammatory agents or opiates agents)</p> </li> <li> <p>Steroids (prednisone, dexamethasone, or methylprednisolone)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0026"> <li> <p>Each other</p> </li> <li> <p>Placebo</p> </li> <li> <p>Standard care</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0009" title="Martí‐CarvajalAJ , Simancas‐RacinesD . Interventions for treating intrahepatic cholestasis in people with sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD010985.pub2; CD010985] ">Martí‐Carvajal 2015a</a> </p> <p><b>Intervention for treating intrahepatic cholestasis in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the benefits and harms of the interventions for treating</p> <p>intrahepatic cholestasis in people with SCD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 March 2015 /10 October 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0027"> <li> <p>SCD with intrahepatic cholestasis</p> </li> <li> <p>Any age</p> </li> <li> <p>Male or female</p> </li> <li> <p>Hospital or community setting</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0028"> <li> <p>Simple RBC transfusion</p> </li> <li> <p>Exchange transfusion</p> </li> <li> <p>Liver transplant</p> </li> <li> <p>Bile acid binding resins (cholestyramine colestipol)</p> </li> <li> <p>Rifampin</p> </li> <li> <p>Opiate antagonists (naltrexone, nalmefene)</p> </li> <li> <p>Sertraline</p> </li> <li> <p>Dexamethasone</p> </li> <li> <p>Guar gum</p> </li> <li> <p>Activated charcoal</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0029"> <li> <p>Conventional care</p> </li> <li> <p>Each other</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0013" title="OringanjeC , NemecekE , OniyangiO . Hematopoietic stem cell transplantation for people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD007001.pub4; CD007001] ">Oringanje 2016</a> </p> <p><b>Hematopoietic stem cell transplantation for people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To determine whether stem cell transplantation can improve survival and prevent symptoms and complications associated with SCD. To examine the risks of stem cell transplantation against the potential long‐term gain for people with SCD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 March 2016 / 11 December 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0030"> <li> <p>Children and adults with SCD of all phenotypes, either gender and in all settings</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0031"> <li> <p>Methods of stem cell transplantation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0032"> <li> <p>Methods of stem cell transplantation compared with each other</p> </li> <li> <p>Ssupportive care (e.g. periodic transfusion, use of hydroxyurea,</p> </li> <li> <p>Antibiotics, pain relievers, supplemental oxygen)</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0014" title="Owusu‐OforiS , RemmingtonT . Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD003425.pub3; CD003425] ">Owusu‐Ofori 2015</a> </p> <p><b>Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess whether splenectomy (total or partial), to prevent acute splenic sequestration crises in people with SCD, improved survival and decreased morbidity in people with SCD, as compared with regular blood transfusions. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 July 2015 / 10 June 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any SCD:</p> <p> <ul id="CD012082-list-0033"> <li> <p>Confirmed diagnosis of SCD: SS; SC; Sβº; Sβ⁺</p> </li> <li> <p>Experienced at least one acute splenic sequestration crisis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0034"> <li> <p>Full or partial splenectomy</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012082-list-0035"> <li> <p>Conservative management</p> </li> <li> <p>No treatment</p> </li> <li> <p>Rregimen of regular RBC transfusions (e.g. 4‐weekly)</p> </li> </ul> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>RBC: red blood cell<br/> SCD: sickle cell disease </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of reviews with no studies that met inclusion criteria</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full#CD012082-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012082-tbl-0004"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">AMSTAR quality assessment: Reviews with an RBC transfusion intervention</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AMSTAR Criteria<sup>1, 2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a> </p> <p><b>Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a> </p> <p><b>Interventions for preventing silent cerebral infarcts in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a> </p> <p><b>Preoperative blood transfusions for sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a> </p> <p><b>Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0002" title="DastgiriS , DolatkhahR . Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD007843.pub3; CD007843] ">Dastgiri 2016</a> </p> <p><b>Blood transfusions for treating acute chest syndrome in people with sickle cell disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><sup>1</sup> We applied a modified AMSTAR based on the univariable questions developed for the overview by Pollock 2014. See <a href="./appendices#CD012082-sec-0094">Appendix 2</a> AMSTAR Checklist </p> <p><sup>2</sup> Modified AMSTAR answers are reported as: Y = yes; N = no; U = unsure; NA = not applicable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1. Was an ’a priori’ design provided</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available ‐ objectives, participants, interventions and comparisons and primary and secondary outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available ‐ objectives, participants, interventions and comparisons and primary and secondary outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available ‐ objectives, participants, interventions and comparisons and primary and secondary outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available ‐ objectives, participants, interventions and comparisons, and primary and secondary outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol first published: Issue 2, 2009.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2. Was there duplicate study selection and data extraction?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two independent review screened all electronically‐derived citations and abstracts of papers identified in the search for relevance. We excluded trials that were clearly irrelevant at this stage based on a review of the abstract. </p> <p>Two independent review authors formally assessed the full texts of all potentially‐relevant trials for eligibility against the criteria outlined above. We resolved all disagreements by discussion without the need for a third review author. </p> <p>Two review authors conducted the data extraction according to the guidelines proposed by Cochrane. We resolved disagreements between the review authors by consensus. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two independent review authors screened all electronically‐derived citations and abstracts of papers identified by the review search strategy for relevance. </p> <p>Two independent review authors (LE, PF) formally assessed the full texts of all potentially relevant trials for eligibility against the criteria outlined above. We requested additional information from study authors as necessary. </p> <p>The two review authors discussed the results of study selection and resolved our discrepancies.</p> <p>Two review authors conducted the data extraction according to the guidelines proposed by the Cochrane Collaboration. Disagreements were resolved by consensus. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two independent review authors screened all electronically‐derived citations and abstracts of papers identified by the review search strategy for relevance. </p> <p>Two independent review authors (PF, LE) formally assessed the full texts of all potentially‐relevant trials for eligibility against the criteria outlined above. </p> <p> We resolved all disagreements by discussion without the need for a third review author.</p> <p>Two review authors conducted the data extraction according to the guidelines proposed by the Cochrane Collaboration. Disagreements were resolved by consensus. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two review authors independently assessed for inclusion all the potential studies identified as a result of the search strategy. </p> <p>For eligible studies, both review authors independently extracted the data using the agreed form. We resolved discrepancies through discussion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two authors independently assessed the abstracts of trials identified from the searches. The two review authors independently assessed the full text papers independently and resolved any disagreement on their eligibility for this review through discussion and consensus; or if necessary through a third party. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3. Was a comprehensive literature search performed?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Searched Haemoglobinopathies Trials Register. We also searched the following databases for RCTs and SRs on April 4 2016: </p> <p>The Cochrane Library (CENTRAL &amp; DARE) – issue 4, 2016; issue 2, 2015 respectively MEDLINE (OvidSP, 1946 to April 4 2016) EMBASE (OvidSP, last 6 months to April 4 2016) CINAHL (EBSCOHost, to April 4 2016) PubMed (e publications only to April 4 2016) Transfusion Evidence Library (1950 to April 4 2016) LILACS (1982 to April 4 2016) IndMed (1986 to April 4 2016) KoreaMed (1997 to April 4 2016) Web of Science (Conference Proceedings Citation Index‐ Science (CPCI‐S) ‐1990 to April 4 2016) We also searched the following trial databases for ongoing trials on 4 April 2016: ClinicalTrials.gov; WHO International Clinical Trials Registry Platform (ICTRP). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Searched haemoglobinopathies trials register and the following databases for RCTs on 19 September 2016. </p> <p>The Cochrane Library (CENTRAL, DARE, HTA, NHSEED) MEDLINE (OvidSP, Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE Daily and </p> <p>Ovid MEDLINE, 1946 to 19 September 2016) PubMed (Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Embase (OvidSP) CINAHL (EBSCOHost, 1937 to 19 September 2016)Transfusion Evidence Library (1950 to 19 September 2016) LILACS (1982 to 19 September 2016) Web of Science (Conference Proceedings Citation Index‐ Science (CPCI‐S) ‐ 1990 to 19 September 2016) We also searched the following trial databases for ongoing trials on 19 Sepetember 2016. </p> <p>ClinicalTrials.gov</p> <p>WHO International Clinical Trials Registry Platform (ICTRP).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Searched haemoglobinopathies trials register and supplemented searches with a search of current MEDLINE, Embase, clinical trial registries, included mesh terms, key words and dates. Search strategies in appendix. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>The Cochrane Pregnancy and Childbirth Group’s Trials Register which includes at least 2 major databases – and handsearches was searched 30 May 2016. </p> <p>Provided Mesh terms but no key words. Trial registries were not searched.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We conducted searches in the Cochrane Cystic Fibrosis and Genetic</p> <p>Disorders Group’s Haemoglobinopathies Trials Register using the terms: sickle cell AND acute chest syndrome. We also searched the (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>) database to identify any additional relevant clinical studies and registered clinical trials of the same topic. Regarding the relatively high prevalence of hereditary sickle cell disease (SS) and others associated disorders in south provinces of Iran (Zandian 2012), we tried to find any additional RCT studies registered in Iranian Registry of </p> <p>Clinical Trials (<a href="http://www.irct.ir" target="_blank">www.irct.ir</a>). Other databases and trial sites not search such as EMBASE and ICSTR. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4. Was the status of publication</b> </p> <p><b>(i.e. grey literature) used as an Inclusion criterion?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>no limits on language or publication status.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Searches for unpublished work included in search of the Register. No language restrictions.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Searches for unpublished work included in search of the Register. No language restrictions.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Searches for unpublished work included in search of the Register. No language restrictions.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We contacted the trial authors of the PROACTIVE trial for further data and information, but to date have received no. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5. Was a list of studies (included</b> </p> <p><b>and excluded) provided?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Includes study flow diagram.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Includes a flow diagram.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Includes a flow diagram.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Includes study flow diagram.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> <p>No study flow diagram provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6. Were the characteristics of the included studies provided?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Detailed descriptions of participants interventions and outcomes of included studies provided </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Detailed descriptions of participants interventions and outcomes of included studies provided. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Detailed descriptions of participants interventions and outcomes of included studies provided. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Detailed descriptions of participants interventions and outcomes of included studies provided. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Detailed descriptions of participants interventions and outcomes provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7. Was the scientific quality of the Included studies assessed and documented?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Assessed by two authors independently with Cochrane Risk of Bias tool, and Summary of findings table included and documented. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Assessed by two authors independently with Cochrane Risk of Bias tool and Summary of findings table included and documented. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Assessed by two authors independently with Cochrane Risk of Bias tool and Summary of findings table included and documented. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Assessed by two authors independently with Cochrane Risk of Bias tool, and Summary of findings table included and documented. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Not applicable</b>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8. Was the scientific quality of the Included studies used appropriately in formulating conclusions?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>The quality of the evidence was very low to moderate across different outcomes according to GRADE methodology. This was due to the trials being at a high risk of bias due to lack of blinding, indirectness and imprecise outcome estimates. Due to lack of evidence this review cannot comment on management for adults with HbSS disease or children and adults with HbSβ<sup>0</sup>, HbSC or HbSβ<sup>+</sup> disease. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>The quality of the evidence was very low to moderate across different outcomes according to GRADE methodology. This was due to: trials being at high risk of bias because they were unblinded; indirectness (the available evidence was for children with HbSS); and imprecise outcome estimates. There is low‐quality evidence that long‐term RBC transfusions may reduce the incidence of SCI in children with abnormal TCD velocities but have little or no effect on children with normal TCD velocities. In children who are at higher risk of stroke and have not had previous long‐term transfusions, there is moderate‐quality evidence that long‐term RBC transfusions. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Overall, the quality of the evidence was rated as low to very low across different outcomes according to GRADE methodology. This was due to two of the studies being at high </p> <p>or unclear risk of bias, and many of the outcome estimates being imprecise.</p> <p>Due to lack of evidence this review cannot comment on management for people with HbSC or HbSβ⁺ disease or patients with high baseline haemoglobin concentrations, or management of patients undergoing low risk surgery. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Evidence from one small trial of very low quality suggests that prophylactic blood transfusion to pregnant women with sickle cell </p> <p>anaemia (HbSS) confers no clear clinical benefits when compared with selective transfusion. Currently, there is no evidence from randomised or quasi‐randomised trials to provide reliable advice on the optimal blood transfusion policy for women with other variants of sickle cell disease (i.e. HbSC and HbS_Thal). The available data and quality of evidence on this subject are insufficient to advocate for a change in existing clinical practice and policy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Not applicable</b>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9. Were the methods used to combine the findings of studies</b> </p> <p><b>appropriate?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Risk ratio reported and Peto odds ratio reported for outcomes with low event rates all confidence intervals included. Heterogeneity defined, There was no statistical heterogeneity, but if statistical heterogeneity was found to be above 75%, we would identify a reason for clinical heterogeneity and not perform a meta‐analysis but comment instead on the results as a narrative. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Risk ratio reported and Peto odds ratio reported for outcomes with low event rates all confidence intervals included. Heterogeneity defined, There was no statistical heterogeneity, but if statistical heterogeneity was found to be above 75%, we would identify a reason for clinical heterogeneity and not perform a meta‐analysis but comment instead on the results as a narrative. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Risk ratio reported and Peto odds ratio reported for outcomes with low event rates all confidence intervals included. Heterogeneity defined, identified and reported. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>For dichotomous data, we presented results as summary risk ratio with 95% confidence intervals. No continuous data were analysed in this review. In future updates, if appropriate, we will use the mean difference if outcomes are measured in the same way between trials.We will use the standardised mean difference to combine trials that measure the same outcome, but use different methods. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Not applicable</b>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10. Was the likelihood of publication bias assessed?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Mentioned that too few studies to assess publication bias.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Mentioned that too few studies to assess publication bias.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Mentioned that too few studies to assess publication bias.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Mentioned that too few studies to assess publication bias.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Not applicable</b>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11. Was the conflict of interest</b> </p> <p><b>stated?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Lise Estcourt is partly funded by an NIHR Cochrane Programme Grant. Patricia Fortin is funded by an NIHR Cochrane Programme Grant. Sally Hopwell is partly funded by an NIHR Programme Grant. Marialena Trivella is partly funded by an NIHR Programme Grant. Winfred Wang was a PI on several of the included trials. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Lise Estcourt is partly funded by an NIHR Cochrane Programme Grant.</p> <p>Carolyn Doree: none to declare. Patricia Fortin is funded by an NIHR Cochrane Programme Grant. </p> <p>Sally Hopwell is partly funded by an NIHR Programme Grant.</p> <p>Marialena Trivella is partly funded by an NIHR Programme Grant.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Lise Estcourt is partly funded by an NIHR Cochrane Programme Grant.</p> <p>Carolyn Doree: none to declare. Patricia Fortin is funded by an NIHR Cochrane Programme Grant. </p> <p>Sally Hopwell is partly funded by an NIHR Programme Grant.</p> <p>Marialena Trivella is partly funded by an NIHR Programme Grant.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>None known.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>There are no financial conflicts of interest and the review authors declare that they do not have any associations with any parties who may have vested interests in the results of this review. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>NIHR: National Institute for Health Research<br/> PI: principal investigator<br/> TCD: transcranial doppler </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">AMSTAR quality assessment: Reviews with an RBC transfusion intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full#CD012082-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012082-tbl-0005"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">AMSTAR quality assessment: Reviews with other interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AMSTAR</b> </p> <p><b>Criteria<sup>1, 2, 3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0001" title="ChinegwundohFI , AnieKA . Treatments for priapism in boys and men with sickle cell disease. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD004198.pub2; CD004198] ">Chinegwundoh 2004</a> </p> <p><b>Treatments for priapism in boys and men with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0008" title="Martí‐CarvajalAJ , Knight‐MaddenJM , Martinez‐ZapataMJ . Interventions for treating leg ulcers in people with sickle cell disease. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD008394.pub3; CD008394] ">Martí‐Carvajal 2014</a> </p> <p><b>Interventions for treating leg ulcers in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0010" title="Martí‐CarvajalAJ , SolàI , Agreda‐PérezLH . Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD004344.pub6; CD004344] ">Martí‐Carvajal 2016</a> </p> <p><b>Treatment for avascular necrosis of bone in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0015" title="RoyNB , FortinPM , BullKR , DoreeC , TrivellaM , HopewellS , et al. Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database of Systematic Reviews 201, Issue 7. [DOI: 10.1002/14651858.CD012380; CD012380] ">Roy 2017</a> </p> <p><b>Interventions for chronic kidney disease in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0012" title="OniyangiO , CohallDH . Phytomedicines (medicines derived from plants) for sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.CD004448.pub5; CD004448] ">Oniyangi 2015</a> </p> <p><b>Phytomedicines (medicines derived from plants) for sickle cell disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><sup>1</sup> We applied a modified AMSTAR based on the univariable questions developed for the overview by Pollock 2014. See <a href="./appendices#CD012082-sec-0094">Appendix 2</a> modified AMSTAR questions </p> <p><sup>2</sup> Modified AMSTAR answers are reported as: Y = yes; N = no; U = unsure; NA = not applicable </p> <p><sup>3</sup> Items 5 ‐ 10 of AMSTAR were not assessed in the quality appraisal as the reviews did not include any studies with a red cell transfusion comparison </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1. Was an ’a priori’ design provided</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2. Was there duplicate study selection and data extraction?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Each author independently identified potentially relevant trials. Each author independently extracted data. No disagreement occurred, so no other expert in the field was invited to make an independent assessment based on the selection criteria. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two authors independently selected studies for inclusion, and extracted data. A third author was always included when two authors disagreed, all disagreements resolved by group discussion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>The authors screened the search results for potentially relevant trials and independently assessed them. Each author used this form to extract data from each relevant study. We independently extracted information from the papers. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two independent review authors screened all citations and abstracts of papers identified by the search strategy for relevance. </p> <p>Two review authors independently and formally assessed the full texts of all</p> <p>potentially relevant trials for eligibility. Two review authors conducted the data extraction. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two authors (OO, DC) independently selected the trials for inclusion in the review using pre‐defined inclusion criteria. two authors (NC, OO) had independently </p> <p>extracted the data and resolved differences by referring to the original trial. The process was repeated for this update by both authors. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3. Was a comprehensive literature search performed?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Studies identified in the Group’s Haemoglobinopathies Trials Register. Searched Embase (1974 to 2003) (<a href="./appendices#CD012082-sec-0093">Appendix 1</a>) and the Internet (December 2003). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We identified relevant trials from the Group’s Haemoglobinopathies Trials Register. Also searched– LILACS and several other databases and websites. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>U</b> </p> <p>Trials were identified from the Group’s Haemoglobinopathies Trials Register.</p> <p>No Embase or trial registry search.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We identified trials from the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register. In addition to this we searched the following databases for RCTs on 05 April 2016. CENTRAL, the Cochrane Library (current issue) MEDLINE (Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE Daily and Ovid </p> <p>MEDLINE, Embase CINAHL PubMed;Transfusion Evidence Library LILACS; IndMed; KoreaMed;</p> <p>PakMediNet; Web of Science;</p> <p>ClinicalTrials.gov; WHO International Clinical Trials Registry Platform (ICTRP).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Relevant trials were identified from the Group’s Haemoglobinopathies Trials Register. Relevant trials were also identified from the International Standard Randomised </p> <p>Controlled Trial Number Registry (ISCTN). An additional search of the Allied and Complimentary Medicine </p> <p>(AMED) bibliographic database.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4. Was the status of publication (i.e. grey literature) used as an Inclusion criterion?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Attempts were also made to identify any unpublished trials through contact with experts in the field and personal communication </p> <p>with known authors.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We searched for trials, irrespective of publication status (trials may be unpublished or published as an article, an abstract, or a letter), language or country. No limit was applied with respect to the period of follow‐up. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>U</b> </p> <p>Did not mention if any language restrictions.</p> <p>Stated that bibliographic references of all retrieved literature were reviewed for additional reports of trials. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We did not limit searches by language, year</p> <p>of publication or publication type.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>U</b> </p> <p>The bibliographic references of all retrieved trials and reviews were assessed for additional reports of trials; lead authors were to be contacted if necessary. </p> <p>No mention of limitation by language.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11. Was the conflict of interest stated?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>None known.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>In 2004 Arturo Martí‐Carvajal was employed by Eli Lilly to run a four‐hour workshop on ’How to critically appraise clinical trials. In 2007 Arturo Martí‐Carvajal was employed by Merck to run a four‐hour workshop on ’How to critically appraise clinical trials. Jennifer Knight‐Madden and María José Martínez‐Zapata: none known. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> <p>None known.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Noemi Roy: none known.</p> <p>Patricia Fortin: funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components. </p> <p>Katherine Bull: none known.</p> <p>Carolyn Doree: none known.</p> <p>Sally Hopewell: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components. Marialena Trivella: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components. </p> <p>Lise Estcourt: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>None known.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>NIHR: National Institute for Health Research</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">AMSTAR quality assessment: Reviews with other interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full#CD012082-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012082-tbl-0006"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">AMSTAR quality assessment: Reviews with no studies identified</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AMSTAR</b> </p> <p><b>Criteria<sup>1, 2, 3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0003" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , HambletonIR , ChoG . Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD008360.pub4; CD008360] ">Estcourt 2016a</a> </p> <p><b>Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0007" title="Martí‐CarvajalAJ , Peña‐MartíGE , Comunián‐CarrascoG , Martí‐PeñaAJ . Interventions for treating painful sickle cell crisis during pregnancy. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006786.pub2; CD006786] ">Martí‐Carvajal 2009</a> </p> <p><b>Interventions for treating painful sickle cell crisis during pregnancy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0009" title="Martí‐CarvajalAJ , Simancas‐RacinesD . Interventions for treating intrahepatic cholestasis in people with sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD010985.pub2; CD010985] ">Martí‐Carvajal 2015a</a> </p> <p><b>Interventions for treating intrahepatic cholestasis in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0013" title="OringanjeC , NemecekE , OniyangiO . Hematopoietic stem cell transplantation for people with sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD007001.pub4; CD007001] ">Oringanje 2016</a> </p> <p><b>Hematopoietic stem cell transplantation for people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0014" title="Owusu‐OforiS , RemmingtonT . Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD003425.pub3; CD003425] ">Owusu‐Ofori 2015</a> </p> <p><b>Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><sup>1</sup> We applied a modified AMSTAR based on the univariable questions developed for the overview by Pollock 2014. See appendix xx modified AMSTAR questions </p> <p><sup>2</sup> Modified AMSTAR answers are reported as: Y = yes; N = no; U = unsure; NA = not applicable </p> <p><sup>3</sup> Items 5 ‐ 10 of AMSTAR were not assessed in the quality appraisal as the reviews did not include any studies with a red cell transfusion comparison </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1. Was an ’a priori’ design provided</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Protocol available – participants, interventions and comparisons and outcomes clearly defined. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2. Was there duplicate study selection and data extraction?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two review authors independently screened all the remaining references for relevance against the full eligibility criteria. We retrieved full‐text articles for all references for which a decision on eligibility could not be made from title and abstract alone. The two review authors discussed the results of study selection and resolved any disagreements on trial inclusions by consensus. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We planned to screen the results of our search strategy for potentially relevant trials, and independently assess them. We will independently extract the data. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two authors will screen the search results for potentially relevant trials and independently assess them. One author will extract data from the included trials using a spreadsheet data extraction form and one author will check the data entered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Two authors independently screened the ten trials found by the initial search of all the databases and reference lists to identify papers with potential relevance to the review. We obtained the full text of selected articles. Two authors independently selected trials for inclusion by applying the inclusion </p> <p>criteria to all potential trials.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We did not apply the process described below, as we were not able to identify any trials eligible for inclusion. However, if we include any trials in future updates of this review, we will apply the following methods. The two authors will independently identify potentially relevant </p> <p>trials from the results of the searches. Each author will independently extract data on trial information. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3. Was a comprehensive literature search performed?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Potentially relevant trials were identified from the Group’s haemoglobinopathies Trials Register We also searched for RCTs in the following databases: </p> <p>CENTRAL &amp; DARE; MEDLINE); Embase; CINAHL; Pubmed; Transfusion Evidence Library; LILACS(BIREME/PAHO/WHO); KoreaMed; IndMed; PakMediNet; Web of Science; ClinicalTrials.gov; The WHO International Clinical Trials Registry (ICTRP); the ISRCTN Register EU Clinical Trials Register and the Hong Kong Clinical Trials Register. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Searched the Cochrane Pregnancy and Childbirth Group’s Trials Register. In addition, we searched using the terms using the terms sickle cell AND pregnancy: Cystic Fibrosis and Genetic Disorders Group’s Trials Register (October 2007); <i>LILACS</i> database (1982 to Dec 5 2007); ClinicalTrials.gov <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Relevant studies from Disorders Group’s Haemoglobinopathies Trials Register using the terms: </p> <p>Also searched LILACS; Epistemonikos; WHO International Clinical Trials Registry.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>U</b> </p> <p>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Group’s Haemoglobinopathies Trials Register. We searched the Meetings of the American society for Blood and </p> <p>Marrow Transplantation; Center for the International Blood and Marrow Transplant Research; and European Group for Blood and Marrow </p> <p>Transplantation .</p> <p>No additional databases or clinical trials sites searched.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Relevant trials were identified from Relevant trials were identified from the Group’s Haemoglobinopathies Trials Register. In addition to the above, further subject specific electronic searched of MEDLINE and Embase. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4. Was the status of publication (i.e. grey literature) used as an Inclusion criterion?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We did not limit searches by language or publication</p> <p>status.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>U</b> </p> <p>Did not mention if any language restrictions</p> <p>Stated that bibliographic references of all retrieved literature were reviewed for additional reports of trials. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>We did not adopt any language or publication restrictions.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>U</b> </p> <p>All randomised controlled and quasi‐randomised studies.</p> <p>Not stated if any language or publication status limitations.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>A comprehensive search strategy was formulated in an attempt to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11. Was the conflict of interest stated?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Lise Estcourt: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components. </p> <p>Patricia Fortin: funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components. Sally Hopewell: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components. Marialena Trivella: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components. Ian Hambleton: none declared. </p> <p>Gavin Cho: none declared.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> <p>None known.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>In 2004 Arturo Martí‐Carvajal was employed by Eli Lilly to run a four‐hour workshop on ’How to critically appraise clinical trials </p> <p>In 2007 Arturo Martí‐Carvajal was employed by Merck to run a four‐hour workshop on ’How to critically appraise clinical trials </p> <p>Daniel Simancas‐Racines: none known.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Chioma Oringanje: none known.</p> <p>Eneida Nemecek: none known.</p> <p>Oluseyi Oniyangi: none known.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Y</b> </p> <p>Dr Shirley Owusu‐Ofori: none known.</p> <p>Tracey Remmington: Managing Editor of the Cochrane Cystic Fibrosis and Genetic Disorders Group. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>NIHR: National Institute for Health Research</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">AMSTAR quality assessment: Reviews with no studies identified</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full#CD012082-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012082-tbl-0007"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Mortality: Summary of findings</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N Participants </b> </p> <p><b>(N RCTs)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect estimate (95% confidence interval)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GRADE quality rating</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interpretation </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a> </p> <p><b>Primary and secondary stroke</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Long‐term RBC transfusions versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children with no previous long‐term RBC transfusions</p> <p>(Follow‐up 18 to 36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether long‐term RBC transfusions decrease mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children and adolescents with previous long‐term RBC transfusions</p> <p>(Follow‐up 18 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 8.0 (0.16 to 404.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether long‐term RBC transfusions decrease mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RBC transfusion versus disease‐modifying agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary prevention</p> <p>Children with abnormal TCD velocities but no severe vasculopathy on MRI/MRA, who have received at least one year of RBC transfusions </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether hydroxyurea and phlebotomy decreases mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary prevention</p> <p>Children and adolescents with previous stroke, at least 18 months of RBC transfusions, and evidence of iron overload </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 0.98 (0.06 to 15.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether hydroxyurea and phlebotomy decreases mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a> </p> <p><b>Silent cerebral infarcts</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Long‐term RBC transfusions versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children or adolescents with abnormal TCD velocities 18 to 21 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether long‐term RBC transfusions decrease mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children or adolescents with normalised TCD velocities 18 months of follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 8.00 (0.16 to 404.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether long‐term RBC transfusions decrease mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children with normal TCD velocities and silent stroke</p> <p>(median 3 years follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether long‐term RBC transfusions decrease mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RBC transfusion versus disease‐modifying agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary prevention</p> <p>Children with abnormal TCD velocities but no severe vasculopathy on MRI/MRA, who have received at least one year of red cell transfusions </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether hydroxyurea and phlebotomy decreases mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary prevention</p> <p>Children and adolescents with previous stroke, at least 18 months of RBC transfusions, and evidence of iron overload </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 1.02 (0.06 to 16.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether hydroxyurea with phlebotomy decreases mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a> </p> <p><b>Preoperative blood transfusions for sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Restrictive (to increase the total haemoglobin) versus liberal (to decrease the haemoglobin S level below a specified percentage) RBC transfusion strategy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with SCD undergoing cholecystectomy</p> <p>(Follow‐up: 30 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> <p>(1 RCT)<sup>a</sup> cholecystectomy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions decrease mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term RBC transfusion versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with SCD undergoing low to medium risk surgery or any surgery other than cardiac surgery </p> <p>(Follow‐up 30 days in one trial; not stated in 1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>434</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions decrease mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a> </p> <p><b>Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Long‐term RBC transfusions versus RBC transfusions to treat complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pregnant women with SCD</p> <p>(Follow‐up for 21.5 to 24.5 weeks of prenatal care)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether prophylactic RBC transfusions decrease maternal mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (76 births)</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.85 (0.61 to 13.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether prophylactic RBC transfusions decrease perinatal mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><sup>1</sup> High Risk of bias in one or more domains using the Cochrane Risk of Bias tool </p> <p><sup>2</sup> Indirectness as specific population or procedure reported may not be generalisable to review question </p> <p><sup>3</sup> Imprecision as effect has wide confidence intervals and/or study has small number of people or low event rates </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>MRI/MRA: magnetic resonance imaging/magnetic resonance angiography <br/> RBC: red blood cell<br/> RCT: randomised controlled trial<br/> SCD: sickle cell disease<br/> TCD: transcranial doppler </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Mortality: Summary of findings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full#CD012082-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012082-tbl-0008"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">SCD‐related SAEs: Summary of findings</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>GRADE summary of findings for SCD‐related serious adverse events<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systematic Review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population</b> </p> <p><b>(Follow‐up)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N Participants (N RCTs)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reported outcomes and time points</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect estimate (95% confidence interval)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GRADE quality rating</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interpretation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="13" valign="top"> <p><a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a> </p> <p><b>Primary and secondary stroke</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Long‐term RBC transfusions versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Children with no previous long‐term RBC transfusions</p> <p>(Follow‐up 18 to 36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.12<br/> (0.03 to 0.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions probably reduce the risk of stroke</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.24<br/> (0.12 to 0.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may reduce the incidence of ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Painful crises</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.62 (0.46 to 0.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may reduce the incidence of painful crisis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Children and adolescents with previous long‐term RBC transfusions</p> <p>(Follow‐up 18 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.22 (0.01 to 4.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether continuing long‐term red cell transfusions reduces the incidence of clinical stroke </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>_</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>_</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>RBC transfusion versus disease‐modifying agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Primary prevention</p> <p>Children with abnormal TCD velocities but no severe vasculopathy on MRI/MRA, who have received at least one year of red cell transfusions </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No stroke occurred in either arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on the risk of stroke </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.03</p> <p>(0.39 to 10.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.08</p> <p>(0.61 to 42.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on pain crisis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Secondary prevention</p> <p>Children and adolescents with previous stroke, at least 18 months of RBC transfusions, and evidence of iron overload </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 14.78<br/> (0.86 to 253.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>2.3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on the risk of stroke </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global SCD SAEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.10 (1.42 to 6.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switching to hydroxyurea and phlebotomy may increase the risk of SCD related serious adverse events </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33 (0.04 to 3.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very uncertain whether switching to hydroxyurea and phlebotomy has any effect on the risk of ACS </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.15 (1.23 to 8.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switching to hydroxyurea and phlebotomy may increase the risk of painful crisis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p><a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a> </p> <p><b>Silent cerebral infarcts</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>Long‐term RBC transfusions versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Children and adolescents with abnormal TCD velocities</p> <p>(18 – 21 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New or progressive SCI lesions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.11 (0.02 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>1, 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may reduce the incidence of SCIs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.30</p> <p>(0.11 to 0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may reduce the incidence of ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90</p> <p>(0.44 to 1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may be no different than standard care in reducing the incidence of pain crisis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Children and adolescents with normalised TCD velocities</p> <p>(18 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New or progressive SCI lesions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.29</p> <p>(0.09 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>1, 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuing RBC transfusions may reduce the incidence of SCIs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Children with normal TCD velocities and silent stroke</p> <p>(median 3 years follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New or progressive SCI lesions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70</p> <p>(0.23 to</p> <p>2.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may be no different than standard care in reducing the incidence of SCIs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute chest syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.20</p> <p>(0.08 to 0.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may reduce the incidence of ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.56</p> <p>(0.40 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may reduce the incidence of pain crisis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>RBC transfusion versus disease‐modifying agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Primary prevention</p> <p>Children with abnormal TCD velocities but no severe vasculopathy on MR/MRA, who have received at least one year of red cell transfusions </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New or progressive SCI lesions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No SCIs occurred in either study arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on SCIs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global SCD SAEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.52 (0.58 to 4.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if switching to hydroxyurea and phlebotomy has any effect on total SAEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.03</p> <p>(0.39 to 10.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.08</p> <p>(0.61 to 42.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on pain crisis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Secondary prevention</p> <p>Children and adolescents with previous stroke, at least 18 months of RBC transfusions, and evidence of iron overload </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New or progressive SCI lesions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 7.28</p> <p>(0.14 to</p> <p>366.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on SCIs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33</p> <p>(0.04 to</p> <p>3.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether switching to hydroxyurea and phlebotomy has any effect on ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.15</p> <p>(1.23 to</p> <p>8.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>1, 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switching to hydroxyurea and phlebotomy may increase the risk of pain crisis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p><a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a> </p> <p><b>Preoperative blood transfusions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Restrictive (to increase the total haemoglobin) versus liberal (to decrease the haemoglobin S level below a specified percentage) RBC transfusion strategy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>People undergoing cholecystectomy</p> <p>(Follow‐up: 30 days)</p> <p>(results for the tonsillectomy / adenoidectomy groups are similar)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> <p>No effect estimate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions reduce the risk of acute stroke</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.84</p> <p>(0.38 to 1.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions reduce the risk of ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Painful crises</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.30</p> <p>(0.09 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions reduce the risk of painful crisis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> <p>No effect estimate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions reduce the risk of renal complications</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.75 (0.59 to 5.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions reduce the risk of serious infection</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Short‐term RBC transfusion versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>People undergoing low‐to medium‐risk surgery or any surgery other than cardiac surgery</p> <p>(Follow‐up 30 days in 1 trial; not stated in 1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>434 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 7.22 (1.24 to 41.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions increase the risk of neurological complications (no events in no preoperative transfusion group) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.11 (0.01 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Preoperative RBC transfusions may reduce the risk of ACS the population of African haplotypes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369 (1)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.81 (0.23 to 99.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions increase the risk of ACS (no events in control group) in the population of Arabic haplotypes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>434 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Painful crises</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 1.91 (0.61 to 6.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions reduce the risk of painful crisis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> <p>No effect estimate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions reduce the risk of renal complications (no events) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>434 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 1.29 (0.29 to 5.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions reduce the risk of serious infection</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a> </p> <p><b>Prophylactic vs selective blood transfusion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Long‐term RBC transfusions versus RBC transfusions to treat complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Pregnant women with SCD</p> <p>(Follow‐up for 21.5‐24.5 weeks of prenatal care)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.67</p> <p>(0.12 to 3.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether prophylactic RBC transfusions reduce the risk of ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Painful crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.28 (0.12 to 0.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic RBC transfusions may reduce the risk of painful crisis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Renal complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (0.07 to 15.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether prophylactic RBC transfusions reduce the risk of renal complications</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (0.07 to 15.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether prophylactic RBC transfusions reduce the risk of serious infection</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><sup>a</sup> Sickle cell serious adverse events include: neurological, ophthalmological, respiratory, orthopaedic, vascular, hepatic or renal complications, vaso‐occlusive pain crisis, priapism, infections </p> <p><sup>b</sup> Rated down by 2 for very serious risk of bias </p> <p><sup>1</sup> High Risk of bias in one or more domains using the Cochrane Risk of Bias tool </p> <p><sup>2</sup> Indirectness as specific population or procedure reported may not be generalisable to review question </p> <p><sup>3</sup> Imprecision as effect has wide confidence intervals and/or study has small number of people or low event rates </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>ACS: acute chest syndrome<br/> MRI/MRA: magnetic resonance imaging/magnetic resonance angiography<br/> OR: odds ratio<br/> RBC: red blood cell<br/> RCT: randomised controlled trial<br/> RR: risk ratio<br/> SAEs: serious adverse events<br/> SCI: silent cerebral infarct<br/> TCD: transcranial doppler </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">SCD‐related SAEs: Summary of findings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full#CD012082-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012082-tbl-0009"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Transfusion‐related AEs (serious and non‐serious): Summary of findings</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Table: Transfusion related adverse events (serious and non‐serious)<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systematic Review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population </b> </p> <p><b>(Follow‐up)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N Participants (N RCTs)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reported outcomes and </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect estimate</b> </p> <p><b>(95% confidence interval)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GRADE quality rating </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interpretation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD012082-bbs2-0005" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , WangWC . Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] ">Estcourt 2017a</a> </p> <p><b>Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Long‐term RBC transfusions versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Children with no previous long‐term RBC transfusions</p> <p>(Follow‐up 18 to 36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.16 (0.18 to 57.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if long‐term RBC transfusions increase the risk of alloimmunisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.17 (0.71 to 37.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if long‐term RBC transfusions increase the risk of transfusion reactions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron overload (serum ferritin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased in children receiving long‐term RBC transfusions, incidence rate ratio 14.42 (5.41 to 875.17 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may increase the risk of iron overload</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Children and adolescents with previous long‐term RBC transfusions</p> <p>(Follow‐up 18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participant who was in the continuing transfusion arm developed an alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 participants in the continuing transfusion arm had 9 reactions to transfusions. 1 required hospitalisation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RBC Transfusion versus disease‐modifying agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary prevention</p> <p>Children with abnormal TCD velocities but no severe vasculopathy on MRI/MRA, who have received at least one year of red cell transfusions </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver iron concentrations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐1.80 (‐5.16 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switching to hydroxyurea and phlebotomy may have little or no effect on liver iron concentrations </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary prevention</p> <p>Children and adolescents with previous stroke, at least 18 months of RBC transfusions, and evidence of iron overload </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver iron concentrations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea: 17.3 mg Fe/g dry weight iron, (IQR 10.0 to 30.6); transfusion: 17.3 mg Fe/g dry weight iron, (IQR 8.8 to 30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switching to hydroxyurea and phlebotomy may have little or no effect on liver iron concentrations </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign="top"> <p><a href="./references#CD012082-bbs2-0006" title="EstcourtLJ , FortinPM , HopewellS , TrivellaM , DoreeC , AbboudMR . Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] ">Estcourt 2017b</a> </p> <p><b>Interventions for preventing silent cerebral infarcts in people with sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>Long‐term RBC transfusions versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Children or adolescents with abnormal TCD velocities</p> <p>(18 to 21 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 participants in the transfusion arm developed an alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 participants in the transfusion arm had 16 mild reactions to blood products or transfusion </p> <p>procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron overload</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron overload developed faster than anticipated in children receiving transfusion, with mean (SD) </p> <p>serum ferritin rising to and 2509 μg/L (974 μg/L) at 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Children and adolescents with normalised TCD velocities</p> <p>(18 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participant who was in the continuing transfusion arm developed an alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 participants in the continuing transfusion arm had 9 reactions to transfusions. 1 required hospitalisation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comparative numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Children with normal TCD velocities and silent stroke</p> <p>(median 3 years follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.16 (0.18 to 57.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very Low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if long‐term RBC transfusions increase the risk of alloimmunisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.17 (0.71 to 37.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if long‐term RBC transfusions increase the risk of transfusion reactions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron overload (serum ferritin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased in children receiving long‐term RBC transfusions, incidence rate ratio 14.42 (5.41 to 875.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>2.3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions may increase the risk of iron overload</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RBC transfusion versus disease‐modifying agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary prevention</p> <p>Children with abnormal TCD velocities but no severe vasculopathy on MRI/MRA, who have received at least one year of red cell transfusions </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver iron concentrations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐1.80 (‐5.16 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switching to hydroxyurea and phlebotomy may have little or no effect on liver iron concentrations </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary prevention</p> <p>Children and adolescents with previous stroke, at least 18 months of RBC transfusions, and evidence of iron overload </p> <p>(6 months follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver iron concentrations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea: 17.3 mg Fe/g dry weight iron, IQR 10.0 to 30.6; transfusion: 17.3 mg Fe/g dry </p> <p>weight iron, IQR 8.8 to 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switching to hydroxyurea and phlebotomy may have little or no effect on liver iron concentrations </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD012082-bbs2-0004" title="EstcourtLJ , FortinPM , TrivellaM , HopewellS . Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] ">Estcourt 2016b</a> </p> <p><b>Preoperative blood transfusions for sickle cell disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Restrictive (to increase the total haemoglobin) versus liberal (to decrease the haemoglobin S level below a specified percentage) RBC transfusion strategy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>People with SCD undergoing cholecystectomy</p> <p>(Follow‐up: 30 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.05 (1.14 to 8.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions increase the risk of alloimmunisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.18 (0.77 to 6.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions increase the risk of transfusion reactions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any transfusion complication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.85 (0.89 to 3.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1, 2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether aggressive RBC transfusions increase the risk of transfusion complications </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Short‐term RBC transfusion versus standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>People with SCD undergoing low to medium risk surgery or any surgery other than cardiac surgery </p> <p>(Follow‐up for 30 days in 1 trial; not stated in 1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>434 (2)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious transfusion complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events in 1 trial, circulatory overload reported in the preoperative transfusion group in 1 trial </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions increase the risk of serious transfusion complications </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (1)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alloimmunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peto OR 7.17 (0.14 to 361.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions increase the risk of alloimmunisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>434 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events in 1 trial; 2 reactions reported in the preoperative transfusion group in 1 trial </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether preoperative RBC transfusions increase the risk of transfusion reactions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012082-bbs2-0011" title="OkusanyaBO , OladapoOT . Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] ">Okusanya 2016</a> </p> <p><b>Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term RBC transfusions versus RBC transfusions to treat complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pregnant women with SCD</p> <p>(Follow‐up for 21.5‐24.5 weeks of prenatal care)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.00 (0.54 to 7.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether prophylactic RBC transfusions increase the risk of transfusion reactions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><sup>a</sup> Serious and non‐serious transfusion related adverse events can include: acute and delayed transfusion reactions, transfusion‐related acute lung injury, transfusion‐associated circulatory overload, transfusion‐associated dyspnoea, alloimmunisation, iron overload, problems of venous access) </p> <p><sup>b</sup> Rated down by 1 for serious risk of bias and rated down by 2 for very serious risk of bias </p> <p><sup>1</sup> High Risk of bias in one or more domains using the Cochrane Risk of Bias tool </p> <p><sup>2</sup> Indirectness as specific population or procedure reported may not be generalisable to review question </p> <p><sup>3</sup> Imprecision as effect has wide CIs and/or study has small number of people or low event rates </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI: confidence interval<br/> IQR: inter‐quartile range<br/> OR: odds ratio<br/> MRI/MRA: magnetic resonance imaging/magnetic resonance angiography<br/> RBC: red blood cell<br/> RCT: randomised controlled trial<br/> RR: risk ratio<br/> SAEs: serious adverse events<br/> SCD: sickle cell disease<br/> TCD: transcranial doppler </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Transfusion‐related AEs (serious and non‐serious): Summary of findings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012082.pub2/full#CD012082-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012082.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012082-note-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012082-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012082-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD012082-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012082-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012082-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"/> </img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012082\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012082\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012082\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012082\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012082\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012082\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012082\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012082\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012082\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012082\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012082\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012082\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012082\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012082\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012082\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012082\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012082\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012082\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QO4KtYGW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012082.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012082.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012082.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012082.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012082.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728152077"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012082.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728152081"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012082.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ebd7e8f02f498',t:'MTc0MDcyODE1My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 